

**Table S1** PRISMA 2009 Checklist

| Section and Topic             | Item # | Checklist item   | Location where item is reported      |
|-------------------------------|--------|--|--------------------------------------|
| <b>TITLE</b>                  |        |  |                                      |
| Title                         | 1      | Identify the report as a systematic review.  | Page 1                               |
| <b>ABSTRACT</b>               |        |  |                                      |
| Abstract                      | 2      | See the PRISMA 2020 for Abstracts checklist.   | Page 3                               |
| <b>INTRODUCTION</b>           |        |  |                                      |
| Rationale                     | 3      | Describe the rationale for the review in the context of existing knowledge.  | Page 6                               |
| Objectives                    | 4      | Provide an explicit statement of the objective(s) or question(s) the review addresses.   | Page 7                               |
| <b>METHODS</b>                |        |  |                                      |
| Eligibility criteria          | 5      | Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.  | Section 2.1                          |
| Information sources           | 6      | Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.  | Section 2.1                          |
| Search strategy               | 7      | Present the full search strategies for all databases, registers and websites, including any filters and limits used.   | Section 2.1                          |
| Selection process             | 8      | Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.                     | Section 2.1                          |
| Data collection process       | 9      | Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. | Section 2.1                          |
| Data items                    | 10a    | List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.                        | Section 2.1                          |
|                               | 10b    | List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.   | Supplementary page 5                 |
| Study risk of bias assessment | 11     | Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.                                    | Section 2.2<br>Supplementary Table 2 |
| Effect measures               | 12     | Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.  | Section 2.3                          |
| Synthesis methods             | 13a    | Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics)  | Section 2.1                          |

| Section and Topic             | Item # | Checklist item   | Location where item is reported                 |
|-------------------------------|--------|--|---|
|                               |        | and comparing against the planned groups for each synthesis (item #5)).  | Section 2.3                                     |
|                               | 13b    | Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.  | Section 2.3<br>Supplementary Figure 1           |
|                               | 13c    | Describe any methods used to tabulate or visually display results of individual studies and syntheses.   | Section 2.3                                     |
|                               | 13d    | Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.                          | Section 2.3                                     |
|                               | 13e    | Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).   | Section 2.3                                     |
|                               | 13f    | Describe any sensitivity analyses conducted to assess robustness of the synthesized results.   | Section 2.3                                     |
| Reporting bias assessment     | 14     | Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).  | Section 2.3                                     |
| Certainty assessment          | 15     | Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.  | Not applicable                                  |
| <b>RESULTS</b>                |        |  |   |
| Study selection               | 16a    | Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.   | Figure 2  |
|                               | 16b    | Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.  | Supplementary Table 3                           |
| Study characteristics         | 17     | Cite each included study and present its characteristics.  | Section 3.1<br>Table 1                          |
| Risk of bias in studies       | 18     | Present assessments of risk of bias for each included study.   | Supplementary Table 9                           |
| Results of individual studies | 19     | For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.   | Figure 3<br>Supplementary Table 4               |
| Results of syntheses          | 20a    | For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.   | Supplementary Table 10                          |
|                               | 20b    | Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect. | Figure 3<br>Supplementary Table 4               |
|                               | 20c    | Present results of all investigations of possible causes of heterogeneity among study results.   | Supplementary Table 6<br>Supplementary Table 7  |
|                               | 20d    | Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.   | Supplementary Figure 3<br>Supplementary Table 8 |
| Reporting biases              | 21     | Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.  | Supplementary Figure 4<br>Supplementary Table 4 |

| Section and Topic                              | Item # | Checklist item   | Location where item is reported |
|--|--------|--|---------------------------------|
| Certainty of evidence                          | 22     | Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.  | Not applicable                  |
| <b>DISCUSSION</b>                              |        |  |                                 |
| Discussion                                     | 23a    | Provide a general interpretation of the results in the context of other evidence.  | Pages 17-19                     |
|  | 23b    | Discuss any limitations of the evidence included in the review.  | Pages 19-20                     |
|  | 23c    | Discuss any limitations of the review processes used.  | Pages 19-20                     |
|  | 23d    | Discuss implications of the results for practice, policy, and future research.   | Page 20                         |
| <b>OTHER INFORMATION</b>                       |        |  |                                 |
| Registration and protocol                      | 24a    | Provide registration information for the review, including register name and registration number, or state that the review was not registered.   | Section 2.3                     |
|  | 24b    | Indicate where the review protocol can be accessed, or state that a protocol was not prepared.   | Section 2.3                     |
|  | 24c    | Describe and explain any amendments to information provided at registration or in the protocol.  | Section 2.3                     |
| Support  | 25     | Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.  | Not applicable                  |
| Competing interests                            | 26     | Declare any competing interests of review authors.   | Pages 21-22                     |
| Availability of data, code and other materials | 27     | Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. | Supplementary page 5            |

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71  
For more information, visit: <http://www.prisma-statement.org/>

**List of variables extracted**

- Last author
- Year of publication
- Journal
- Year data was collected
- Continent, country, city
- TRS criteria:
  - How was TRS criteria defined?
  - Use of clozapine also included as criteria for TRS?
- Proportion of TRS subjects provided by the original study?
- Response criteria
- Study design
- Duration of follow-up (months)
- Shortest duration of a trial (weeks)
- Recruitment strategy
- Type of facility
- Study only evaluated symptomatic at baseline as inclusion criteria?
- Subjects described as "chronic"?
- Study only included subjects who had already not responded to one AP trial?
- Number of episodes
- Diagnosis:
  - Method and criteria
  - Which diagnosis are included?
- Dropout rate (%)
- FEP studies:
  - % early-TRS subjects
  - % late-TRS subjects
  - % non-responders on 1<sup>st</sup> trial
  - % non-responders on 2<sup>nd</sup> trial
- Mean age (years)
- Race
- Mean duration of illness (years)
- Mean age of illness onset (years)
- Mean DUP (months)
- Final mean PANSS or eq. (score)
- Final mean GAF (score)
- Final mean CGI (core)
- Final mean AP dose (CPZ eq.)
- % of subjects on clozapine
- Adherence to TRRIP criteria:
  - Current symptoms
  - Adequate treatment
  - Symptom domain
- Time course

**Table S2** Modified Newcastle-Ottawa scale – criteria

|                | Representativeness   | Sample size | Non-respondents  | Ascertainment of TRS                                     | Statistical quality   |
|----------------|--|-------------|--|--|---|
| <b>1 point</b> | Truly (population-based studies)<br>OR Somewhat representative                   | ≥ 200       | 2 adequate trials (≥ 4w., ≥400mg CPZ eq., scale with cutoff) | At least one prospective trial                           | Statistics to describe the population (age, sex) w/ proper measures of dispersion (SD, SE, range) |
| <b>0 point</b> | Clear selection bias (e.g. long-term admissions, clozapine clinics, chronic SCZ) | < 200       | If any of the above data is missing or not satisfactory      | Both retrospective (e.g. chart review, previous history) | Statistics not reported/incomplete, or no proper measures of dispersion                           |

|                           |   |
|---------------------------|---|
| <b><u>Final score</u></b> | < 3 points - <i>High risk of bias</i><br>≥ 3 points - <i>Low risk of bias</i> |
|---------------------------|---|

**Figure S1** TRS prevalence calculation

|                          |                   |   |
|--------------------------|-------------------|---|
| Intent-to-treat analysis | Most conservative | Numerator: only subjects considered TRS according to criteria. Dropouts were not considered as TRS.   |
|                          |                   | Denominator: initial sample including all dropouts.   |
|                          | Less conservative | Numerator: subjects considered TRS according to criteria. Dropouts due to lack of efficacy and side-effects were considered as TRS.   |
|                          |                   | Denominator: initial sample including all dropouts.   |
| Observed cases analysis  | Most conservative | Numerator: only subjects considered TRS according to criteria. Dropouts were not considered as TRS.   |
|                          |                   | Denominator: number of subjects effectively analyzed, therefore excluding all dropouts.   |
|                          | Less conservative | Numerator: subjects considered TRS according to criteria. Dropouts due to lack of efficacy and side-effects were considered as TRS.   |
|                          |                   | Denominator: number of subjects effectively analyzed. In this case, all that finished the study and dropouts due to lack of efficacy and side-effects. Excludes other kinds of dropouts or non-specified. |

**Table S3** List of excluded studies (with reasons of exclusion)

| Year of publication | First author          | Title  | Journal   | Reason for exclusion             |
|---------------------|-----------------------|--|---|----------------------------------|
| 2022                | Bioque et al.         | Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia.   | Schizophrenia research  | No TRS assessment                |
| 2022                | Brodeur et al.        | Association between previous and future antipsychotic adherence in patients initiating clozapine: real-world observational study.  | The British journal of psychiatry : the journal of mental science                                 | Insufficient or Wrong population |
| 2022                | Brodeur et al.        | Comparative effectiveness and safety of antipsychotic drugs in patients with schizophrenia initiating or reinitiating treatment: A Real-World Observational Study.   | Acta psychiatrica Scandinavica  | No TRS assessment                |
| 2022                | Chan et al.           | Longitudinal relapse pattern of patients with first-episode schizophrenia-spectrum disorders and its predictors and outcomes: A 10-year follow-up study  | Asian Journal of Psychiatry   | No TRS assessment                |
| 2022                | de Freitas et al.     | Ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia: a retrospective cohort study using data from electronic clinical records.  | Social psychiatry and psychiatric epidemiology  | Insufficient or Wrong population |
| 2022                | Hatta et al.          | Real-world effectiveness of antipsychotic treatments in 1011 acutely hospitalized patients with schizophrenia: A one-year follow-up study.   | Asian journal of psychiatry   | No TRS assessment                |
| 2022                | Iasevoli et al.       | Relationships between early age at onset of psychotic symptoms and treatment resistant schizophrenia.  | Early intervention in psychiatry  | Overlapping sample               |
| 2022                | Joo et al.            | Comparative effectiveness of antipsychotic monotherapy and polypharmacy in schizophrenia patients with clozapine treatment: A nationwide, health insurance data-based study.   | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology | Wrong definition of TRS          |
| 2022                | Khau et al.           | Measurement Based Care in a first episode psychosis program: Development of an algorithm of care based on the Clinical Global Impressions Scale.   | Journal of psychiatric research   | No TRS assessment                |
| 2022                | Lähteenvuo et al.     | Associations between antipsychotic use, substance use and relapse risks in patients with schizophrenia - real-world evidence from two national cohorts   | Br J Psychiatry   | No TRS assessment                |
| 2022                | Lieslehto et al.      | Primary Nonadherence to Antipsychotic Treatment Among Persons with Schizophrenia.  | Schizophrenia bulletin  | No TRS assessment                |
| 2022                | Ochi et al.           | Investigating structural subdivisions of the anterior cingulate cortex in schizophrenia, with implications for treatment resistance and glutamatergic levels.  | Journal of psychiatry & neuroscience  | Insufficient or Wrong population |
| 2022                | Pai et al.            | Antipsychotic prescribing patterns in Australia: a retrospective analysis.   | BMC psychiatry  | No TRS assessment                |
| 2022                | Pardiñas et al.       | Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia.  | JAMA psychiatry   | Wrong definition of TRS          |
| 2022                | Shakir et al.         | The effect on relapse rate and psychiatric symptomatology: Switching a combination of first- and second-generation antipsychotic polypharmacy to antipsychotic monotherapy in long-term inpatients with schizophrenia and related disorders. A pragmatic randomized open-label trial (SwAP trial). | Schizophrenia research  | No TRS assessment                |
| 2022                | van de Giessen et al. | Neuromelanin MRI as Biomarker for Treatment Resistance in First Episode Schizophrenia  | Biological Psychiatry   | Wrong publication type           |

| Year of publication | First author               | Title   | Journal  | Reason for exclusion                                     |
|---------------------|----------------------------|---|--|--|
| 2022                | Yang et al.                | A multimodal study of a first episode psychosis cohort: potential markers of antipsychotic treatment resistance.  | Molecular psychiatry   | No TRS assessment  |
| 2022                | Yasui-Furukori et al.      | Association between the examination rate of treatment-resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation study. | Neuropsychopharmacology reports                                | No TRS assessment  |
| 2021                | Ajnakina et al.            | Structural Covariance of Cortical Gyriification at Illness Onset in Treatment Resistance: A Longitudinal Study of First-Episode Psychoses                                 | Schizophrenia bulletin   | Wrong publication type                                   |
| 2021                | Akamine, Kikuchi and Miura | Effects on monotherapy and reduction of antipsychotic drugs by clozapine therapy in Japanese patients with treatment-resistant schizophrenia                              | Journal of Clinical Pharmacy and Therapeutics                  | Insufficient or Wrong population                         |
| 2021                | Aytac et al.               | Macrophage Migration Inhibitory Factor - 173 G/C Polymorphism is Associated With The Age of Onset and Insight in Schizophrenia in the Turkish Population.                 | Neurological research  | Overlapping sample                                       |
| 2021                | Baltazar et al.            | Long term course and outcome of first episode schizophrenia: a 27-to-31-year follow-up.   | Social psychiatry and psychiatric epidemiology                 | Wrong definition of TRS                                  |
| 2021                | Cui et al.                 | Baseline structural and functional magnetic resonance imaging predicts early treatment response in schizophrenia with radiomics strategy                                  | European Journal of Neuroscience                               | No TRS assessment  |
| 2021                | Dempster et al.            | Treatment Resistance: A Time-Based Approach for Early Identification in First Episode Psychosis.  | Journal of personalized medicine                               | Wrong definition of TRS                                  |
| 2021                | Fond et al.                | Depressive symptoms and chronic peripheral inflammation are associated with impaired functional remission in schizophrenia independently of psychotic remission           | Journal of Affective Disorders                                 | No TRS assessment  |
| 2021                | Ganoci et al.              | ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone   | Progress in Neuro-Psychopharmacology and Biological Psychiatry | Insufficient trials / duration or lacking AP information |
| 2021                | Gosek et al.               | Treatment resistance and prolonged length of stay among schizophrenia inpatients in forensic institutions   | Psychiatry Research  | No TRS assessment  |
| 2021                | Gracias et al.             | Genomic Variation Within the C4 Locus and Cerebrospinal Fluid Levels of C4 Isoform Proteins in Acute and Chronic Schizophrenia  | Biological Psychiatry  | Wrong publication type                                   |
| 2021                | Hannon et al.              | Dna methylation meta-analysis reveals cellular alterations in psychosis and markers of treatment-resistant schizophrenia  | eLife  | No TRS assessment  |
| 2021                | Harrow et al.              | Twenty-year effects of antipsychotics in schizophrenia and affective psychotic disorders  | Psychological medicine   | No TRS assessment  |
| 2021                | Hudgens-Haney et al.       | Effects of Medication on Intrinsic EEG Activity: A BSNIP Study  | Biological Psychiatry  | Wrong publication type                                   |
| 2021                | Iwata et al.               | Glutathione Levels and Glutathione-Glutamate Correlation in Patients With Treatment-Resistant Schizophrenia   | Schizophrenia bulletin open                                    | Insufficient or Wrong population                         |
| 2021                | Jo et al.                  | Use of olanzapine compared with clozapine for treatment-resistant schizophrenia in a real-world setting: nationwide register-based study.                                 | BJPsych open   | Insufficient or Wrong population                         |
| 2021                | Joo et al.                 | Antipsychotic treatment and risk of discontinuation and hospitalization in first-episode schizophrenia: a nationwide population-based study                               | Psychological medicine   | No TRS assessment  |



| Year of publication | First author    | Title  | Journal  | Reason for exclusion                                     |
|---------------------|-----------------|--|--|--|
| 2021                | Kang et al.     | Clinical usefulness of amisulpride add-on therapy in schizophrenia patients without treatment response to second-generation antipsychotics   | Clinical Psychopharmacology and Neuroscience             | No TRS assessment  |
| 2021                | Kokurcan et al. | Treatment strategies in management of schizophrenia patients with persistent symptoms in daily practice: a retrospective study   | International Journal of Psychiatry in Clinical Practice | Insufficient or Wrong population                         |
| 2021                | Kowalec et al.  | Increased schizophrenia family history burden and reduced premorbid IQ in treatment-resistant schizophrenia: a Swedish National Register and Genomic Study.  | Molecular psychiatry                                     | Wrong definition of TRS                                  |
| 2021                | Leclerc et al.  | A Chart Audit Study of Clozapine Utilization in Early Psychosis  | Journal of clinical psychopharmacology                   | No TRS assessment  |
| 2021                | Lintunen et al. | Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective Disorder   | Schizophrenia bulletin                                   | No TRS assessment  |
| 2021                | Liu et al.      | Challenging the Minimum Effective Antipsychotic Dose During Maintenance: Implications From 10-Year Follow-Up of First Episode Psychosis.   | Frontiers in psychiatry                                  | No TRS assessment  |
| 2021                | Moges et al.    | Lifetime relapse and its associated factors among people with schizophrenia spectrum disorders who are on follow up at Comprehensive Specialized Hospitals in Amhara region, Ethiopia: a cross-sectional study | International Journal of Mental Health Systems           | No TRS assessment  |
| 2021                | Nikolic et al.  | Early access to clozapine in Early Intervention in Psychosis: Hope vs reality A mixed method service analysis  | Early Intervention in Psychiatry                         | Overlapping sample                                       |
| 2021                | Paul et al.     | Initiating clozapine in the outpatient setting: A retrospective study examining the service utilization, tolerability and cost effectiveness   | Australian and New Zealand Journal of Psychiatry         | Insufficient or Wrong population                         |
| 2021                | Reist et al.    | Using claims data to assess treatment quality of first-episode psychosis   | Psychiatric Services                                     | No TRS assessment  |
| 2021                | Rentrop et al.  | [Clozapine in the Treatment of Schizophrenic Psychosis: Patient Characteristics and Antipsychotic Combinations in One Cohort at a Psychiatric Care Hospital].  | Fortschritte der Neurologie-Psychiatrie                  | No TRS assessment  |
| 2021                | Salim et al.    | Command voices and aggression in a Lebanese sample patients with schizophrenia   | Psychiatria Danubina                                     | No TRS assessment  |
| 2021                | Shin et al.     | Influence of cytochrome P450 2D6 polymorphism on hippocampal white matter and treatment response in schizophrenia  | npj Schizophrenia  | Insufficient trials / duration or lacking AP information |
| 2021                | Son et al.      | Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3)          | Revista de Psiquiatria y Salud Mental                    | Insufficient trials / duration or lacking AP information |
| 2021                | Spangaro et al. | Treatment-resistance as a predictor of cognitive remediation outcome in schizophrenia  | European Neuropsychopharmacology                         | Wrong publication type                                   |
| 2021                | Tao et al.      | Morphological alterations of the corpus callosum in antipsychotic-naïve first-episode schizophrenia before and 1-year after treatment  | Schizophrenia Research                                   | No TRS assessment  |
| 2021                | Thomas et al.   | Cognitive performance in early, treatment-resistant psychosis patients: Could cognitive control play a role in persistent symptoms?  | Psychiatry Research                                      | Overlapping sample                                       |
| 2021                | Toyoda et al.   | A descriptive study of 10-year clozapine use from the nationwide database in Japan   | Psychiatry Research                                      | No TRS assessment  |
| 2021                | Wang et al.     | Network Structure of Clinical Variables and a Schizophrenia Polygenic Risk Score in Treatment Resistant Psychosis  | Biological Psychiatry                                    | Wrong publication type                                   |

| Year of publication | First author      | Title  | Journal   | Reason for exclusion                                     |
|---------------------|-------------------|--|---|--|
| 2021                | Wellesley et al.  | Gender disparities in clozapine prescription in a cohort of treatment-resistant schizophrenia in the South London and Maudsley case register.  | Schizophrenia research                                    | No TRS assessment  |
| 2021                | Whiskey et al.    | An evaluation of the variation and underuse of clozapine in the United Kingdom   | Acta Psychiatrica Scandinavica                            | No TRS assessment  |
| 2021                | Yu et al.         | Safety and related factors of treatment with long-term atypical antipsychotic in Chinese patients with schizophrenia: observational study  | General psychiatry  | No TRS assessment  |
| 2021                | Zeng et al.       | Pretreatment abnormalities in white matter integrity predict one-year clinical outcome in first episode schizophrenia  | Schizophrenia Research                                    | No TRS assessment  |
| 2021                | Zhang et al.      | Analysis of the status of drug treatment in 746 inpatients with early-onset schizophrenia in China: a retrospective study  | BMC Psychiatry  | No TRS assessment  |
| 2021                | Zhu et al.        | Drug-naive first-episode schizophrenia spectrum disorders: Pharmacological treatment practices in inpatient units in Hunan Province, China   | Early intervention in psychiatry                          | No TRS assessment  |
| 2020                | Ajnakina et al.   | Predicting onset of early- and late-treatment resistance in first-episode schizophrenia patients using advanced shrinkage statistical methods in a small sample  | Psychiatry Research                                       | Overlapping sample                                       |
| 2020                | Albus et al.      | Neurocognitive functioning in patients with first-episode schizophrenia: results of a prospective 15-year follow-up study  | European Archives of Psychiatry and Clinical Neuroscience | Insufficient trials / duration or lacking AP information |
| 2020                | Ambrosen et al.   | A machine-learning framework for robust and reliable prediction of short- and long-term treatment response in initially antipsychotic-naive schizophrenia patients based on multimodal neuropsychiatric data | Translational Psychiatry                                  | Insufficient trials / duration or lacking AP information |
| 2020                | Barone et al.     | P185 The role for rare structural variants in the genetics of treatment resistant schizophrenia: preliminary data  | European Neuropsychopharmacology                          | Wrong publication type                                   |
| 2020                | Barone et al.     | Genetic characterization of a cohort of patients affected by schizophrenia The role for rare structural variants in modulating treatment resistant endophenotypes: Preliminary data                          | Schizophrenia Bulletin                                    | Wrong publication type                                   |
| 2020                | Bucci et al.      | Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning  | European Neuropsychopharmacology                          | Insufficient trials / duration or lacking AP information |
| 2020                | Camporesi et al.  | Profiling glutamate and d-serine pathways in treatment resistant early psychosis patients  | Schizophrenia Bulletin                                    | Wrong publication type                                   |
| 2020                | Dehelean , et al. | Clinical factors influencing antipsychotic choice, dose and augmentation in patients treated with long acting antipsychotics   | Farmacia  | Insufficient or Wrong population                         |
| 2020                | Drake et al.      | Effect of delaying treatment of first-episode psychosis on symptoms and social outcomes: a longitudinal analysis and modelling study   | The Lancet Psychiatry                                     | No TRS assessment  |
| 2020                | Drosos et al.     | One-Year Outcome and Adherence to Pharmacological Guidelines in First-Episode Schizophrenia: Results from a Consecutive Cohort Study   | Journal of Clinical Psychopharmacology                    | Insufficient trials / duration or lacking AP information |
| 2020                | Emsley et al.     | Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia  | Schizophrenia Research                                    | Insufficient or Wrong population                         |
| 2020                | Enatescu et al.   | Study on tolerability and efficacy of paliperidone palmitate, olanzapine pamoate and risperidone long acting injection in a romanian sample of patients with schizophrenia                                   | Farmacia  | No TRS assessment  |

| Year of publication | First author        | Title  | Journal  | Reason for exclusion             |
|---------------------|---------------------|--|--|----------------------------------|
| 2020                | Fanta et al.        | The prevalence and associated factors of depression among patients with schizophrenia in Addis Ababa, Ethiopia, cross-sectional study  | BMC psychiatry   | No TRS assessment                |
| 2020                | Fond et al.         | Chronic peripheral inflammation is associated with impaired functional remission independently of symptomatic remission and depression in schizophrenia  | Progress in neuro-psychopharmacology & biological psychiatry   | No TRS assessment                |
| 2020                | Fond et al.         | Confirmations, advances and recommendations for the daily care of schizophrenia based on the French national FACE-SZ cohort  | Progress in Neuro-Psychopharmacology and Biological Psychiatry | No TRS assessment                |
| 2020                | Forma , et al.      | Antipsychotic medication adherence and healthcare services utilization in two cohorts of patients with serious mental illness  | ClinicoEconomics and Outcomes Research                         | No TRS assessment                |
| 2020                | Fu et al.           | Altered expression of the DISC1 gene in peripheral blood of patients with schizophrenia  | BMC Medical Genetics   | No TRS assessment                |
| 2020                | Fusar-Poli et al.   | Real-World clinical outcomes two years after transition to psychosis in individuals at clinical high risk: Electronic health record cohort study   | Schizophrenia Bulletin   | No TRS assessment                |
| 2020                | Fusar-Poli et al.   | Early Intervention Services for First Episode of Psychosis in South London and the Maudsley (SLaM): 20 Years of Care and Research for Young People   | Frontiers in Psychiatry  | No TRS assessment                |
| 2020                | Galletly et al.     | Living with psychosis in later life  | Schizophrenia Bulletin   | Wrong publication type           |
| 2020                | Gosek et al.        | Factors Influencing Length of Stay of Forensic Patients: Impact of Clinical and Psychosocial Variables in Medium Secure Setting  | Frontiers in Psychiatry  | No TRS assessment                |
| 2020                | Hariman et al.      | Clinical risk model to predict 28-day unplanned readmission via the accident and emergency department after discharge from acute psychiatric units for patients with psychotic spectrum disorders  | BJPsych open   | No TRS assessment                |
| 2020                | Hatzimanolis et al. | Familial and socioeconomic contributions to premorbid functioning in psychosis: Impact on age at onset and treatment response  | European Psychiatry  | No TRS assessment                |
| 2020                | He , et al.         | The role of cytokines in predicting the efficacy of acute stage treatment in patients with schizophrenia   | Neuropsychiatric Disease and Treatment                         | No TRS assessment                |
| 2020                | Hochberger et al.   | Deviation from expected cognitive ability is a core cognitive feature of schizophrenia related to neurophysiologic, clinical and psychosocial functioning  | Schizophrenia research   | No TRS assessment                |
| 2020                | Iasevoli et al.     | Relationships between age at onset of psychotic symptoms and poor response to antipsychotics in a sample of TRS/non-TRS patients   | Schizophrenia Bulletin   | Wrong publication type           |
| 2020                | Kelleher et al.     | Prevalence of N-Methyl-D-Aspartate Receptor antibody (NMDAR-Ab) encephalitis in patients with first episode psychosis and treatment resistant schizophrenia on clozapine, a population based study | Schizophrenia Research   | Insufficient or Wrong population |
| 2020                | Kim et al.          | EEG Source Network for the Diagnosis of Schizophrenia and the Identification of Subtypes Based on Symptom Severity- A Machine Learning Approach  | Journal of Clinical Medicine                                   | No TRS assessment                |
| 2020                | Kudo et al.         | Plasma levels of matrix metalloproteinase-9 (MMP-9) are associated with cognitive performance in patients with schizophrenia   | Neuropsychopharmacology Reports                                | No TRS assessment                |
| 2020                | Lin et al.          | Temporal trends in clozapine use at time of discharge among people with schizophrenia at   | Scientific reports   | No TRS assessment                |

| Year of publication | First author            | Title   | Journal                                   | Reason for exclusion                                     |
|---------------------|-------------------------|---|---|--|
|                     |                         | two public psychiatric hospitals in Taiwan, 2006-2017   |   |  |
| 2020                | Lindenmayer et al.      | Impaired clinical insight as a predictor of relapse in schizophrenia  | Schizophrenia Bulletin                    | Wrong publication type                                   |
| 2020                | Lindgren et al.         | Neurocognition and Social Cognition Predicting 1-Year Outcomes in First-Episode Psychosis   | Frontiers in Psychiatry                   | No TRS assessment  |
| 2020                | Liu et al.              | Ten-year follow-up after first episode psychosis: Focused on low dose antipsychotic maintenance and functioning   | Schizophrenia Bulletin                    | Wrong publication type                                   |
| 2020                | Lizano et al.           | Trajectory of neurological examination abnormalities in antipsychotic-naïve first-episode psychosis population: a 1 year follow-up study  | Psychological medicine                    | No TRS assessment  |
| 2020                | Luisa et al.            | The role of ace as possible biomarker for treatment resistance to antipsychotics in first episode of psychosis  | Schizophrenia Bulletin                    | Wrong publication type                                   |
| 2020                | Makowski et al.         | Probing Myelin in First Episode of Psychosis With MRI: A Framework to Understand Negative Symptoms and Verbal Memory  | Biological Psychiatry                     | Wrong publication type                                   |
| 2020                | Masvidal et al.         | P526 Structural covariance networks predict clinical outcome in first-episode psychosis   | European Neuropsychopharmacology          | Wrong publication type                                   |
| 2020                | Miley et al.            | Causal relationships between empathy, motivation and functional outcomes in early schizophrenia identified with causal discovery modeling   | Schizophrenia Bulletin                    | Wrong publication type                                   |
| 2020                | Nikolac et al.          | Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia   | Scientific reports                        | No TRS assessment  |
| 2020                | Oh et al.               | Effectiveness of antipsychotic drugs in schizophrenia: a 10-year retrospective study in a Korean tertiary hospital  | npj Schizophrenia                         | No TRS assessment  |
| 2020                | Onu et al.              | Using Data From Schizophrenia Outcome Study to Estimate the Time to Treatment Outcome and the Early-Response Cut-Off Score That Predicts Outcome at Week 16                       | Biological Psychiatry                     | No TRS assessment  |
| 2020                | Onu et al.              | Naturalistic clinical and psychosocial outcome of incident cases of schizophrenia in Enugu Federal Psychiatric Hospital: A preliminary report at 4-month follow-up                | The Nigerian postgraduate medical journal | Insufficient trials / duration or lacking AP information |
| 2020                | Ortiz et al.            | A symptom combination predicting treatment-resistant schizophrenia – A strategy for real-world clinical practice  | Schizophrenia Research                    | Overlapping sample                                       |
| 2020                | Rey et al.              | Overexpression of complement component C4 in the dorsolateral prefrontal cortex, parietal cortex, superior temporal gyrus and associative striatum of patients with schizophrenia | Brain, Behavior, and Immunity             | No TRS assessment  |
| 2020                | Rodrigues-Amorim et al. | Plasma $\alpha$ -III tubulin, neurofilament light chain and glial fibrillary acidic protein are associated with neurodegeneration and progression in schizophrenia                | Scientific reports                        | No TRS assessment  |
| 2020                | Rohde et al.            | Antipsychotic medication exposure, clozapine, and pneumonia: results from a self-controlled study   | Acta Psychiatrica Scandinavica            | No TRS assessment  |
| 2020                | Rowntree et al.         | Clozapine use - has practice changed?   | Journal of Psychopharmacology             | Insufficient trials / duration or lacking AP information |
| 2020                | Saiz-Masvidal et al.    | Structural covariance predictors of clinical improvement at 2-year follow-up in first-episode psychosis   | Schizophrenia Bulletin                    | Wrong publication type                                   |

| Year of publication | First author              | Title   | Journal  | Reason for exclusion                                     |
|---------------------|---------------------------|---|--|--|
| 2020                | Schennach et al.          | What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a "real-world" 2-year follow-up trial                   | European Archives of Psychiatry and Clinical Neuroscience  | No TRS assessment  |
| 2020                | Sommer et al.             | The clinical course of schizophrenia in women and men-a nation-wide cohort study  | npj Schizophrenia  | No TRS assessment  |
| 2020                | Stokes et al.             | Prevalence of treatment resistance and clozapine use in early intervention services   | BJPsych open   | Insufficient or Wrong population                         |
| 2020                | Taipale et al.            | Comparative effectiveness of antipsychotics for risk of attempted or completed suicide among persons with schizophrenia   | Pharmacoepidemiology and Drug Safety   | Wrong publication type                                   |
| 2020                | Taipale et al.            | Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences  | Nordic Journal of Psychiatry   | No TRS assessment  |
| 2020                | Taipale et al.            | 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20) | World Psychiatry   | No TRS assessment  |
| 2020                | Tarumi et al.             | Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study                          | Neuropsychopharmacology  | Insufficient or Wrong population                         |
| 2020                | Teferra                   | Initiating clozapine treatment service and characteristics of clozapine-treated patients in a general hospital in Addis Ababa, Ethiopia                                     | South African Journal of Psychiatry  | No TRS assessment  |
| 2020                | Ucok et al.               | To whom we prescribe long acting antipsychotics at discharge from hospital?   | Schizophrenia Bulletin   | Wrong publication type                                   |
| 2020                | van der Pluijm et al.     | P523 Neuromelanin MRI as biomarker for treatment resistance in first episode schizophrenia patients   | European Neuropsychopharmacology   | Wrong publication type                                   |
| 2020                | van der Zalm et al.       | Clozapine and mortality: A comparison with other antipsychotics in a nationwide Danish cohort study   | Acta Psychiatrica Scandinavica   | No TRS assessment  |
| 2020                | van der Zalm et al.       | Use of cardiovascular and antidiabetic drugs before and after starting with clozapine versus other antipsychotic drugs: a Dutch database study                              | International clinical psychopharmacology  | No TRS assessment  |
| 2020                | Vázquez-Bourgon et al.    | A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients              | European Neuropsychopharmacology   | Insufficient trials / duration or lacking AP information |
| 2020                | Villasante-Tezanos et al. | Pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-resistant schizophrenia  | Acta Psychiatrica Scandinavica   | No TRS assessment  |
| 2020                | Xenaki et al.             | Organization framework and preliminary findings from the Athens First-Episode Psychosis Research Study  | Early Intervention in Psychiatry   | No TRS assessment  |
| 2020                | Xu et al.                 | Predictors of outcome in early onset schizophrenia: a 10-year follow-up study   | BMC psychiatry   | Insufficient or Wrong population                         |
| 2020                | Xu et al.                 | Clozapine prescription pattern in patients with schizophrenia in Asia: The REAP survey (2016)   | Psychiatry Research  | Insufficient or Wrong population                         |
| 2020                | Yi et al.                 | Clozapine use in patients with early-stage schizophrenia in a chinese psychiatric hospital  | Neuropsychiatric Disease and Treatment   | No TRS assessment  |
| 2020                | Zeng et al.               | A preliminary study on schizophrenia of distinct antipsychotic response based on diffusion tensor imaging   | Sheng Wu Yi Xue Gong Cheng Xue za Zhi = Journal of Biomedical Engineering = Shengwu Yixue Gongchengxue Zazhi | Insufficient trials / duration or lacking AP information |

| Year of publication | First author            | Title   | Journal  | Reason for exclusion             |
|---------------------|-------------------------|---|--|----------------------------------|
| 2020                | Zhu et al.              | Drug-naive first-episode schizophrenia spectrum disorders: Pharmacological treatment practices in inpatient units in Hunan Province, China  | Schizophrenia Bulletin                                       | No TRS assessment                |
| 2020                | Zuschlag et al.         | Clozapine utilization at the United States Veterans Health Administration: A descriptive report of prescribing patterns and patient characteristics among Operation Enduring Freedom/Operation Iraqi Freedom Veterans | International Clinical Psychopharmacology                    | Insufficient or Wrong population |
| 2019                | Agid et al.             | Treatment-resistant schizophrenia (TRS): Subtypes and trajectories of response to clozapine   | Neuropsychopharmacology                                      | Wrong publication type           |
| 2019                | Arsalan et al.          | Association of smoked cannabis with treatment resistance in schizophrenia   | Psychiatry Research  | No TRS assessment                |
| 2019                | Bardell-Williams et al. | Rates, determinants and outcomes associated with the use of community treatment orders in young people experiencing first episode psychosis   | International Journal of Law and Psychiatry                  | Overlapping sample               |
| 2019                | Beck et al.             | Prevalence of treatment-resistant psychoses in the community: A naturalistic study  | Journal of Psychopharmacology                                | Overlapping sample               |
| 2019                | Bellay et al.           | 8 years' evolution of antipsychotics prescriptions in a mental health public institution  | European Journal of Hospital Pharmacy                        | Wrong publication type           |
| 2019                | Breitborde et al.       | Specialized, multi-component care for individuals with first-episode psychosis: Effects on autonomy, competence and relatedness   | Early Intervention in Psychiatry                             | No TRS assessment                |
| 2019                | Bugarski-Kirola et al.  | ENHANCE: A phase 3, randomized, double-blind, placebo-controlled study of adjunctive pimavanserin for treatment of schizophrenia in patients with an inadequate response to antipsychotic treatment                   | Neuropsychopharmacology                                      | Wrong publication type           |
| 2019                | Cho et al.              | Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study   | Acta Psychiatrica Scandinavica                               | Overlapping sample               |
| 2019                | Correll et al.          | Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists   | BMC psychiatry   | No TRS assessment                |
| 2019                | Correll et al.          | Exploration of treatment-resistant schizophrenia subtypes based on a survey of 204 US psychiatrists   | Neuropsychiatric Disease and Treatment                       | No TRS assessment                |
| 2019                | Dania , et al.          | Effect of atypical antipsychotic on blood pressure in inpatients with schizophrenia of Prof Dr Soerojo Mental Health Hospital Magelang  | Journal of Pharmacy and Bioallied Sciences                   | No TRS assessment                |
| 2019                | Emsley et al.           | Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia   | Schizophrenia research                                       | No TRS assessment                |
| 2019                | Fang et al.             | Associations among antipsychotics, metabolism-related diseases, and cataracts in patients with schizophrenia: A retrospective cohort study  | Schizophrenia research                                       | No TRS assessment                |
| 2019                | Fond et al.             | Illness and drug modifiable factors associated with violent behavior in homeless people with severe mental illness: results from the French Housing First (FHF) program   | Progress in neuro-psychopharmacology & biological psychiatry | No TRS assessment                |
| 2019                | Fond et al.             | Hypovitaminosis D is associated with negative symptoms, suicide risk, agoraphobia, impaired functional remission, and antidepressant consumption in schizophrenia   | European archives of psychiatry and clinical neuroscience    | No TRS assessment                |
| 2019                | Fond et al.             | Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia Results from the FACE-SZ cohort  | European archives of psychiatry and clinical neuroscience    | Insufficient or Wrong population |

| Year of publication | First author        | Title   | Journal   | Reason for exclusion                                     |
|---------------------|---------------------|---|---|--|
| 2019                | Fomer et al.        | Genetic and biochemical biomarkers related to oxidative stress in patients with schizophrenia   | Genetics and Molecular Research                                   | Overlapping sample                                       |
| 2019                | Gasse et al.        | Schizophrenia polygenic risk scores, urbanicity and treatment-resistant schizophrenia   | Schizophrenia research  | Overlapping sample                                       |
| 2019                | Hajj et al.         | Clinical and Genetic Factors Associated with Resistance to Treatment in Patients with Schizophrenia: A Case-Control Study   | International journal of molecular sciences                       | Insufficient or Wrong population                         |
| 2019                | Hallgren et al.     | Exercise effects on cognitive functioning in young adults with first-episode psychosis: FitForLife  | Psychological medicine  | Insufficient trials / duration or lacking AP information |
| 2019                | Holt et al.         | Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): Randomised controlled trial                            | British Journal of Psychiatry                                     | No TRS assessment  |
| 2019                | Hou et al.          | Psychotropic medication treatment patterns in community-dwelling schizophrenia in China: comparisons between rural and urban areas  | BMC psychiatry  | No TRS assessment  |
| 2019                | Howes               | The dopaminergic sub-type hypothesis of psychosis and treatment response: New in vivo evidence  | Neuropsychopharmacology   | Wrong publication type                                   |
| 2019                | Iruetagoiena et al. | High prevalence of metabolic alterations in Latin American patients at initial stages of psychosis  | Early intervention in psychiatry                                  | No TRS assessment  |
| 2019                | Jönsson et al.      | Identifying and characterizing treatment-resistant schizophrenia in observational database studies  | Int J Methods Psychiatr Res                                       | Insufficient or Wrong population                         |
| 2019                | Julaeha et al.      | The prescription patterns of second-generation antipsychotics in schizophrenia outpatient setting   | Journal of basic and clinical physiology and pharmacology         | Insufficient trials / duration or lacking AP information |
| 2019                | Kesserwani et al.   | Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine  | Journal of psychopharmacology                                     | No TRS assessment  |
| 2019                | Kim et al.          | Frontostriatal functional connectivity and striatal dopamine synthesis capacity in schizophrenia in terms of antipsychotic responsiveness: an [(18)F]DOPA PET and fMRI study          | Psychological medicine  | Insufficient or Wrong population                         |
| 2019                | Kochunov et al.     | White Matter in Schizophrenia Treatment Resistance  | The American journal of psychiatry                                | Insufficient or Wrong population                         |
| 2019                | Kokurcan et al.     | Comparison of clinical characteristics between the patients with schizophrenia on clozapine treatment with those taking combination of long-acting injectable and oral antipsychotics | Noropsikiyatri Arsivi   | Insufficient or Wrong population                         |
| 2019                | Kowalec et al.      | Increased schizophrenia family history burden and reduced premorbid IQ in treatment-resistant schizophrenia: a Swedish National Register and Genomic Study                            | Molecular psychiatry  | Wrong publication type                                   |
| 2019                | Kravariti et al.    | Neuropsychological function at first episode in treatment-resistant psychosis: findings from the ÆSOP-10 study  | Psychological medicine  | Overlapping sample                                       |
| 2019                | Krivoy et al.       | [There Is Room for Improvement: the Rate of Clozapine Use Among Patients With Schizophrenia in Israel]  | Harefuah  | No TRS assessment  |
| 2019                | Krivoy et al.       | Real-World Outcomes in the Management of Refractory Psychosis   | The Journal of clinical psychiatry                                | Insufficient or Wrong population                         |
| 2019                | Krzystanek et al.   | Risk Factors for Noncompliance with Antipsychotic Medication in Long-Term Treated Chronic Schizophrenia Patients  | Psychiatria Danubina  | Insufficient or Wrong population                         |
| 2019                | Legge et al.        | Clinical indicators of treatment-resistant psychosis  | The British journal of psychiatry : the journal of mental science | No TRS assessment  |

| Year of publication | First author        | Title   | Journal   | Reason for exclusion                                     |
|---------------------|---------------------|---|---|--|
| 2019                | Leppik et al.       | Profiling of lipidomics before and after antipsychotic treatment in first-episode psychosis   | European Archives of Psychiatry and Clinical Neuroscience | Insufficient trials / duration or lacking AP information |
| 2019                | Lho et al.          | Predicting prognosis in patients with first-episode psychosis using auditory P300: A 1-year follow-up study   | Clinical Neurophysiology                                  | Wrong publication type                                   |
| 2019                | Li , et al.         | Association of serotonin <sub>2C</sub> receptor polymorphisms with antipsychotic drug response in schizophrenia   | Frontiers in Psychiatry                                   | No TRS assessment  |
| 2019                | Lin et al.          | Severity in sustained attention impairment and clozapine-resistant schizophrenia: a retrospective study   | BMC psychiatry  | Insufficient or Wrong population                         |
| 2019                | Lin et al.          | Long-term Use of Clozapine is Protective for Bone Density in Patients with Schizophrenia  | Scientific reports  | No TRS assessment  |
| 2019                | Lisshammar , et al. | The immunomodulatory effect of clozapine in patients with treatment resistant schizophrenia: A retrospective cohort study   | Journal of Neurology, Neurosurgery and Psychiatry         | Wrong publication type                                   |
| 2019                | Lizano et al.       | Trajectory of neurological examination abnormalities in antipsychotic-naïve first-episode psychosis population: a 1 year follow-up study  | Psychological medicine                                    | Insufficient trials / duration or lacking AP information |
| 2019                | Luckhoff et al.     | Relationship between changes in metabolic syndrome constituent components over 12 months of treatment and cognitive performance in first-episode schizophrenia                    | Metabolic Brain Disease                                   | Insufficient trials / duration or lacking AP information |
| 2019                | Malaspina et al.    | Features of schizophrenia following premorbid eating disorders  | Psychiatry research                                       | No TRS assessment  |
| 2019                | Martinuzzi et al.   | Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study   | Translational Psychiatry                                  | Overlapping sample                                       |
| 2019                | Mørup et al.        | Pmh35 a Modelling Approach To Estimate the Prevalence of Treatment-Resistant Schizophrenia in the United States   | Value in Health   | Wrong publication type                                   |
| 2019                | Nakajima et al.     | Glutamatergic neurometabolite levels in patients with severe treatment-resistant schizophrenia: A cross-sectional 3T proton magnetic resonance spectroscopy study                 | Neuropsychopharmacology                                   | No TRS assessment  |
| 2019                | Naneishvili et al.  | Assessment of Intelligence in Patients With Schizophrenia Manifested in Childhood and Adolescence   | Georgian medical news                                     | No TRS assessment  |
| 2019                | Nettis et al.       | Metabolic-inflammatory status as predictor of clinical outcome at 1-year follow-up in patients with first episode psychosis   | Psychoneuroendocrinology                                  | Overlapping sample                                       |
| 2019                | O'Keeffe et al.     | The iHOPE-20 study: Relationships between and prospective predictors of remission, clinical recovery, personal recovery and resilience 20 years on from a first episode psychosis | Australian and New Zealand Journal of Psychiatry          | Insufficient trials / duration or lacking AP information |
| 2019                | Oluwoye et al.      | Impact of tobacco, alcohol and cannabis use on treatment outcomes among patients experiencing first episode psychosis: Data from the national RAISE-ETP study                     | Early Intervention in Psychiatry                          | No TRS assessment  |
| 2019                | Park et al.         | Establishing the cut-off scores for the severity ranges of schizophrenia on the BPRS-6 scale: findings from the REAP-AP   | Psychiatry and Clinical Psychopharmacology                | No TRS assessment  |
| 2019                | Ringen et al.       | Predictors for antipsychotic dosage change in the first year of treatment in schizophrenia spectrum and bipolar disorders   | Frontiers in Psychiatry                                   | Insufficient trials / duration or lacking AP information |
| 2019                | Samara et al.       | How many patients with schizophrenia do not respond to antipsychotic drugs in the short term?   | Schizophrenia Bulletin                                    | Overlapping sample                                       |



| Year of publication | First author           | Title  | Journal   | Reason for exclusion                                     |
|---------------------|------------------------|--|---|--|
|                     |                        | An analysis based on individual patient data from randomized controlled trials   |   |  |
| 2019                | Shah et al.            | Drug utilization study of antipsychotic drugs in the psychiatry outpatient department of a tertiary care hospital  | National Journal of Physiology, Pharmacy and Pharmacology | No TRS assessment  |
| 2019                | Smart et al.           | T66 Predicting treatment resistant schizophrenia at first-episode of psychosis   | Schizophr Bull  | Wrong publication type                                   |
| 2019                | Stralin et al.         | Early recovery and employment outcome 13 years after first episode psychosis   | Psychiatry Research                                       | Insufficient trials / duration or lacking AP information |
| 2019                | Strauss et al.         | Network Analysis Reveals Which Negative Symptom Domains Are Most Central in Schizophrenia vs Bipolar Disorder  | Schizophrenia Bulletin                                    | Insufficient trials / duration or lacking AP information |
| 2019                | Sun et al.             | The mediating effect of family function and medication adherence between symptoms and mental disability among Chinese patients with schizophrenia: a cross-sectional study | Psychology, health & medicine                             | Insufficient trials / duration or lacking AP information |
| 2019                | Swets et al.           | Longitudinal association between motor and obsessive compulsive symptoms in patients with psychosis and their unaffected siblings  | European archives of psychiatry and clinical neuroscience | No TRS assessment  |
| 2019                | Takács et al.          | Comparative effectiveness of second generation long-acting injectable antipsychotics based on nationwide database research in Hungary                                      | PloS one  | No TRS assessment  |
| 2019                | Takeuchi et al.        | Does relapse contribute to treatment resistance? Antipsychotic response in first- vs second-episode schizophrenia  | Neuropsychopharmacology                                   | Wrong publication type                                   |
| 2019                | Tiihonen et al.        | Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia  | JAMA psychiatry   | No TRS assessment  |
| 2019                | Toto et al.            | Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study  | The international journal of neuropsychopharmacology      | No TRS assessment  |
| 2019                | van der Pluijm et al.  | Plasma dopa decarboxylase activity in treatment-resistant recent-onset psychosis patients  | Therapeutic Advances in Psychopharmacology                | Insufficient or Wrong population                         |
| 2019                | Vázquez-Bourgon et al. | Effect of cannabis on weight and metabolism in first-episode non-affective psychosis: Results from a three-year longitudinal study   | Journal of psychopharmacology (Oxford, England)           | No TRS assessment  |
| 2019                | Velasco , et al.       | Prevalence of prescription of antipsychotic polypharmacy in a psychiatric hospital   | European Journal of Hospital Pharmacy                     | Wrong publication type                                   |
| 2019                | Ventriglio et al.      | Metabolic syndrome in psychotic disorder patients treated with oral and long-acting injected antipsychotics  | Frontiers in Psychiatry                                   | No TRS assessment  |
| 2019                | Verdoux et al.         | Functioning and cognitive characteristics of clozapine users referred to psychosocial rehabilitation centers: A REHABase cohort study                                      | Psychiatry research                                       | Insufficient or Wrong population                         |
| 2019                | Wannan et al.          | Evidence for Network-Based Cortical Thickness Reductions in Schizophrenia  | The American journal of psychiatry                        | Insufficient or Wrong population                         |
| 2019                | Weiser et al.          | Real-world effectiveness of antipsychotic treatments in 37,368 patients with schizophrenia in the US VA system   | Neuropsychopharmacology                                   | Wrong publication type                                   |
| 2019                | Wessels et al.         | Predictors of treatment response to psychological interventions in people at clinical high risk of first-episode psychosis   | Early Intervention in Psychiatry                          | Insufficient trials / duration or lacking AP information |
| 2019                | Woo et al.             | Switching antipsychotics to blonanserin in patients with schizophrenia: An open-label, prospective, multicenter study  | Clinical Psychopharmacology and Neuroscience              | No TRS assessment  |

| Year of publication | First author         | Title  | Journal                          | Reason for exclusion                                     |
|---------------------|----------------------|--|----------------------------------|--|
| 2019                | Xiong et al.         | Association of blood cell counts with the risk of olanzapine- or clozapine-induced dyslipidemia in Chinese schizophrenia patients  | Human psychopharmacology         | Insufficient or Wrong population                         |
| 2019                | Xu et al.            | Clozapine prescription pattern in patients with schizophrenia in Asia: The REAP survey (2016)  | Psychiatry research              | No TRS assessment  |
| 2019                | Yoshimura et al.     | Predictors of remission in the acute treatment of first-episode schizophrenia involuntarily hospitalized and treated with an algorithm-based pharmacotherapy: Secondary analysis of an observational study | Early Interv Psychiatry          | No TRS assessment  |
| 2019                | Yoshimura et al.     | Algorithm-based pharmacotherapy for first-episode schizophrenia involuntarily hospitalized: A retrospective analysis of real-world practice  | Early Interv Psychiatry          | No TRS assessment  |
| 2019                | Zhang et al.         | Schizophrenia polygenic risk score as a predictor of antipsychotic efficacy in first-episode psychosis   | American Journal of Psychiatry   | Insufficient trials / duration or lacking AP information |
| 2019                | Zhang et al.         | Prescription practices in the treatment of agitation in newly hospitalized Chinese schizophrenia patients: data from a non-interventional naturalistic study   | BMC psychiatry                   | No TRS assessment  |
| 2018                | Abdel-Baki et al.    | Immigrants' outcome after a first-episode psychosis  | Early Intervention in Psychiatry | Insufficient trials / duration or lacking AP information |
| 2018                | Ajnakina et al.      | Treatment resistant schizophrenia and gyrification-based connectome  | Schizophrenia Bulletin           | Wrong publication type                                   |
| 2018                | Ajnakina et al.      | Validation of an algorithm-based definition of treatment resistance in patients with schizophrenia   | Schizophrenia Research           | Overlapping sample                                       |
| 2018                | Ajnakina et al.      | Utilising symptom dimensions with diagnostic categories improves prediction of time to first remission in first-episode psychosis  | Schizophrenia Research           | Overlapping sample                                       |
| 2018                | Ajnakina et al.      | Different types of childhood adversity and 5-year outcomes in a longitudinal cohort of first-episode psychosis patients  | Psychiatry Research              | Overlapping sample                                       |
| 2018                | Allott et al.        | Stress hormones and verbal memory in young people over the first 12 weeks of treatment for psychosis   | Psychiatry Research              | Overlapping sample                                       |
| 2018                | Austin et al.        | Persistent negative symptoms in first episode psychosis: Prevalence, predictors and prognosis  | Schizophrenia Bulletin           | Wrong publication type                                   |
| 2018                | Ayasa-Arriola et al. | The dynamic relationship between insight and suicidal behavior in first episode psychosis patients over 3-year follow-up   | European Neuropsychopharmacology | Insufficient trials / duration or lacking AP information |
| 2018                | Bergstrom et al.     | The family-oriented open dialogue approach in the treatment of first-episode psychosis: Nineteen-year outcomes   | Psychiatry Research              | No TRS assessment  |
| 2018                | Bertolucci et al.    | Does treatment resistant schizophrenia present a characteristic symptomatic signature?   | Schizophrenia Bulletin           | Wrong publication type                                   |
| 2018                | Bowie et al.         | Cognitive and functional deficits in bipolar disorder and schizophrenia as a function of the presence and history of psychosis   | Bipolar Disorders                | Insufficient trials / duration or lacking AP information |
| 2018                | Breitborde et al.    | An uncontrolled trial of multi-component care for first-episode psychosis: Effects on social cognition   | Early Intervention in Psychiatry | No TRS assessment  |
| 2018                | Browne et al.        | Character strengths of individuals with first episode psychosis in Individual Resiliency Training  | Schizophrenia Research           | Insufficient trials / duration or lacking AP information |
| 2018                | Chang et al.         | Patterns and predictors of trajectories for social and occupational functioning in patients  | Schizophrenia Research           | Insufficient trials / duration or lacking AP information |

| Year of publication | First author          | Title   | Journal  | Reason for exclusion                                     |
|---------------------|-----------------------|---|--|--|
|                     |                       | presenting with first-episode non-affective psychosis: A three-year follow-up study   |  |  |
| 2018                | Chang et al.          | Motivational impairment predicts functional remission in first-episode psychosis: 3-Year follow-up of the randomized controlled trial on extended early intervention                          | Australian and New Zealand Journal of Psychiatry               | Insufficient trials / duration or lacking AP information |
| 2018                | Chen et al.           | The effect of early medication discontinuation on long-term clinical outcome in first episode psychosis   | Schizophrenia Bulletin   | Wrong publication type                                   |
| 2018                | Chong et al.          | Predictors of functioning in people suffering from first-episode psychosis 1 year into entering early intervention service in Hong Kong   | Early Intervention in Psychiatry                               | Insufficient trials / duration or lacking AP information |
| 2018                | Cuesta et al.         | Motor abnormalities in first-episode psychosis patients and long-term psychosocial functioning  | Schizophrenia Research   | No TRS assessment  |
| 2018                | de Bartolomeis et al. | Treatment resistant schizophrenia and neurological soft signs may converge on the same pathology: Evidence from explanatory analysis on clinical, psychopathological, and cognitive variables | Progress in Neuro-Psychopharmacology and Biological Psychiatry | Overlapping sample                                       |
| 2018                | de Moura et al.       | Corpus callosum volumes in the 5years following the first-episode of schizophrenia: Effects of antipsychotics, chronicity and maturation  | NeuroImage: Clinical   | Insufficient trials / duration or lacking AP information |
| 2018                | Delbert et al.        | Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention  | The American journal of psychiatry                             | No TRS assessment  |
| 2018                | Dempster et al.       | Defining treatment response and resistance in first episode schizophrenia   | Schizophrenia Bulletin   | Wrong publication type                                   |
| 2018                | Drosos et al.         | One-year outcome and use of clozapine in first-episode schizophrenia  | Schizophrenia Bulletin   | Wrong publication type                                   |
| 2018                | Favrod et al.         | Electrophysiological correlates of visual backward masking in patients with first episode psychosis   | Psychiatry Research - Neuroimaging                             | Insufficient or Wrong population                         |
| 2018                | Firth et al.          | Exercise as an intervention for first-episode psychosis: a feasibility study  | Early Intervention in Psychiatry                               | Insufficient trials / duration or lacking AP information |
| 2018                | Fulford et al.        | Prospective relationships between motivation and functioning in recovery after a first episode of schizophrenia   | Schizophrenia Bulletin   | Insufficient trials / duration or lacking AP information |
| 2018                | Ganella et al.        | Resting-state functional brain networks in first-episode psychosis: A 12-month follow-up study  | Australian and New Zealand Journal of Psychiatry               | Insufficient or Wrong population                         |
| 2018                | Gardsjord et al.      | Depression and functioning are important to subjective quality of life after a first episode psychosis  | Comprehensive Psychiatry                                       | Insufficient trials / duration or lacking AP information |
| 2018                | Gardsjord et al.      | Is going into stable symptomatic remission associated with a more positive development of life satisfaction? A 10-year follow-up study of first episode psychosis                             | Schizophrenia Research   | No TRS assessment  |
| 2018                | Gearing et al.        | First-episode psychosis: Ongoing mental health service utilization during the stable period for adolescents   | Early Intervention in Psychiatry                               | No TRS assessment  |
| 2018                | Gjerde et al.         | Increase in serum HDL level is associated with less negative symptoms after one year of antipsychotic treatment in first-episode psychosis  | Schizophrenia Research   | No TRS assessment  |
| 2018                | Hajebi et al.         | Twelve-month course and outcome of methamphetamine-induced psychosis compared with first episode primary psychotic disorders  | Early Intervention in Psychiatry                               | No TRS assessment  |

| Year of publication | First author          | Title  | Journal  | Reason for exclusion                                     |
|---------------------|-----------------------|--|--|--|
| 2018                | Hui et al.            | Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial   | The Lancet Psychiatry                            | Insufficient or Wrong population                         |
| 2018                | Iasevoli et al.       | Disease Severity in Treatment Resistant Schizophrenia Patients Is Mainly Affected by Negative Symptoms, Which Mediate the Effects of Cognitive Dysfunctions and Neurological Soft Signs  | Frontiers in Psychiatry                          | Overlapping sample                                       |
| 2018                | Iasevoli et al.       | Clinical evaluation of functional capacity in treatment resistant schizophrenia patients: Comparison and differences with non-resistant schizophrenia patients   | Schizophrenia Research                           | Overlapping sample                                       |
| 2018                | Jauhar et al.         | Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study   | Molecular Psychiatry                             | Insufficient or Wrong population                         |
| 2018                | Jordan et al.         | Pathways to functional outcomes following a first episode of psychosis: The roles of premorbid adjustment, verbal memory and symptom remission   | Australian and New Zealand Journal of Psychiatry | No TRS assessment  |
| 2018                | Joyce et al.          | Incidence of treatment resistance schizophrenia in a community sample using the tripp consensus  | Schizophrenia Bulletin                           | Wrong publication type                                   |
| 2018                | Kahn                  | Optimising the treatment and management of first-episode schizophrenia: The optimise clinical trial  | Schizophrenia Bulletin                           | Wrong publication type                                   |
| 2018                | Kahn et al.           | Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study  | The Lancet Psychiatry                            | Insufficient trials / duration or lacking AP information |
| 2018                | Kaminga et al.        | Rate of and time to symptomatic remission in first-episode psychosis in Northern Malawi: A STROBE-compliant article  | Medicine   | No TRS assessment  |
| 2018                | Kanahara et al.       | First-episode psychosis in treatment-resistant schizophrenia: a cross-sectional study of a long-term follow-up cohort  | BMC Psychiatry                                   | Overlapping sample                                       |
| 2018                | Karambelas et al.     | The contribution of employment duration to 18-month neurocognitive outcomes in first-episode psychosis   | Psychiatric rehabilitation journal               | No TRS assessment  |
| 2018                | Keymer-Gausset et al. | Gray and white matter changes and their relation to illness trajectory in first episode psychosis  | European Neuropsychopharmacology                 | No TRS assessment  |
| 2018                | Kingston et al.       | Functional outcome and service engagement in major depressive disorder with psychotic features: comparisons with schizophrenia, schizoaffective disorder and bipolar disorder in a 6-year follow-up of the Cavan-Monaghan First Episode Psychosis Study (CAMFEP) | CNS Neuroscience and Therapeutics                | No TRS assessment  |
| 2018                | Kinson et al.         | Stigma and discrimination in individuals with first episode psychosis   one year after first contact with psychiatric services   | Psychiatry Research                              | No TRS assessment  |
| 2018                | Kuzman et al.         | Effects of long-term multimodal psychosocial treatment on antipsychotic-induced metabolic changes in patients with first episode psychosis   | Frontiers in Psychiatry                          | No TRS assessment  |
| 2018                | Laidlaw et al.        | Trace elements concentrations association with schizophrenia symptoms  | Psychiatria Danubina                             | No TRS assessment  |
| 2018                | Langeveld et al.      | A 10-year follow-up study of violent victimization in first episode psychosis: Risk and protective factors   | Psychiatry Research                              | No TRS assessment  |
| 2018                | Lappin et al.         | Early sustained recovery following first episode psychosis: Evidence from the AESOP10 follow-up study  | Schizophrenia Research                           | No TRS assessment  |

| Year of publication | First author          | Title   | Journal   | Reason for exclusion                                     |
|---------------------|-----------------------|---|---|--|
| 2018                | Leppik et al.         | Profiling of amino acids and their derivatives biogenic amines before and after antipsychotic treatment in first-episode psychosis                                  | Frontiers in Psychiatry                                   | No TRS assessment  |
| 2018                | Lik et al.            | Antipsychotic prescribing patterns on admission to and at discharge from a tertiary care program for treatment-resistant psychosis                                  | PLoS ONE  | No TRS assessment  |
| 2018                | Lopez-Morinigo et al. | Insight and risk of suicidal behaviour in two first-episode psychosis cohorts: Effects of previous suicide attempts and depression                                  | Schizophrenia Research                                    | No TRS assessment  |
| 2018                | Lyngstad et al.       | Consequences of persistent depression and apathy in first-episode psychosis - A one-year follow-up study  | Comprehensive Psychiatry                                  | No TRS assessment  |
| 2018                | Malinowski et al.     | Investigation of formal thought disorder and response to treatment in schizophrenia   | Schizophrenia Bulletin                                    | Wrong publication type                                   |
| 2018                | Malla et al.          | Outcome in patients converting to psychosis following a treated clinical high risk state  | Early Intervention in Psychiatry                          | Insufficient or Wrong population                         |
| 2018                | Marise et al.         | Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study        | Schizophrenia research                                    | No TRS assessment  |
| 2018                | Medrano et al.        | Three-Year Naturalistic Study On Early Use Of Long-Acting Injectable Antipsychotics In First Episode Psychosis  | Psychopharmacology bulletin                               | Insufficient trials / duration or lacking AP information |
| 2018                | Mohn et al.           | Details of attention and learning change in first-episode schizophrenia.  | Psychiatry Research                                       | Insufficient trials / duration or lacking AP information |
| 2018                | Morrison et al.       | Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study | The Lancet Psychiatry                                     | No TRS assessment  |
| 2018                | Mouchlianitis et al.  | Glutamatergic dysfunction and treatment response in minimally treated and chronic schizophrenia patients  | Schizophrenia Bulletin                                    | Wrong publication type                                   |
| 2018                | Nishida et al.        | A randomized controlled trial of comprehensive early intervention care in patients with first-episode psychosis in Japan: 15-year outcomes from the J-CAP study     | Journal of Psychiatric Research                           | No TRS assessment  |
| 2018                | O'Donoghue et al.     | Clozapine: When to start, how to augment and guidelines for management  | Australian and New Zealand Journal of Psychiatry          | Wrong publication type                                   |
| 2018                | O'Keeffe et al.       | Recovery' in the Real World: Service User Experiences of Mental Health Service Use and Recommendations for Change 20 Years on from a First Episode Psychosis        | Administration and policy in mental health                | No TRS assessment  |
| 2018                | Oluwoye et al.        | Racial-ethnic disparities in first-episode psychosis treatment outcomes from the RAISE-ETP study  | Psychiatric Services                                      | No TRS assessment  |
| 2018                | Pelayo-Teran et al.   | Duration of active psychosis and functional outcomes in first-episode non-affective psychosis   | European Psychiatry                                       | No TRS assessment  |
| 2018                | Puntis et al.         | Discharge pathways and relapse following treatment from early intervention in psychosis services  | BJPsych Open  | No TRS assessment  |
| 2018                | Sanchez-Torres et al. | Individual trajectories of cognitive performance in first episode psychosis: a 2-year follow-up study   | European Archives of Psychiatry and Clinical Neuroscience | No TRS assessment  |
| 2018                | Schwarz et al.        | Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response                                  | Schizophrenia Research                                    | No TRS assessment  |

| Year of publication | First author        | Title   | Journal  | Reason for exclusion                                     |
|---------------------|---------------------|---|--|--|
| 2018                | Shafritz et al.     | Frontal lobe functioning during a simple response conflict task in first-episode psychosis and its relationship to treatment response                                   | Brain Imaging and Behavior                                     | Insufficient trials / duration or lacking AP information |
| 2018                | Simonsen et al.     | Self-rated disability in first treated episode of psychosis: A 1-year follow-up study   | Comprehensive Psychiatry                                       | No TRS assessment  |
| 2018                | Sullivan et al.     | Duration of untreated psychosis and clinical outcomes of first episode psychosis: An observational and an instrumental variables analysis                               | Early Intervention in Psychiatry                               | No TRS assessment  |
| 2018                | Taipale et al.      | Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia - A nationwide study with 20-year follow-up                                     | Schizophrenia Bulletin   | No TRS assessment  |
| 2018                | Treen et al.        | Targeting recovery in first episode psychosis: The importance of neurocognition and premorbid adjustment in a 3-year longitudinal study                                 | Schizophrenia Research   | No TRS assessment  |
| 2018                | van der Zalm et al. | Deployment of dedicated nursing staff to stimulate the initiation of clozapine A cluster-randomized trial   | Schizophrenia Bulletin   | Wrong publication type                                   |
| 2017                | Ajnakina et al.     | Clinical predictors of 2 types of treatment resistance in patients with psychosis   | Schizophrenia Bulletin   | Wrong publication type                                   |
| 2017                | Ajnakina et al.     | Polygenic risk score for schizophrenia is associated with treatment resistant schizophrenia during the first five years after first contact with mental health services | European Neuropsychopharmacology                               | Wrong publication type                                   |
| 2017                | Balotsev et al.     | Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first-episode psychosis patients: A 7-month follow-up study          | Early Intervention in Psychiatry                               | No TRS assessment  |
| 2017                | Bani-Fatemi et al.  | The effect of ethnicity and immigration on treatment resistance in schizophrenia  | Schizophrenia Bulletin   | Wrong publication type                                   |
| 2017                | Bas et al.          | Level of serum thioredoxin and correlation with neurocognitive functions in patients with schizophrenia using clozapine and other atypical antipsychotics               | Psychiatry Res   | No TRS assessment  |
| 2017                | Brostedt et al.     | Health care use, drug treatment and comorbidity in patients with schizophrenia or non-affective psychosis in Sweden: A cross-sectional study                            | BMC Psychiatry   | No TRS assessment  |
| 2017                | Chan et al.         | A case-control study of demographics and clinical predictors of treatment-resistant schizophrenia in patients 12 years after first-episode                              | Schizophrenia Bulletin   | Wrong publication type                                   |
| 2017                | Chen et al.         | Maintenance discontinuation after first episode psychosis may increase treatment non-responsiveness: 10-year follow-up of an RCT  | Schizophrenia Bulletin   | Wrong publication type                                   |
| 2017                | Doyle et al.        | Clozapine Use in a Cohort of First-Episode Psychosis  | J Clin Psychopharmacol   | No TRS assessment  |
| 2017                | Homman et al.       | The importance and challenges of longitudinal studies among patients diagnosed with schizophrenia: Predicting response to antipsychotic medication using strata         | Schizophrenia Bulletin   | Wrong publication type                                   |
| 2017                | Horsdal et al.      | C-reactive protein levels and treatment resistance in schizophrenia-A Danish population-based cohort study  | Human Psychopharmacology                                       | Overlapping sample                                       |
| 2017                | Kriisa et al.       | Profiling of Acylcarnitines in First Episode Psychosis before and after Antipsychotic Treatment   | J Proteome Res   | No TRS assessment  |
| 2017                | Mallet et al.       | Cigarette smoking and schizophrenia: a specific clinical and therapeutic profile? Results from the FACE-Schizophrenia cohort  | Progress in Neuro-Psychopharmacology and Biological Psychiatry | No TRS assessment  |

| Year of publication | First author        | Title  | Journal   | Reason for exclusion                                     |
|---------------------|---------------------|--|---|--|
| 2017                | O'Connell et al.    | Examining variation in the dopamine receptor genes (DRD1-5) with regards to antipsychotic treatment response in a South African first episode schizophrenia cohort               | European Neuropsychopharmacology                          | Wrong publication type                                   |
| 2017                | Pinzon et al.       | MDR1 and CYP3A4 genes variants association with clinical response measured on a five-factor model in multiepisodic schizophrenia and related disorders                           | European Neuropsychopharmacology                          | Wrong publication type                                   |
| 2017                | Seppala et al.      | Treatment-resistant and difficult-to treat schizophrenia as a challenge for clinical practices Data from Finnish samples: Northern Finland birth cohort 1966 and Perfect-project | European Archives of Psychiatry and Clinical Neuroscience | Wrong publication type                                   |
| 2017                | Shi et al.          | Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in chinese han schizophrenia patients  | Translational Psychiatry                                  | Insufficient trials / duration or lacking AP information |
| 2017                | Szymona et al.      | Correlations of Kynurenic Acid, 3-Hydroxykynurenine, sIL-2R, IFN-alpha, and IL-4 with Clinical Symptoms During Acute Relapse of Schizophrenia                                    | Neurotox Res  | Insufficient or Wrong population                         |
| 2017                | Tiihonen et al.     | Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29823 Patients With Schizophrenia   | JAMA Psychiatry   | No TRS assessment  |
| 2017                | Tungaraza et al.    | Prescribing pattern of clozapine and other antipsychotics for patients with first-episode psychosis: a cross-sectional survey of early intervention teams                        | Therapeutic Advances in Psychopharmacology                | No TRS assessment  |
| 2017                | van der Zalm et al. | Clozapine in Dutch ambulatory care: Prescription rates and proportions of patients with an indication for this drug  | European Archives of Psychiatry and Clinical Neuroscience | Wrong publication type                                   |
| 2017                | Vincent et al.      | One year mirror-image study using paliperidone palmitate for relapse prevention of schizophrenia in four university hospitals in Canada  | Schizophr Res   | Insufficient or Wrong population                         |
| 2017                | Wimberley et al.    | Polygenic risk score for schizophrenia and treatment-resistant schizophrenia   | Schizophrenia Bulletin                                    | Overlapping sample                                       |
| 2017                | Zamani et al.       | Sensitivity of the positive and negative syndrome scale (PANSS) in detecting treatment effects via network analysis  | Innovations in Clinical Neuroscience                      | Overlapping sample                                       |
| 2017                | Zhou et al.         | Risperidone improves interpersonal perception and executive function in patients with schizophrenia  | Neuropsychiatric disease and treatment                    | Insufficient or Wrong population                         |
| 2016                | Al-Bataineh et al.  | Is diagnosis indeed prognosis? 12 months outcome for schizophrenia, schizophreniform and schizoaffective disorder  | European Neuropsychopharmacology                          | Wrong publication type                                   |
| 2016                | Alacam et al.       | miR-181b-5p, miR-195-5p and miR-301a-3p are related with treatment resistance in schizophrenia   | Psychiatry Research                                       | Insufficient or Wrong population                         |
| 2016                | Berge et al.        | Predictors of relapse and functioning in first-episode psychosis: A two-year follow-up study   | Psychiatric Services                                      | No TRS assessment  |
| 2016                | Brandl et al.       | The role of the ITIH3 rs2535629 variant in antipsychotic response  | Schizophr Res   | No TRS assessment  |
| 2016                | Buoli et al.        | Haloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia  | Hum Psychopharmacol                                       | No TRS assessment  |
| 2016                | Chang et al.        | Three-year clinical and functional outcome comparison between first-episode mania with psychotic features and first-episode schizophrenia  | Journal of Affective Disorders                            | No TRS assessment  |
| 2016                | Charan et al.       | Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia   | Psychiatry Res  | No TRS assessment  |

| Year of publication | First author           | Title  | Journal                                   | Reason for exclusion             |
|---------------------|------------------------|--|---|----------------------------------|
| 2016                | Chiliza et al.         | Combining depot antipsychotic with an assertive monitoring programme for treating first-episode schizophrenia in a resource-constrained setting  | Early Interv Psychiatry                   | Wrong definition of TRS          |
| 2016                | Eaves et al.           | Evaluation of prescribing trends associated with clozapine use and an antipsychotic polypharmacy prior authorization process in the Indiana Medicaid adult population  | Journal of Pharmacy Practice              | Wrong publication type           |
| 2016                | Einarson et al.        | Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland   | J Med Econ                                | No TRS assessment                |
| 2016                | Friis et al.           | Early predictors of ten-year course in first-episode psychosis   | Psychiatric Services                      | No TRS assessment                |
| 2016                | Hou et al.             | Antipsychotic polypharmacy and quality of life in patients with schizophrenia treated in primary care in China   | Int J Clin Pharmacol Ther                 | No TRS assessment                |
| 2016                | Iasevoli et al.        | Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones | Prog Neuropsychopharmacol Biol Psychiatry | Overlapping sample               |
| 2016                | Kane et al.            | Comprehensive versus usual community care for first-episode psychosis: 2-Year outcomes from the NIMH RAISE early treatment program   | American Journal of Psychiatry            | No TRS assessment                |
| 2016                | Kreyenbuhl et al.      | The RAISE Connection Program: Psychopharmacological Treatment of People With a First Episode of Schizophrenia  | Psychiatr Serv                            | No TRS assessment                |
| 2016                | Li et al.              | Increased serum brain-derived neurotrophic factor levels following electroconvulsive therapy or antipsychotic treatment in patients with schizophrenia   | Eur Psychiatry                            | No TRS assessment                |
| 2016                | Mayoral-Van et al.     | Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: A 3-year naturalistic follow-up study   | Journal of Clinical Psychiatry            | No TRS assessment                |
| 2016                | Oriolo et al.          | Combination of clozapine with paliperidone in treatment-resistant schizophrenia  | European Neuropsychopharmacology          | Wrong publication type           |
| 2016                | Patel et al.           | Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: An observational study   | BMJ Open                                  | No TRS assessment                |
| 2016                | Ruderfer et al.        | Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach   | Lancet Psychiatry                         | Wrong definition of TRS          |
| 2016                | Sarpal et al.          | Relationship between untreated psychosis and intrinsic corticostriatal connectivity in patients with first-episode schizophrenia   | Neuropsychopharmacology                   | Wrong publication type           |
| 2016                | Schooler et al.        | Cognitive functioning in first episode psychosis: Comparison of a two-year coordinated specialty care program to community care  | Neuropsychopharmacology                   | Wrong publication type           |
| 2016                | Softic et al.          | Rehospitalization rate of first episode and chronic schizophrenia patients one year after discharge  | European Psychiatry                       | Wrong publication type           |
| 2016                | Szkulicka-Debek et al. | Treatment patterns of schizophrenia based on the data from seven Central and Eastern European Countries  | Psychiatr Danub                           | Wrong definition of TRS          |
| 2016                | Ucok et al.            | Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study   | CNS Drugs                                 | Insufficient or Wrong population |



| Year of publication | First author              | Title   | Journal                                  | Reason for exclusion                                     |
|---------------------|---------------------------|---|--|--|
| 2016                | Vanasse et al.            | Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study  | Acta Psychiatr Scand                     | No TRS assessment  |
| 2016                | Vazquez-Bourgon et al.    | Variations in Disrupted-in-Schizophrenia 1 gene modulate long-term longitudinal differences in cortical thickness in patients with a first-episode of psychosis   | Brain Imaging and Behavior               | No TRS assessment  |
| 2016                | Wimberley et al.          | Inverse association between urbanicity and treatment resistance in schizophrenia  | Schizophr Res                            | Overlapping sample                                       |
| 2016                | Xu et al.                 | Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population            | Pharmacogenomics J                       | No TRS assessment  |
| 2016                | Yamanaka et al.           | Impact of dopamine supersensitivity psychosis in treatment-resistant schizophrenia: An analysis of multi-factors predicting long-term prognosis                   | Schizophr Res                            | Overlapping sample                                       |
| 2016                | Zhang et al.              | Effectiveness of antipsychotic drugs for 24-month maintenance treatment in first-episode schizophrenia: Evidence from a community-based "real-world" study        | Journal of Clinical Psychiatry           | No TRS assessment  |
| 2015                | Agid et al.               | Antipsychotic re-challenge in previous first episode schizophrenia responders   | Schizophrenia Bulletin                   | Wrong publication type                                   |
| 2015                | Ajnakina et al.           | Ethnic variations in outcome during the 5-years following a first episode of psychosis  | Schizophrenia Bulletin                   | Wrong publication type                                   |
| 2015                | Baeza                     | Clinical and functional outcome 5 years after a first episode of early-onset psychosis  | European Child and Adolescent Psychiatry | Wrong publication type                                   |
| 2015                | Catalan et al.            | May genetic variation in multi-drug resistance 1 gene influence psychotic and functional improvement in schizophrenia and related disorders patients?             | European Neuropsychopharmacology         | Wrong publication type                                   |
| 2015                | Chiliza et al.            | Rate and predictors of non-response to first-line antipsychotic treatment in first-episode schizophrenia  | Hum Psychopharmacol                      | No TRS assessment  |
| 2015                | Corrao et al.             | Do patterns of mental healthcare predict treatment failure in young people with schizophrenia? Evidence from an Italian population-based cohort study.            | BJP Open                                 | Insufficient trials / duration or lacking AP information |
| 2015                | Dazzan                    | Structural MRI studies of treatment response and disease progression after the first episode of psychosis   | Schizophrenia Bulletin                   | Wrong publication type                                   |
| 2015                | Eftekhari et al.          | Antipsychotic treatment in schizophrenia and related psychosis, real life data analysis of oral and long acting antipsychotics                                    | European Neuropsychopharmacology         | Wrong publication type                                   |
| 2015                | Elkis et al.              | Cross-sectional findings from the pattern study in stable patients with schizophrenia   | Schizophrenia Bulletin                   | Wrong publication type                                   |
| 2015                | Ferreiro-Fernandez et al. | Treatment with multiple antipsychotics in psychiatric inpatients  | European Neuropsychopharmacology         | Wrong publication type                                   |
| 2015                | Flamarique et al.         | Long-term effectiveness of electroconvulsive therapy in adolescents with schizophrenia spectrum disorders   | Eur Child Adolesc Psychiatry             | Insufficient or Wrong population                         |
| 2015                | Franza et al.             | Management of primary negative symptoms in schizophrenia: an one-year observational study   | Psychiatr Danub                          | No TRS assessment  |
| 2015                | Gasse et al.              | Predictors of treatment resistance in schizophrenia   | Schizophrenia Bulletin                   | Wrong publication type                                   |
| 2015                | Haring et al.             | Antipsychotic treatment reduces psychotic symptoms and markers of low-grade inflammation in first episode psychosis patients, but increases their body mass index | Schizophrenia Research                   | No TRS assessment  |

| Year of publication | First author              | Title  | Journal  | Reason for exclusion                                     |
|---------------------|---------------------------|--|--|--|
| 2015                | Hassan et al.             | The effect of lifetime adversities on resistance to antipsychotic treatment in schizophrenia patients  | Schizophr Res  | Overlapping sample                                       |
| 2015                | Heeramun-Aubeeluck et al. | Effect of time and duration of untreated psychosis on cognitive and social functioning in Chinese patients with first-episode schizophrenia: A 1-year study                                    | Nordic Journal of Psychiatry   | No TRS assessment  |
| 2015                | Hou et al.                | Clozapine prescription and quality of life in Chinese patients with schizophrenia treated in primary care  | Pharmacopsychiatry   | No TRS assessment  |
| 2015                | Howes                     | PET to predict treatment response and outcome  | European Neuropsychopharmacology   | Wrong publication type                                   |
| 2015                | Jaracz et al.             | Psychosocial functioning in relation to symptomatic remission: A longitudinal study of first episode schizophrenia.  | European psychiatry : the journal of the Association of European Psychiatrists | Insufficient trials / duration or lacking AP information |
| 2015                | Kane et al.               | The RAISE early treatment program for first-episode psychosis: Background, rationale, and study design   | Journal of Clinical Psychiatry   | No TRS assessment  |
| 2015                | Larkin et al.             | The prevalence and disability of patients with treatment resistant schizophrenia within three security levels of secure in patient forensic care   | European Psychiatry  | Wrong publication type                                   |
| 2015                | Lee et al.                | Positive symptoms are associated with clinicians' global impression in treatment-resistant schizophrenia   | J Clin Psychopharmacol   | Insufficient or Wrong population                         |
| 2015                | Li et al.                 | Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002-2012) | Schizophr Res  | Insufficient or Wrong population                         |
| 2015                | Lin et al.                | Minor physical anomalies and craniofacial measures in patients with treatment-resistant schizophrenia  | Psychol Med  | Insufficient or Wrong population                         |
| 2015                | Loebel et al.             | Lurasidone treatment response in patients with schizophrenia assessed using the DSM-5 dimensions of psychosis severity scale   | European Neuropsychopharmacology   | Wrong publication type                                   |
| 2015                | Loebel et al.             | Treatment response and dimensions of psychosis symptom severity in patients with schizophrenia   | Schizophrenia Bulletin   | Wrong publication type                                   |
| 2015                | Malherbe et al.           | Phenotypic features of patients with schizophrenia carrying de novo gene mutations: a pilot study  | Psychiatry Res   | Wrong definition of TRS                                  |
| 2015                | McNabb et al.             | Classification of people with treatment-resistant and ultra-treatment-resistant schizophrenia using resting-state EEG and the neucube  | Schizophrenia Bulletin   | Wrong publication type                                   |
| 2015                | Melle                     | Negative symptoms, early intervention and outcome in first episode psychosis   | European Archives of Psychiatry and Clinical Neuroscience                      | Wrong publication type                                   |
| 2015                | Meltzer et al.            | Lurasidone is an effective treatment for treatment resistant schizophrenia   | Neuropsychopharmacology  | Wrong publication type                                   |
| 2015                | Monestes et al.           | [Influence of resistance to voices on depression]  | Encephale  | No TRS assessment  |
| 2015                | Nasrallah et al.          | The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: a focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization        | Schizophr Res  | No TRS assessment  |
| 2015                | Oda et al.                | Genetic association between G protein-coupled receptor kinase 6/beta-arrestin 2 and dopamine supersensitivity psychosis in schizophrenia   | Neuropsychiatric Disease and Treatment   | Wrong definition of TRS                                  |
| 2015                | Oji et al.                | A pharmacist-led approach to increasing clozapine utilization at the south texas veterans healthcare system: A continuous quality improvement project  | Journal of Pharmacy Practice   | Wrong publication type                                   |

| Year of publication | First author       | Title   | Journal   | Reason for exclusion             |
|---------------------|--------------------|---|---|----------------------------------|
| 2015                | Patel et al.       | Cannabis use and treatment resistance in first episode psychosis: A natural language processing study   | The Lancet  | Wrong publication type           |
| 2015                | Pridan et al.      | Effectiveness and safety of clozapine in elderly patients with chronic resistant schizophrenia  | Int Psychogeriatr   | Wrong definition of TRS          |
| 2015                | Privat et al.      | Decreased incidence of readmissions in first episode psychosis in treatment with long - Acting injectable antipsychotics  | Current Psychopharmacology                                  | Wrong publication type           |
| 2015                | Schneider et al.   | Clozapine use in childhood and adolescent schizophrenia: A nationwide population-based study  | Eur Neuropsychopharmacol                                    | No TRS assessment                |
| 2015                | Sigurdsson et al.  | Polygenetic risk scores and metabolic side effects in clozapine treatment of schizophrenia  | European Psychiatry   | Wrong publication type           |
| 2015                | Sneider et al.     | Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study  | European Neuropsychopharmacology                            | No TRS assessment                |
| 2015                | Spaniel et al.     | Psychiatrist's adherence: a new factor in relapse prevention of schizophrenia. A randomized controlled study on relapse control through telemedicine system.  | Journal of psychiatric and mental health nursing            | No TRS assessment                |
| 2015                | Stanton et al.     | Clozapine pharmacotherapy in treatment resistant schizophrenia in an acute-care psychiatric setting   | Journal of Pharmacy Practice                                | Wrong publication type           |
| 2015                | Stroup et al.      | Comparative effectiveness and safety of clozapine versus standard antipsychotic treatment in adults with schizophrenia  | Clinical Pharmacology and Therapeutics                      | Wrong publication type           |
| 2015                | Tao et al.         | Effects of cognitive rehabilitation training on schizophrenia: 2 years of follow-up.  | International journal of clinical and experimental medicine | No TRS assessment                |
| 2015                | Terzic et al.      | Genetic variability testing of neurodevelopmental genes in schizophrenic patients   | J Mol Neurosci  | Overlapping sample               |
| 2015                | Terzic et al.      | Influence of 5-HT1A and 5-HTTLPR genetic variants on the schizophrenia symptoms and occurrence of treatment-resistant schizophrenia   | Neuropsychiatric Disease and Treatment                      | Overlapping sample               |
| 2015                | Terzie et al.      | CYP3A4 RS35599367 does not influence antipsychotic treatment in Slovenian patients with Schizophrenia [Slovene]   | Farmaceutski Vestnik  | Overlapping sample               |
| 2015                | Tracy et al.       | Skating on thin ice: Pragmatic prescribing for medication refractory schizophrenia  | BMC Psychiatry  | Insufficient or Wrong population |
| 2015                | van de Bilt et al. | Cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment   | Schizophr Res   | Wrong publication type           |
| 2015                | Vernal et al.      | Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study | Journal of Child and Adolescent Psychopharmacology          | No TRS assessment                |
| 2015                | White et al.       | Characteristics, pharmacotherapy, and treatment outcomes of a large cohort of patients with treatment-resistant psychosis   | Schizophrenia Bulletin                                      | Wrong publication type           |
| 2015                | Xiang et al.       | QTc prolongation in schizophrenia patients in Asia: clinical correlates and trends between 2004 and 2008/2009   | Hum Psychopharmacol   | No TRS assessment                |
| 2015                | Zink               | Effects of antipsychotic treatment on obsessive-compulsive symptoms in schizophrenia  | European Neuropsychopharmacology                            | Wrong publication type           |
| 2014                | Andersen et al.    | Involuntary treatment of schizophrenia patients 2004-2010 in Denmark  | Acta Psychiatr Scand  | No TRS assessment                |

| Year of publication | First author    | Title  | Journal   | Reason for exclusion                                     |
|---------------------|-----------------|--|---|--|
| 2014                | Austin et al.   | Persistent negative symptoms in first episode psychosis: predictors and outcomes at 10-year follow-up  | Early Intervention in Psychiatry                    | Wrong publication type                                   |
| 2014                | Beck et al.     | The practical management of refractory schizophrenia--the Maudsley Treatment REview and Assessment Team service approach   | Acta Psychiatr Scand                                | No TRS assessment  |
| 2014                | Beduin et al.   | Obsessive-compulsive symptoms in patients with schizophrenia comparing treatment with clozapine olanzapine, risperidone and no antipsychotics: A longitudinal study of 550 patients after 3 years of treatment | Schizophrenia Research                              | Wrong publication type                                   |
| 2014                | Bhui et al.     | Which pathways to psychiatric care lead to earlier treatment and a shorter duration of first-episode psychosis?  | BMC Psychiatry                                      | No TRS assessment  |
| 2014                | Brain et al.    | Twelve months of electronic monitoring (MEMS®) in the Swedish COAST-study: a comparison of methods for the measurement of adherence in schizophrenia   | European Neuropsychopharmacology                    | No TRS assessment  |
| 2014                | Bressan et al.  | Clozapine prescription to treatment-resistant schizophrenia patients in community mental health services in Sao Paulo Brazil   | Schizophrenia Research                              | Wrong publication type                                   |
| 2014                | Chan et al.     | Predictors of treatment resistant schizophrenia-spectrum disorder: 10-year retrospective study of first-episode psychosis  | Early Intervention in Psychiatry                    | Wrong publication type                                   |
| 2014                | Chang et al.    | Three-year outcome comparison between patients presenting with first-episode psychotic mania and schizophrenia to easy program in Hong Kong  | Schizophrenia Research                              | Wrong publication type                                   |
| 2014                | Citrome et al.  | Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.   | CNS spectrums                                       | No TRS assessment  |
| 2014                | Cocchi et al.   | Patients with first-episode psychosis are not a homogeneous population: Implications for treatment   | Clinical Practice and Epidemiology in Mental Health | No TRS assessment  |
| 2014                | Demjaha et al.  | Clinical course and predictors of antipsychotic treatment resistance in a 10-year follow-up first episode psychosis study  | Early Intervention in Psychiatry                    | Wrong publication type                                   |
| 2014                | Demjaha et al.  | Is treatment resistant schizophrenia a "type" or a "stage" of psychotic illness?   | Schizophrenia Research                              | Wrong publication type                                   |
| 2014                | Drosos et al.   | Compliance to medication algorithm for first-episode psychoses   Experiences from tips-2 project   | Schizophrenia Research                              | Wrong publication type                                   |
| 2014                | Einarson et al. | Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden   | Nord J Psychiatry                                   | Wrong publication type                                   |
| 2014                | Gabernet et al. | Antipsychotic treatment and outcome in first-episode psychosis: A 2-year longitudinal, multicenter, pragmatic study  | European Neuropsychopharmacology                    | Wrong publication type                                   |
| 2014                | Gilbert et al.  | Cluster analysis of cognitive deficits may mark heterogeneity in schizophrenia in terms of outcome and response to treatment   | Eur Arch Psychiatry Clin Neurosci                   | Wrong definition of TRS                                  |
| 2014                | Haro et al.     | Understanding the impact of persistent symptoms in schizophrenia: Cross-sectional findings from the Pattern study  | European Neuropsychopharmacology                    | Wrong publication type                                   |
| 2014                | Hassan et al.   | Effect of lifetime stress on resistance to antipsychotic treatment   | Schizophrenia Research                              | Wrong publication type                                   |
| 2014                | Hatta et al.    | Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia   | Schizophr Res                                       | Insufficient trials / duration or lacking AP information |

| Year of publication | First author      | Title   | Journal  | Reason for exclusion                                     |
|---------------------|-------------------|---|--|--|
| 2014                | Hui et al.        | Comparing illness presentation, treatment and functioning between patients with early-and adult-onset psychosis   | Schizophrenia Research                           | Wrong publication type                                   |
| 2014                | Hui et al.        | Smoking as predictor of relapse at 3 years following first-episode psychosis: A retrospective cohort study in Hong Kong   | Early Intervention in Psychiatry                 | Wrong publication type                                   |
| 2014                | Jenkins et al.    | Identification of candidate single-nucleotide polymorphisms in NRXN1 related to antipsychotic treatment response in patients with schizophrenia   | Neuropsychopharmacology                          | No TRS assessment  |
| 2014                | Kalali et al.     | DSM-5 dimensions of psychosis symptom severity: Understanding treatment response in patients with schizophrenia   | Neuropsychopharmacology                          | Wrong publication type                                   |
| 2014                | Keller et al.     | Community adherence to schizophrenia treatment and safety monitoring guidelines   | J Nerv Ment Dis                                  | No TRS assessment  |
| 2014                | Klier et al.      | Sex differences in schizophrenia spectrum disorders revisited: Findings from the early psychosis prevention and intervention centre long-term follow-up study   | Early Intervention in Psychiatry                 | Wrong publication type                                   |
| 2014                | Kubera et al.     | Source-based morphometry of gray matter volume in patients with schizophrenia who have persistent auditory verbal hallucinations  | Prog Neuropsychopharmacol Biol Psychiatry        | Wrong definition of TRS                                  |
| 2014                | Kuzmanovic et al. | Demographic characteristics of superresponders on treatment with atypical antipsychotics  | European Neuropsychopharmacology                 | Wrong publication type                                   |
| 2014                | Langeveld et al.  | Treatment and violent behavior in persons with first episode psychosis during a 10-year prospective follow-up study   | Schizophrenia Research                           | No TRS assessment  |
| 2014                | Lovell et al.     | An exploratory randomized controlled study of a healthy living intervention in early intervention services for psychosis: the INTERvention to encourage ACTivity, improve diet, and reduce weight gain (INTERACT) study | J Clin Psychiatry                                | No TRS assessment  |
| 2014                | McNabb et al.     | Classification of people with treatment-resistant and ultra-treatment-resistant schizophrenia using personalised computer modelling and EEG data  | Schizophrenia Research                           | Wrong publication type                                   |
| 2014                | Murray            | Schizophrenia is not progressive: The clinical evidence   | International Journal of Neuropsychopharmacology | Wrong publication type                                   |
| 2014                | Nikolac et al.    | Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients  | Psychopharmacology (Berl)                        | Insufficient trials / duration or lacking AP information |
| 2014                | Park et al.       | Patterns of antipsychotic prescription to patients with schizophrenia in Korea: results from the health insurance review & assessment service-national patient sample   | J Korean Med Sci                                 | No TRS assessment  |
| 2014                | Patel et al.      | Association of cannabis use with hospital admission and treatment resistance in people with first episode psychosis in South London   | Early Intervention in Psychiatry                 | Wrong publication type                                   |
| 2014                | Phahladira et al. | Clinical and functional outcome of treatment-refractory first-episode schizophrenia   | South African Journal of Psychiatry              | Wrong publication type                                   |
| 2014                | Pinna et al.      | Long-term outcome of schizoaffective disorder Are there any differences with respect to schizophrenia?  | Rivista di Psichiatria                           | No TRS assessment  |
| 2014                | Pompili et al.    | [Psychiatric case management Chronic Disease Management application experience in a public Mental Health Service]   | Riv Psichiatr                                    | No TRS assessment  |

| Year of publication | First author             | Title  | Journal                             | Reason for exclusion                                     |
|---------------------|--------------------------|--|-------------------------------------|--|
| 2014                | Robinson et al.          | Medication prescription practices for the treatment of first episode schizophrenia-spectrum disorders: Data from the national raise-ETP study                    | Neuropsychopharmacology             | Wrong publication type                                   |
| 2014                | Rodriguez-Toscano et al. | Association between duration of untreated psychosis and functionality within family environment in early-onset first episode psychosis                           | European Neuropsychopharmacology    | Wrong publication type                                   |
| 2014                | Russell et al.           | Using personalised computer modelling to classify people with treatment-resistant or ultra-treatment-resistant schizophrenia based on cognitive measures         | Schizophrenia Research              | Wrong publication type                                   |
| 2014                | Sarkar et al.            | Unheard voices: Outcomes of tertiary care for treatment-refractory psychosis   | Psychiatric Bulletin                | Insufficient or Wrong population                         |
| 2014                | Schnell et al.           | Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study                | Am J Addict                         | Insufficient or Wrong population                         |
| 2014                | Shuhama et al.           | Preliminary sample description of first episode psychosis in a Brazilian large catchment area  | Schizophrenia Research              | Wrong publication type                                   |
| 2014                | Stroup et al.            | Geographic and clinical variation in clozapine use in the United States  | Psychiatr Serv                      | Wrong definition of TRS                                  |
| 2014                | Swerdlow et al.          | Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS   | Schizophrenia Research              | No TRS assessment  |
| 2014                | Tang et al.              | Prescription patterns prior to clozapine initiation in first-episode psychosis   | Schizophrenia Research              | Wrong publication type                                   |
| 2014                | Tang et al.              | Sociodemographic and clinical factors associated with clozapine use in first-episode psychosis   | Early Intervention in Psychiatry    | Wrong publication type                                   |
| 2014                | Temmingh et al.          | A comparative study of the clinical characteristics and symptom profile in outpatients diagnosed with methamphetamine-induced psychotic disorder v schizophrenia | South African Journal of Psychiatry | Wrong publication type                                   |
| 2014                | Terzic et al.            | Treatment resistant schizophrenia in Slovenian population [Slovene]  | Zdravniški Vestnik                  | Overlapping sample                                       |
| 2014                | Thomas et al.            | A randomised controlled trial of acceptance and commitment therapy (ACT) for psychosis: study protocol   | BMC Psychiatry                      | No TRS assessment  |
| 2014                | Thorup et al.            | Gender differences in first-episode psychosis at 5-year follow-up-two different courses of disease? Results from the OPUS study at 5-year follow-up              | European Psychiatry                 | No TRS assessment  |
| 2014                | Walters et al.           | Dopamine or glutamate: Using genetic copy number variant pathway analysis and treatment resistance to adjudicate schizophrenia hypotheses                        | Schizophrenia Research              | Wrong publication type                                   |
| 2014                | Wimberley et al.         | Prognostic factors for treatment resistance in schizophrenia   | Schizophrenia Research              | Wrong publication type                                   |
| 2014                | Xu et al.                | Executive function as predictors of persistent thought disorder in first-episode schizophrenia: a one-year follow-up study                                       | Schizophrenia research              | No TRS assessment  |
| 2013                | Agid                     | Where to position clozapine: Re-examining the evidence   | Schizophrenia Bulletin              | Wrong publication type                                   |
| 2013                | Agid et al.              | Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching  | Eur Neuropsychopharmacol            | Overlapping sample                                       |
| 2013                | Agid et al.              | Early prediction of clinical and functional outcome in schizophrenia   | Eur Neuropsychopharmacol            | Insufficient trials / duration or lacking AP information |
| 2013                | Alessi-Severini et al.   | Clozapine prescribing in a Canadian outpatient population  | PLoS One                            | Insufficient or Wrong population                         |

| Year of publication | First author          | Title  | Journal   | Reason for exclusion                                     |
|---------------------|-----------------------|--|---|--|
| 2013                | Assion et al.         | Psychopharmacological treatment of patients with schizoaffective disorder in comparison to schizophrenia and bipolar disorder  | European Neuropsychopharmacology                          | Wrong publication type                                   |
| 2013                | Barnes et al.         | Effect of prior treatment with antipsychotic long-acting injection on randomised clinical trial treatment outcomes   | Br J Psychiatry   | No TRS assessment  |
| 2013                | Bishop et al.         | Psychiatric medication utilization in patients with schizophrenia, psychotic bipolar disorder, and schizoaffective disorder  | Schizophrenia Bulletin                                    | Wrong publication type                                   |
| 2013                | Bitter et al.         | Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary  | Eur Neuropsychopharmacol                                  | No TRS assessment  |
| 2013                | Ciobanu               | Schizophrenia with obsessive-compulsive disorder comorbidity: Clinical and treatment particularities   | European Archives of Psychiatry and Clinical Neuroscience | Wrong publication type                                   |
| 2013                | de Bartolomeis et al. | Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses | Psychiatry Res  | Wrong publication type                                   |
| 2013                | Demjaha et al.        | Biological and clinical determinants of treatment resistant schizophrenia  | Schizophrenia Bulletin                                    | Wrong publication type                                   |
| 2013                | El-Mallakh et al.     | Organizational fidelity to a medication management evidence-based practice in the treatment of schizophrenia   | J Psychosoc Nurs Ment Health Serv                         | Wrong publication type                                   |
| 2013                | Emsley et al.         | Comparison of treatment response in second-episode versus first-episode schizophrenia  | J Clin Psychopharmacol                                    | Overlapping sample                                       |
| 2013                | Gadelha et al.        | Plasma Ndel1 enzyme activity is reduced in patients with schizophrenia--a potential biomarker?   | J Psychiatr Res   | Overlapping sample                                       |
| 2013                | Garcia et al.         | First episode psychosis during adolescence: Clinical and therapeutic differences from adulthood onset  | European Neuropsychopharmacology                          | Wrong publication type                                   |
| 2013                | Gerhard et al.        | Geographic and clinical variation in clozapine use in the US   | Pharmacoepidemiology and Drug Safety                      | Wrong publication type                                   |
| 2013                | Goren et al.          | Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia  | Psychiatr Serv  | No TRS assessment  |
| 2013                | Hatta et al.          | Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia   | Schizophr Res   | Insufficient trials / duration or lacking AP information |
| 2013                | Kristensen et al.     | Antipsychotic polypharmacy in a treatment-refractory schizophrenia population receiving adjunctive treatment with electroconvulsive therapy  | J ect   | Insufficient or Wrong population                         |
| 2013                | Lammers, et al.       | Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada   | BMC Psychiatry  | Insufficient trials / duration or lacking AP information |
| 2013                | Lappin et al.         | Early illness course predicts relapse and future service use following intervention for first episode psychosis  | Schizophrenia Bulletin                                    | Wrong publication type                                   |
| 2013                | Latimer et al.        | Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Quebec   | Clin Schizophr Relat Psychoses                            | No TRS assessment  |
| 2013                | Mhalla et al.         | Clinical and therapeutic outcomes of 61 patients hospitalised for first-episode psychosis  | European Neuropsychopharmacology                          | Wrong publication type                                   |

| Year of publication | First author             | Title   | Journal                                 | Reason for exclusion                                     |
|---------------------|--------------------------|---|---|--|
| 2013                | Mondelli et al.          | Can cortisol levels predict clinical outcome in patients with first-episode psychosis?  | Schizophrenia Bulletin                  | Wrong publication type                                   |
| 2013                | Orsel et al.             | Efficacy of clozapine in treatment-resistant schizophrenia  | Bulletin of Clinical Psychopharmacology | Wrong publication type                                   |
| 2013                | Ortiz et al.             | Is disorganized schizophrenia a predictor of treatment resistance? Evidence from an observational study   | Rev Bras Psiquiatr                      | Overlapping sample                                       |
| 2013                | Papachristou et al.      | Demographic and clinical characteristics prior to clozapine initiation in early onset schizophrenia: A study based on the danish population-based registers   | Pharmacoepidemiology and Drug Safety    | Wrong publication type                                   |
| 2013                | Picci et al.             | Does substance use disorder affect clinical expression in first-hospitalization patients with schizophrenia? Analysis of a prospective cohort   | Psychiatry Res                          | No TRS assessment  |
| 2013                | Pilla et al.             | Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score   | Schizophr Res                           | Wrong publication type                                   |
| 2013                | Rajagopalan et al.       | Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data | J Med Econ                              | Wrong publication type                                   |
| 2013                | Schmidt-Kraepelin et al. | [Antipsychotic polypharmacy in high-utilising patients with schizophrenia]  | Psychiatr Prax                          | No TRS assessment  |
| 2013                | Teo et al.               | The role of ethnicity in treatment refractory schizophrenia   | Compr Psychiatry                        | Overlapping sample                                       |
| 2013                | Wimberley et al.         | Treatment-resistant schizophrenia and clozapine treatment: A population-based pharmacoepidemiological study   | European Journal of Epidemiology        | Wrong publication type                                   |
| 2013                | Zugman et al.            | Reduced dorso-lateral prefrontal cortex in treatment resistant schizophrenia  | Schizophr Res                           | Insufficient or Wrong population                         |
| 2012                | Alan et al.              | Clozapine and first episode psychosis: Patient characteristics and outcomes   | Early Intervention in Psychiatry        | Wrong publication type                                   |
| 2012                | Buchanan et al.          | Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia  | J Clin Psychopharmacol                  | No TRS assessment  |
| 2012                | Carr et al.              | Broad and strong improvements in cognitive functioning over the first five years of specialized treatment for first episode psychosis   | Early Intervention in Psychiatry        | Wrong publication type                                   |
| 2012                | Ceskova et al.           | Cortisolemia, psychopathology and treatment response in first-episode schizophrenia   | Neuropsychopharmacology                 | Wrong publication type                                   |
| 2012                | Chang et al.             | Relationship of premorbid functioning with negative symptoms and cognition in first-episode schizophrenia: A three-year prospective follow-up study   | Schizophrenia Research                  | Wrong publication type                                   |
| 2012                | Cotton et al.            | First episode schizophrenia and schizoaffective disorder: A psychiatric nosology  | Early Intervention in Psychiatry        | Wrong publication type                                   |
| 2012                | Demontis et al.          | The gene encoding the melanin-concentrating hormone receptor 1 is associated with schizophrenia in a Danish case-control sample   | Psychiatr Genet                         | Insufficient or Wrong population                         |
| 2012                | Emsley et al.            | Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia   | Schizophr Res                           | Insufficient trials / duration or lacking AP information |
| 2012                | Fujimaki et al.          | Predictors of quality of life in inpatients with schizophrenia  | Psychiatry Res                          | No TRS assessment  |
| 2012                | Gadelha et al.           | Plasma ndell1 activity is reduced in patients with schizophrenia  | Schizophrenia Research                  | Wrong publication type                                   |



| Year of publication | First author     | Title   | Journal  | Reason for exclusion                                     |
|---------------------|------------------|---|--|--|
| 2012                | Guo et al.       | Effects of antipsychotic medications on quality of life and psychosocial functioning in patients with early-stage schizophrenia: 1-year follow-up naturalistic study  | Compr Psychiatry                                 | No TRS assessment  |
| 2012                | Hatta et al.     | A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone  | Psychiatry Res                                   | Insufficient trials / duration or lacking AP information |
| 2012                | Henry et al.     | Findings from the EPPIC long term follow-up study of first episode psychosis: Baseline predictors of the deficit syndrome at the long-term outcome  | Early Intervention in Psychiatry                 | Wrong publication type                                   |
| 2012                | Hill et al.      | Prospective relationship of duration of untreated psychosis to psychopathology and functional outcome over 12 years.  | Schizophrenia Research                           | Insufficient trials / duration or lacking AP information |
| 2012                | Iasevoli et al.  | Resistance to antipsychotics is associated with higher cognitive impairment compared to non-resistant schizophrenia   | European Neuropsychopharmacology                 | Wrong publication type                                   |
| 2012                | Iniesta et al.   | [Eligibility of schizophrenia inpatients to participate in clinical trials]   | Rev Psiquiatr Salud Ment                         | No TRS assessment  |
| 2012                | Johnson et al.   | Insight, psychopathology, explanatory models and outcome of schizophrenia in India: a prospective 5-year cohort study   | BMC Psychiatry                                   | No TRS assessment  |
| 2012                | Karadag et al.   | Comparison of polypharmacy in schizophrenia and other psychotic disorders in outpatient and inpatient treatment periods: A naturalistic one year follow-up study  | Klinik Psikofarmakoloji Bulteni                  | Insufficient trials / duration or lacking AP information |
| 2012                | Kayo et al.      | Does lack of improvement in the first two weeks predict treatment resistance in recent-onset psychosis?   | Clinics (Sao Paulo)                              | Overlapping sample                                       |
| 2012                | Kwon et al.      | The efficacy and safety of 12 weeks of treatment with sertindole or olanzapine in patients with chronic schizophrenia who did not respond successfully to their previous treatments: a randomized, double-blind, parallel-group, flexible-dose study. | International clinical psychopharmacology        | Insufficient or Wrong population                         |
| 2012                | Lambert et al.   | Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database.  | BMC psychiatry                                   | Insufficient trials / duration or lacking AP information |
| 2012                | Latimer et al.   | Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Quebec  | Clin Schizophr Relat Psychoses                   | No TRS assessment  |
| 2012                | Liou et al.      | Genome-wide association study of treatment refractory schizophrenia in Han Chinese  | PLoS One   | Wrong definition of TRS                                  |
| 2012                | Manchanda et al. | Family history of schizophrenia, EEG abnormalities and five year outcome in first episode psychosis   | Early Intervention in Psychiatry                 | Wrong publication type                                   |
| 2012                | Meijer et al.    | Cognitive alterations in patients with non-affective psychotic disorder and their unaffected siblings and parents   | Acta Psychiatrica Scandinavica                   | No TRS assessment  |
| 2012                | Morgan et al.    | People living with psychotic illness in 2010: The second Australian national survey of psychosis  | Australian and New Zealand Journal of Psychiatry | No TRS assessment  |
| 2012                | Ota et al.       | DRD1 rs4532 polymorphism: a potential pharmacogenomic marker for treatment response to antipsychotic drugs  | Schizophr Res                                    | Overlapping sample                                       |
| 2012                | Preti et al.     | Predictors of remission and recovery at 3 years after the start of treatment in young people  | Early Intervention in Psychiatry                 | Wrong publication type                                   |

| Year of publication | First author          | Title  | Journal   | Reason for exclusion                                     |
|---------------------|-----------------------|--|---|--|
|                     |                       | presenting with first-episode psychosis at an early intervention program in Italy  |   |  |
| 2012                | Reznik et al.         | The usage of the atypical antipsychotics in treatment of schizophrenia with obsessive-compulsive symptoms  | European Psychiatry Conference: 20th European Congress of Psychiatry, EPA | Wrong publication type                                   |
| 2012                | Rosenbaum et al.      | Supportive psychodynamic psychotherapy versus treatment as usual for first-episode psychosis: Two-year outcome   | Psychiatry (New York)   | No TRS assessment  |
| 2012                | Shrivastava et al.    | Atypical antipsychotics usage in long-term follow-up of first episode schizophrenia  | Indian Journal of Psychiatry  | No TRS assessment  |
| 2012                | Stein et al.          | Naturalistic pharmacotherapy of acute episodes of schizophrenic disorders in comparison to treatment guidelines  | Pharmacopsychiatry  | No TRS assessment  |
| 2012                | Teo et al.            | Analysis of treatment-resistant schizophrenia and 384 markers from candidate genes   | Pharmacogenet Genomics  | Overlapping sample                                       |
| 2012                | Ustohal et al.        | Pharmacological treatment of schizophrenia and schizoaffective disorder-focused on combinations of antipsychotics  | International Journal of Neuropsychopharmacology                          | Wrong publication type                                   |
| 2012                | Valevski et al.       | Antipsychotic monotherapy and adjuvant psychotropic therapies in schizophrenia patients: effect on time to readmission   | Int Clin Psychopharmacol  | No TRS assessment  |
| 2012                | van Dorn et al.       | Longitudinal substance use trajectories for persons with schizophrenia   | Schizophrenia Research  | Wrong publication type                                   |
| 2012                | Verma et al.          | The Singapore Early Psychosis Intervention Programme (EPIP): A programme evaluation  | Asian Journal of Psychiatry   | No TRS assessment  |
| 2012                | Vijayan et al.        | Antipsychotic drug dosage and therapeutic response in schizophrenia is influenced by ABCB1 genotypes: a study from a south Indian perspective  | Pharmacogenomics  | Insufficient trials / duration or lacking AP information |
| 2012                | Walter et al.         | Cost effectiveness of paliperidone palmitate versus oral medication in the treatment of schizophrenia in Austria   | Value in Health   | Wrong publication type                                   |
| 2012                | Ye et al.             | Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan  | Psychiatry Clin Neurosci  | Insufficient trials / duration or lacking AP information |
| 2011                | Chen et al.           | Effects of antipsychotics on the serum BDNF levels in schizophrenia  | Psychiatry Res  | No TRS assessment  |
| 2011                | Crespo-Facorro et al. | Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: Results of a randomized, flexible-dose, open-label 1-year follow-up comparison | Journal of Psychopharmacology   | No TRS assessment  |
| 2011                | de Luca et al.        | Treatment resistant schizophrenia: Analysis of polymorphic CpG sites in 40 annotated genes   | European Neuropsychopharmacology  | Wrong publication type                                   |
| 2011                | El-Badri et al.       | Clozapine use and outcomes among patients with treatment resistant schizophrenia   | Australas Psychiatry  | Insufficient or Wrong population                         |
| 2011                | Essock et al.         | Effectiveness of switching from antipsychotic polypharmacy to monotherapy  | Am J Psychiatry   | No TRS assessment  |
| 2011                | Girgis et al.         | Clozapine v chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial   | Br J Psychiatry   | No TRS assessment  |
| 2011                | Guo et al.            | Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study   | Psychopharmacology (Berl)   | No TRS assessment  |

| Year of publication | First author          | Title  | Journal  | Reason for exclusion                                     |
|---------------------|-----------------------|--|--|--|
| 2011                | Guo et al.            | Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study   | Neurosci Lett                                  | No TRS assessment  |
| 2011                | Hotta et al.          | Association study between Disrupted-in-Schizophrenia-1 (DISC1) and Japanese patients with treatment-resistant schizophrenia (TRS)  | Prog Neuropsychopharmacol Biol Psychiatry      | Overlapping sample                                       |
| 2011                | Huffman et al.        | Antipsychotic polytherapy on an inpatient psychiatric unit: how does clinical practice coincide with Joint Commission guidelines?  | Gen Hosp Psychiatry                            | Insufficient trials / duration or lacking AP information |
| 2011                | Igue et al.           | Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders  | Prog Neuropsychopharmacol Biol Psychiatry      | No TRS assessment  |
| 2011                | Kane et al.           | A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia  | J Clin Psychiatry                              | Insufficient or Wrong population                         |
| 2011                | Kreyenbuhl et al.     | Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia  | Schizophr Res                                  | No TRS assessment  |
| 2011                | Levine et al.         | Trajectories of the course of schizophrenia: from progressive deterioration to amelioration over three decades   | Schizophr Res                                  | No TRS assessment  |
| 2011                | Lindenmayer et al.    | A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder | J Clin Psychopharmacol                         | Insufficient or Wrong population                         |
| 2011                | Liu et al.            | Heterogeneity and the longitudinal recovery of functioning during inpatient psychiatric rehabilitation for treatment-refractory severe mental illness  | American Journal of Psychiatric Rehabilitation | Wrong definition of TRS                                  |
| 2011                | Loga-Zec et al.       | Polypharmacy in the treatment of schizophrenic patients in three University Centers in the Federation of Bosnia and Herzegovina (F/BH)   | Psychiatr Danub                                | No TRS assessment  |
| 2011                | Meszaros et al.       | Predictors of smoking severity in patients with schizophrenia and alcohol use disorders  | Am J Addict                                    | No TRS assessment  |
| 2011                | Molina et al.         | Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine   | Pharmacopsychiatry                             | Insufficient or Wrong population                         |
| 2011                | Molina et al.         | Optimized voxel brain morphometry: association between brain volumes and the response to atypical antipsychotics   | Eur Arch Psychiatry Clin Neurosci              | Wrong definition of TRS                                  |
| 2011                | Mouaffak et al.       | Association of an UCP4 (SLC25A27) haplotype with ultra-resistant schizophrenia   | Pharmacogenomics                               | Insufficient or Wrong population                         |
| 2011                | Mouaffak et al.       | Association of Disrupted in Schizophrenia 1 (DISC1) missense variants with ultra-resistant schizophrenia   | Pharmacogenomics J                             | Insufficient or Wrong population                         |
| 2011                | Robinson et al.       | Should patients with long durations of untreated psychosis be included in studies of first episode schizophrenia?  | Neuropsychopharmacology                        | Wrong publication type                                   |
| 2011                | Schaufelberger et al. | Lack of progression of brain abnormalities in first-episode psychosis: a longitudinal magnetic resonance imaging study   | Psychological medicine                         | No TRS assessment  |
| 2011                | Scott et al.          | Atypical (second generation) antipsychotic treatment response in very late-onset schizophrenia-like psychosis  | International Psychogeriatrics                 | No TRS assessment  |

| Year of publication | First author          | Title  | Journal   | Reason for exclusion                                     |
|---------------------|-----------------------|--|---|--|
| 2011                | Secher et al.         | The Opus-trial: Intensive, early, psycho-social intervention versus treatment as usual for first-episode psychosis patients Results from the 10-year follow-up   | European Archives of Psychiatry and Clinical Neuroscience | Wrong publication type                                   |
| 2011                | Stroup et al.         | A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP) | The American journal of psychiatry                        | No TRS assessment  |
| 2011                | Tiihonen et al.       | A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia   | Am J Psychiatry   | No TRS assessment  |
| 2011                | Uggerby et al.        | Characteristics and predictors of long-term institutionalization in patients with schizophrenia  | Schizophr Res   | No TRS assessment  |
| 2011                | Werneck et al.        | Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine   | Psychiatry Res  | No TRS assessment  |
| 2011                | Zedkova et al.        | Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses  | Neuro Endocrinol Lett                                     | No TRS assessment  |
| 2010                | Balbuena et al.       | Does clozapine promote employability and reduce offending among mentally disordered offenders?   | Can J Psychiatry  | Insufficient or Wrong population                         |
| 2010                | Barrowclough et al.   | HELPER ReCAP: Rethinking Choices after Psychosis - A phasespecific psychological therapy for people with problematic cannabis use following a first episode of psychosis                                     | Early Intervention in Psychiatry                          | Wrong publication type                                   |
| 2010                | Bobo et al.           | Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics  | Psychiatry Res  | Insufficient or Wrong population                         |
| 2010                | Boden et al.          | Five-year outcome of first-episode psychosis before and after the implementation of a modified assertive community treatment programme   | Social psychiatry and psychiatric epidemiology            | No TRS assessment  |
| 2010                | Coentre et al.        | Co-morbid cannabis use/dependence in first-episode psychosis patients: Prevalence and associations   | Early Intervention in Psychiatry                          | Wrong publication type                                   |
| 2010                | Cutler et al.         | A failed 6-week, randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned.                                | Psychopharmacology Bulletin                               | Overlapping sample                                       |
| 2010                | Faerden et al.        | Apathy and social dysfunction in first episode psychosis   | Early Intervention in Psychiatry                          | Wrong publication type                                   |
| 2010                | Gomez-de-Regil et al. | Predictors of outcome in the early course of first-episode psychosis   | European Journal of Psychiatry                            | No TRS assessment  |
| 2010                | Grootens et al.       | Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia  | Eur Neuropsychopharmacol                                  | No TRS assessment  |
| 2010                | Harrison et al.       | Patterns of clozapine prescribing in a mental health service in New Zealand  | Pharm World Sci   | No TRS assessment  |
| 2010                | Henry et al.          | The EPPIC Follow-Up Study of First-Episode Psychosis: Longer-Term Clinical and Functional Outcome 7 Years after Index Admission  | Journal of Clinical Psychiatry                            | No TRS assessment  |
| 2010                | Hong et al.           | Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment  | Pharmacogenetics and Genomics                             | No TRS assessment  |
| 2010                | Huffman et al.        | Antipsychotic polytherapy on an inpatient psychiatric unit: how does clinical practice coincide with Joint Commission guidelines?  | Gen Hosp Psychiatry                                       | Insufficient trials / duration or lacking AP information |

| Year of publication | First author      | Title   | Journal                                   | Reason for exclusion                                     |
|---------------------|-------------------|---|---|--|
| 2010                | Kane et al.       | Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia  | J Clin Psychopharmacol                    | Insufficient trials / duration or lacking AP information |
| 2010                | Li et al.         | Symptomatic resolution among Chinese patients with schizophrenia and associated factors   | J Formos Med Assoc                        | No TRS assessment  |
| 2010                | Malhi et al.      | Time to 'get real': preliminary insights into the long-term management of schizophrenia   | Australas Psychiatry                      | No TRS assessment  |
| 2010                | Marriott et al.   | Use of clozapine in first episode psychosis: Patient characteristics and adherence to UK Clinical Guidelines  | Early Intervention in Psychiatry          | Wrong publication type                                   |
| 2010                | Martinez et al.   | A prospective study of the clinical outcome following treatment discontinuation after 2 years in first-episode schizophrenia  | Early Intervention in Psychiatry          | Wrong publication type                                   |
| 2010                | Meltzer et al.    | A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia   | Psychiatry Res                            | No TRS assessment  |
| 2010                | Mitford et al.    | Ageism in first episode psychosis   | Int J Geriatr Psychiatry                  | No TRS assessment  |
| 2010                | Penfold et al.    | Pediatric uptake of a newly available antipsychotic medication  | Pediatrics                                | No TRS assessment  |
| 2010                | Ramirez et al.    | Predictors of schizophrenia in patients with a first episode of psychosis   | Psychiatry Research                       | Insufficient trials / duration or lacking AP information |
| 2010                | Simonsen et al.   | Early identification of non-remission in first-episode psychosis in a two-year outcome study  | Acta Psychiatrica Scandinavica            | No TRS assessment  |
| 2010                | Srivastava et al. | Do atypical antipsychotics differ in determining long-term outcome of first episode schizophrenia? a naturalistic outcome study in India  | Early Intervention in Psychiatry          | Wrong publication type                                   |
| 2010                | Thorup            | Gender differences in first-episode psychosis at five-year followup - Results from the danish opus study gender differences have been found   | Early Intervention in Psychiatry          | Wrong publication type                                   |
| 2010                | Treuer et al.     | Factors associated with achieving minimally symptomatic status by patients with schizophrenia: results from the 3-year intercontinental schizophrenia outpatients health outcomes study | Int J Clin Pract                          | Overlapping sample                                       |
| 2010                | Xu et al.         | Pharmacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia                          | Prog Neuropsychopharmacol Biol Psychiatry | No TRS assessment  |
| 2010                | Zahid et al.      | Schizophrenia psychopathology in a Kuwaiti Arab sample  | Psychopathology                           | No TRS assessment  |
| 2009                | Afshar et al.     | Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial   | J Psychopharmacol                         | Insufficient or Wrong population                         |
| 2009                | Alenius et al.    | Treatment response in psychotic patients classified according to social and clinical needs, drug side effects, and previous treatment   a method to identify functional remission       | Compr Psychiatry                          | No TRS assessment  |
| 2009                | Brabban et al.    | Predictors of outcome in brief cognitive behavior therapy for schizophrenia   | Schizophr Bull                            | No TRS assessment  |
| 2009                | Cuesta et al.     | Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis  | Br J Psychiatry                           | No TRS assessment  |
| 2009                | Edlinger et al.   | Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia   | Schizophr Res                             | No TRS assessment  |

| Year of publication | First author       | Title   | Journal                                   | Reason for exclusion             |
|---------------------|--------------------|---|---|----------------------------------|
| 2009                | Goldberg et al.    | Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia   | Schizophrenia Research                    | No TRS assessment                |
| 2009                | Karagianis et al.  | Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia  | Curr Med Res Opin                         | No TRS assessment                |
| 2009                | Kennedy et al.     | The association between class of antipsychotic and rates of hospitalization: results of a retrospective analysis of data from the 2005 Medicare current beneficiary survey                      | Clin Ther                                 | No TRS assessment                |
| 2009                | Kim et al.         | A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder.                                     | International clinical psychopharmacology | Insufficient or Wrong population |
| 2009                | Kroken et al.      | Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study   | BMC Psychiatry                            | No TRS assessment                |
| 2009                | Leucht et al.      | The Switch Study - efficacy of an early antipsychotic switch in case of poor initial response to the treatment of schizophrenia   | Eur Arch Psychiatry Clin Neurosci         | No TRS assessment                |
| 2009                | Malla et al.       | The role of social support and therapeutic alliance in promoting adherence to medication in first episode psychosis   | European Neuropsychopharmacology          | Wrong publication type           |
| 2009                | Miclutia et al.    | Short term treatment responsiveness of cognitive impairments in first episode of schizophrenia  | European Neuropsychopharmacology          | Wrong publication type           |
| 2009                | Molina et al.      | Combined treatment with amisulpride in patients with schizophrenia discharged from a short-term hospitalization unit: a 1-year retrospective study  | Clin Neuropharmacol                       | No TRS assessment                |
| 2009                | Morelli et al.     | Insight and clinical outcome in first episode psychosis: 1-Year follow-up study   | European Neuropsychopharmacology          | Wrong publication type           |
| 2009                | Munkner et al.     | The association between psychopathology of first-episode psychosis patients within the schizophrenia spectrum and previous offending  | Nordic Journal of Psychiatry              | No TRS assessment                |
| 2009                | Naber et al.       | The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians   | CNS Drugs                                 | Overlapping sample               |
| 2009                | Novick et al.      | Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study  | Schizophr Res                             | Overlapping sample               |
| 2009                | Opjordsmoen et al. | Stability of medication in early psychosis: a comparison between second-generation and low-dose first-generation antipsychotics   | Early Interv Psychiatry                   | No TRS assessment                |
| 2009                | Pae et al.         | Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study   | Eur Neuropsychopharmacol                  | Insufficient or Wrong population |
| 2009                | Ravanic et al.     | Effectiveness of clozapine, haloperidol and chlorpromazine in schizophrenia during a five-year period   | Arq Neuropsiquiatr                        | Insufficient or Wrong population |
| 2009                | Ryckmans et al.    | Switching to aripiprazole in out-patients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study | Pharmacopsychiatry                        | No TRS assessment                |
| 2009                | Sanchez et al.     | Predictors of longitudinal changes in schizophrenia: the role of processing speed   | J Clin Psychiatry                         | No TRS assessment                |
| 2009                | Shajahan et al.    | Comparing the effectiveness of aripiprazole and quetiapine in schizophrenia and related psychoses: a naturalistic, retrospective chart review study   | J Clin Psychiatry                         | Wrong definition of TRS          |

| Year of publication | First author         | Title  | Journal                                    | Reason for exclusion             |
|---------------------|----------------------|--|--|----------------------------------|
| 2009                | Stauffer et al.      | Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials                                | BMC Psychiatry                             | Wrong publication type           |
| 2009                | Stroup et al.        | Results of phase 3 of the CATIE schizophrenia trial  | Schizophr Res                              | Overlapping sample               |
| 2009                | Suzana et al.        | Adjunctive mood stabilising treatment: The effects on hostility and impulsivity among patients with schizophrenia  | European Neuropsychopharmacology           | Wrong publication type           |
| 2009                | Suzuki et al.        | Augmentation of atypical antipsychotics with valproic acid An open-label study for most difficult patients with schizophrenia  | Hum Psychopharmacol                        | Insufficient or Wrong population |
| 2009                | Weinbrenner et al.   | Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund  | Pharmacopsychiatry                         | No TRS assessment                |
| 2009                | Wheeler et al.       | Impact of audit and feedback on antipsychotic prescribing in schizophrenia   | J Eval Clin Pract                          | Wrong publication type           |
| 2009                | Wheeler et al.       | Outcomes for schizophrenia patients with clozapine treatment: how good does it get?  | J Psychopharmacol                          | No TRS assessment                |
| 2008                | Ascher-Svanum et al. | Treatment discontinuation following randomization to open-label olanzapine, risperidone or typical antipsychotics during a one-year treatment for schizophrenia                          | Clinical Schizophrenia & Related Psychoses | Wrong publication type           |
| 2008                | Ascher-Svanum et al. | Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study   | J Clin Psychiatry                          | No TRS assessment                |
| 2008                | Azarin et al.        | Evaluation of patients on sertindole treatment after failure of other antipsychotics: a retrospective analysis.  | BMC psychiatry                             | Insufficient or Wrong population |
| 2008                | Benmessaoud et al.   | Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics                              | BMC Psychiatry                             | Wrong definition of TRS          |
| 2008                | Bitter et al.        | Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study                          | Eur Neuropsychopharmacol                   | Overlapping sample               |
| 2008                | Brakoulias et al.    | A cross-sectional survey of the frequency and characteristics of delusions in acute psychiatric wards  | Australas Psychiatry                       | No TRS assessment                |
| 2008                | Crebbin et al.       | First-episode psychosis: An epidemiological survey comparing psychotic depression with schizophrenia   | Journal of Affective Disorders             | No TRS assessment                |
| 2008                | Davies et al.        | A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine  | Value Health                               | No TRS assessment                |
| 2008                | de Hert et al.       | Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review | Schizophr Res                              | No TRS assessment                |
| 2008                | Ganesan et al.       | Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia.   | Current medical research and opinion       | No TRS assessment                |
| 2008                | Hamdani et al.       | The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia   | Eur Neuropsychopharmacol                   | Wrong definition of TRS          |
| 2008                | Harvey et al.        | A randomized double-blind comparison of ziprasidone vs clozapine for cognition in patients   | Schizophr Res                              | Insufficient or Wrong population |

| Year of publication | First author      | Title  | Journal                                   | Reason for exclusion                                     |
|---------------------|-------------------|--|---|--|
|                     |                   | with schizophrenia selected for resistance or intolerance to previous treatment  |   |  |
| 2008                | Herceg et al.     | Two-year rehospitalization rates of patients with newly diagnosed or chronic schizophrenia on atypical or typical antipsychotic drugs: retrospective cohort study  | Croat Med J                               | No TRS assessment  |
| 2008                | Ji et al.         | An association between serotonin receptor 3B gene (HTR3B) and treatment-resistant schizophrenia (TRS) in a Japanese population   | Nagoya J Med Sci                          | Insufficient or Wrong population                         |
| 2008                | Ji et al.         | Relationship between three serotonin receptor subtypes (HTR3A, HTR2A and HTR4) and treatment-resistant schizophrenia in the Japanese population  | Neurosci Lett                             | Insufficient or Wrong population                         |
| 2008                | Kinon et al.      | Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia   | Schizophr Res                             | Wrong publication type                                   |
| 2008                | Kinon et al.      | Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study  | J Clin Psychopharmacol                    | No TRS assessment  |
| 2008                | Kohlrausch et al. | Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics  | Pharmacogenet Genomics                    | Wrong definition of TRS                                  |
| 2008                | Kopelowicz et al. | Consistency of Brief Psychiatric Rating Scale factor structure across a broad spectrum of schizophrenia patients   | Psychopathology                           | Wrong definition of TRS                                  |
| 2008                | Lee et al.        | Spontaneous dyskinesia in first-episode psychosis in a Southeast Asian population  | J Clin Psychopharmacol                    | No TRS assessment  |
| 2008                | Magara et al.     | Patient refractory to definition of drug-resistance criteria [Italian]   | Italian Journal of Psychopathology        | Wrong publication type                                   |
| 2008                | Mauri et al.      | Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugs  | Schizophr Res                             | Insufficient trials / duration or lacking AP information |
| 2008                | Melle et al.      | Prevention of negative symptom psychopathologies in first-episode schizophrenia: Two-year effects of reducing the duration of untreated psychosis  | Archives of General Psychiatry            | No TRS assessment  |
| 2008                | Meltzer et al.    | Association of Sult4A1 SNPs with psychopathology and cognition in patients with schizophrenia or schizoaffective disorder  | Schizophr Res                             | No TRS assessment  |
| 2008                | Molina et al.     | Differential clinical, structural and P300 parameters in schizophrenia patients resistant to conventional neuroleptics   | Prog Neuropsychopharmacol Biol Psychiatry | Insufficient or Wrong population                         |
| 2008                | Perkins et al.    | Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: A randomized, double-blind, flexible-dose, multicenter study | Journal of Clinical Psychiatry            | Insufficient trials / duration or lacking AP information |
| 2008                | Petersen et al.   | Predictors of remission and recovery in a first-episode schizophrenia spectrum disorder sample: 2-Year follow-up of the OPUS trial   | Canadian Journal of Psychiatry            | No TRS assessment  |
| 2008                | Shajahan et al.   | Who responds to aripiprazole in clinical practice? An observational study of combination versus monotherapy  | J Psychopharmacol                         | Overlapping sample                                       |
| 2008                | Shmilovich et al. | [The clinical peculiarities of psychogenically-induced exacerbations of paranoid schizophrenia]  | Zh Nevrol Psikhiatr Im S S Korsakova      | Insufficient trials / duration or lacking AP information |
| 2008                | Suarez et al.     | Overview of the findings from the European SOHO study  | Expert Rev Neurother                      | Overlapping sample                                       |



| Year of publication | First author          | Title  | Journal  | Reason for exclusion                                     |
|---------------------|-----------------------|--|--|--|
| 2008                | Suzuki et al.         | Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone | Hum Psychopharmacol                              | Overlapping sample                                       |
| 2008                | Takeuchi et al.       | A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering                                      | J Clin Psychopharmacol                           | Insufficient trials / duration or lacking AP information |
| 2008                | Taylor et al.         | Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study   | J Clin Psychiatry                                | No TRS assessment  |
| 2008                | Wheeler               | Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand   | Ann Pharmacother                                 | Insufficient or Wrong population                         |
| 2008                | Wheeler et al.        | Ethnic comparisons of antipsychotic use in schizophrenia   | Aust N Z J Psychiatry                            | No TRS assessment  |
| 2008                | Yamazawa et al.       | Association between duration of untreated psychosis, premorbid functioning, and cognitive performance and the outcome of first-episode schizophrenia in Japanese patients: Prospective study   | Australian and New Zealand Journal of Psychiatry | No TRS assessment  |
| 2007                | Agid et al.           | Early use of clozapine for poorly responding first-episode psychosis   | J Clin Psychopharmacol                           | Overlapping sample                                       |
| 2007                | Borgio et al.         | Refractory schizophrenia: a neglected clinical problem   | Rev Bras Psiquiatr                               | Wrong publication type                                   |
| 2007                | Caspi et al.          | Premorbid behavioral and intellectual functioning in schizophrenia patients with poor response to treatment with antipsychotic drugs   | Schizophr Res                                    | Insufficient or Wrong population                         |
| 2007                | Cooper et al.         | Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia  | J Clin Psychiatry                                | No TRS assessment  |
| 2007                | Crespo-Facorro et al. | Predictors of acute treatment response in patients with a first episode of non-affective psychosis: Sociodemographics, premorbid and clinical variables  | Journal of Psychiatric Research                  | No TRS assessment  |
| 2007                | Doi et al.            | A resistance gene in disguise for schizophrenia?   | Am J Med Genet B Neuropsychiatr Genet            | No TRS assessment  |
| 2007                | Grolleau et al.       | [Prescription practices of antipsychotic medication in early psychosis: a two-year follow-up survey of subjects admitted in two psychiatric hospitals of South-Western France]   | Encephale  | No TRS assessment  |
| 2007                | Haro et al.           | Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results  | Eur Neuropsychopharmacol                         | Overlapping sample                                       |
| 2007                | Istvan et al.         | [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO]  | Neuropsychopharmacol Hung                        | Overlapping sample                                       |
| 2007                | Kane et al.           | Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine   | J Clin Psychiatry                                | Insufficient or Wrong population                         |
| 2007                | La et al.             | Decreased levels of apolipoprotein A-I in plasma of schizophrenic patients   | J Neural Transm (Vienna)                         | Insufficient or Wrong population                         |
| 2007                | Lambert et al.        | Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride  | Acta Psychiatr Scand                             | Insufficient trials / duration or lacking AP information |

| Year of publication | First author         | Title  | Journal                            | Reason for exclusion                                     |
|---------------------|----------------------|--|------------------------------------|--|
| 2007                | Lee et al.           | Dyskinesia in first-episode psychosis in a Southeast Asian population  | J Clin Psychopharmacol             | No TRS assessment  |
| 2007                | Ling et al.          | Plasma S-100B protein in Chinese patients with schizophrenia: comparison with healthy controls and effect of antipsychotics treatment  | J Psychiatr Res                    | No TRS assessment  |
| 2007                | Manschreck et al.    | The CATIE schizophrenia trial: results, impact, controversy  | Harv Rev Psychiatry                | Overlapping sample                                       |
| 2007                | Molero et al.        | Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: Influence on the severity of psychotic symptoms and on the response to neuroleptic treatment | Pharmacogenomics Journal           | No TRS assessment  |
| 2007                | Morrato et al.       | Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003  | Clin Ther                          | No TRS assessment  |
| 2007                | Neto et al.          | Clinical aspects of super-refractory schizophrenia: A 6-month cohort observational study   | Revista Brasileira de Psiquiatria  | Overlapping sample                                       |
| 2007                | Sim et al.           | A 24-month prospective outcome study of first-episode schizophrenia and schizoaffective disorder within an early psychosis intervention program  | Journal of Clinical Psychiatry     | No TRS assessment  |
| 2007                | Tang et al.          | Cigarette smoking in Chinese male inpatients with schizophrenia: a cross-sectional analysis  | J Psychiatr Res                    | No TRS assessment  |
| 2007                | Taylor et al.        | A prospective 6-month analysis of the naturalistic use of aripiprazole - factors predicting favourable outcome   | Acta Psychiatr Scand               | No TRS assessment  |
| 2007                | Usall et al.         | Gender differences in response to antipsychotic treatment in outpatients with schizophrenia  | Psychiatry Res                     | Overlapping sample                                       |
| 2007                | Wang et al.          | Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients   | Neurosci Lett                      | No TRS assessment  |
| 2007                | Wehmeier et al.      | Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia  | Schizophr Res                      | No TRS assessment  |
| 2007                | Wheeler              | Sociodemographic, functional and clinical correlates in outpatients with schizophrenia: comparison with affective disorders  | Aust N Z J Psychiatry              | No TRS assessment  |
| 2006                | Lehofer              | Switch to new depot antipsychotics - Safe and effective?   | Neuropsychiatrie                   | Insufficient trials / duration or lacking AP information |
| 2006                | Ascher-Svanum et al. | Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia   | BMC Psychiatry                     | No TRS assessment  |
| 2006                | Bai et al.           | Association of initial antipsychotic response to clozapine and long-term weight gain   | Am J Psychiatry                    | Insufficient or Wrong population                         |
| 2006                | Beard et al.         | A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany   | Eur J Health Econ                  | No TRS assessment  |
| 2006                | Brugnoli et al.      | Efficacy of antipsychotic treatment in schizophrenia: Results after 24 months in Italian patients in the Schizophrenia Outpatient Health Outcomes (SOHO) study                                       | Italian Journal of Psychopathology | Overlapping sample                                       |
| 2006                | Emsley et al.        | Remission in first-episode psychosis: Predictor variables and symptom improvement patterns   | Journal of Clinical Psychiatry     | Insufficient trials / duration or lacking AP information |
| 2006                | Flyckt et al.        | Predicting 5-year outcome in first-episode psychosis: Construction of a prognostic rating scale  | Journal of Clinical Psychiatry     | No TRS assessment  |

| Year of publication | First author     | Title  | Journal                    | Reason for exclusion                                     |
|---------------------|------------------|--|----------------------------|--|
| 2006                | Haro et al.      | Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia  | Eur Psychiatry             | Overlapping sample                                       |
| 2006                | Haro et al.      | Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study  | J Clin Psychopharmacol     | No TRS assessment  |
| 2006                | Haro et al.      | The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia  | CNS Drugs                  | Overlapping sample                                       |
| 2006                | Jones et al.     | Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)        | Arch Gen Psychiatry        | No TRS assessment  |
| 2006                | Kampman et al.   | RGS4 genotype is not associated with antipsychotic medication response in schizophrenia  | J Neural Transm (Vienna)   | Wrong definition of TRS                                  |
| 2006                | Lamarque et al.  | [Clinical and socio-demographic profile of patients with schizophrenia according to the antipsychotic treatment prescribed]  | Encephale                  | No TRS assessment  |
| 2006                | Lewis et al.     | Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment | Health Technol Assess      | Wrong publication type                                   |
| 2006                | Lewis et al.     | Randomized Controlled Trial of Effect of Prescription of Clozapine versus Other Second-Generation Antipsychotic Drugs in Resistant Schizophrenia   | Schizophr Bull             | Insufficient or Wrong population                         |
| 2006                | Malla et al.     | Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study  | Psychol Med                | No TRS assessment  |
| 2006                | McEvoy et al.    | Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment   | Am J Psychiatry            | Overlapping sample                                       |
| 2006                | Pae et al.       | Interaction analysis between 5-HTTLPR and TNFA -238/-308 polymorphisms in schizophrenia  | J Neural Transm (Vienna)   | Insufficient trials / duration or lacking AP information |
| 2006                | Potvin et al.    | Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial   | Curr Med Res Opin          | Insufficient or Wrong population                         |
| 2006                | Rosenheck et al. | Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia   | Am J Psychiatry            | Overlapping sample                                       |
| 2006                | Sirota et al.    | Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia   | Hum Psychopharmacol        | Insufficient or Wrong population                         |
| 2006                | Stroup et al.    | Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic  | Am J Psychiatry            | Overlapping sample                                       |
| 2006                | Strous et al.    | Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study   | Hum Psychopharmacol        | No TRS assessment  |
| 2006                | Taylor et al.    | Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome  | Int J Neuropsychopharmacol | Overlapping sample                                       |
| 2006                | Tiihonen et al.  | Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and  | Bmj                        | No TRS assessment  |

| Year of publication | First author        | Title   | Journal  | Reason for exclusion                                     |
|---------------------|---------------------|---|--|--|
|                     |                     | schizoaffective disorder: observational follow-up study   |  |  |
| 2006                | Wade et al.         | Treatment for the initial acute phase of first-episode psychosis in a real-world setting  | Psychiatric Bulletin                             | No TRS assessment  |
| 2006                | Wheeler             | Atypical antipsychotic use for adult outpatients in New Zealand's Auckland and Northland regions  | N Z Med J  | Wrong definition of TRS                                  |
| 2006                | Wheeler et al.      | Trends in antipsychotic prescribing in schizophrenia in Auckland  | Australas Psychiatry                             | Wrong definition of TRS                                  |
| 2006                | Williams et al.     | Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia                                       | Acta Psychiatr Scand Suppl                       | No TRS assessment  |
| 2005                | Anttila et al.      | Lack of association between two polymorphisms of brain-derived neurotrophic factor and response to typical neuroleptics                               | J Neural Transm (Vienna)                         | Insufficient or Wrong population                         |
| 2005                | Brook et al.        | Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaf  | Psychopharmacology (Berl)                        | Insufficient trials / duration or lacking AP information |
| 2005                | Buchanan et al.     | Olanzapine treatment of residual positive and negative symptoms   | Am J Psychiatry                                  | Insufficient or Wrong population                         |
| 2005                | Chue et al.         | Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada  | Pharmacoeconomics                                | No TRS assessment  |
| 2005                | Corripio et al.     | Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol       | Prog Neuropsychopharmacol Biol Psychiatry        | Insufficient trials / duration or lacking AP information |
| 2005                | Cortese et al.      | Relationship of neuromotor disturbances to psychosis symptoms in first-episode neuroleptic-naive schizophrenia patients                               | Schizophrenia Research                           | Insufficient trials / duration or lacking AP information |
| 2005                | Geller et al.       | Clotiapine compared with chlorpromazine in chronic schizophrenia  | Schizophr Res                                    | Insufficient or Wrong population                         |
| 2005                | Goldberger et al.   | Population-based and family-based association study of 5'UTR polymorphism of the reelin gene and schizophrenia  | Am J Med Genet B Neuropsychiatr Genet            | No TRS assessment  |
| 2005                | Gunduz-Bruce et al. | Duration of untreated psychosis and time to treatment response for delusions and hallucinations   | American Journal of Psychiatry                   | No TRS assessment  |
| 2005                | Hamdani et al.      | Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics   | Neurosci Lett                                    | Overlapping sample                                       |
| 2005                | Haro et al.         | Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study | Acta Psychiatr Scand                             | Overlapping sample                                       |
| 2005                | Harris et al.       | Clinical profiles, scope and general findings of the Western Sydney First Episode Psychosis Project   | Australian and New Zealand Journal of Psychiatry | No TRS assessment  |
| 2005                | Lambert et al.      | Olanzapine in subjects with a first-episode psychosis non-responsive, intolerant or non-compliant to a first-line trial of risperidone                | Int J Psychiatry Clin Pract                      | Overlapping sample                                       |
| 2005                | Laux et al.         | Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany                               | Pharmacoeconomics                                | No TRS assessment  |
| 2005                | Leucht et al.       | What does the PANSS mean?   | Schizophr Res                                    | Wrong publication type                                   |
| 2005                | Llorca et al.       | [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical  | Encephale  | Wrong publication type                                   |

| Year of publication | First author           | Title  | Journal                                   | Reason for exclusion                                     |
|---------------------|------------------------|--|---|--|
|                     |                        | antipsychotic under long-acting injection formulation]   |   |  |
| 2005                | Muller et al.          | The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia  | Neurosci Lett                             | No TRS assessment  |
| 2005                | Naber et al.           | Randomized double blind comparison of olanzapine vs clozapine on subjective wellbeing and clinical outcome in patients with schizophrenia  | Acta Psychiatr Scand                      | No TRS assessment  |
| 2005                | Petersen et al.        | A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness  | British Medical Journal                   | No TRS assessment  |
| 2005                | Petersen et al.        | Improving 1-year outcome in first-episode psychosis: OPUS trial  | British Journal of Psychiatry             | No TRS assessment  |
| 2005                | Ritsner et al.         | Cortisol/dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia  | Neuropsychopharmacology                   | Insufficient trials / duration or lacking AP information |
| 2005                | Rosenbaum et al.       | The Danish National Schizophrenia Project: Prospective, comparative longitudinal treatment study of first-episode psychosis  | British Journal of Psychiatry             | No TRS assessment  |
| 2005                | Rosenheck et al.       | Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia   | Am J Psychiatry                           | Overlapping sample                                       |
| 2005                | Schimmelmann et al.    | Diagnostic stability 18 months after treatment initiation for first-episode psychosis  | Journal of Clinical Psychiatry            | No TRS assessment  |
| 2005                | Taylor et al.          | Atypical anti-psychotics in the real world--a naturalistic comparative outcome study   | Scott Med J                               | Wrong definition of TRS                                  |
| 2005                | Thorup et al.          | Integrated treatment ameliorates negative symptoms in first episode psychosis-results from the Danish OPUS trial   | Schizophrenia Research                    | No TRS assessment  |
| 2005                | van der Heijden et al. | Amino acids in schizophrenia: evidence for lower tryptophan availability during treatment with atypical antipsychotics?  | J Neural Transm (Vienna)                  | Insufficient trials / duration or lacking AP information |
| 2005                | Zhang et al.           | Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics                                   | Neuropsychopharmacology                   | Insufficient or Wrong population                         |
| 2005                | Zhao et al.            | Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine   | Int J Neurosci                            | Insufficient or Wrong population                         |
| 2004                | Addington et al.       | Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial | J Clin Psychiatry                         | Wrong publication type                                   |
| 2004                | Advokat et al.         | Comparison of risperidone and olanzapine as used under "real-world" conditions in a state psychiatric hospital   | Prog Neuropsychopharmacol Biol Psychiatry | Insufficient trials / duration or lacking AP information |
| 2004                | Appelbaum et al.       | Persistence and stability of delusions over time   | Compr Psychiatry                          | No TRS assessment  |
| 2004                | Barak et al.           | Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period   | Psychopharmacology (Berl)                 | No TRS assessment  |
| 2004                | Bitter et al.          | Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia   | Prog Neuropsychopharmacol Biol Psychiatry | Overlapping sample                                       |
| 2004                | Bozikas et al.         | Smoking impact on CYP1A2 activity in a group of patients with schizophrenia  | Eur Neuropsychopharmacol                  | No TRS assessment  |

| Year of publication | First author      | Title  | Journal                                   | Reason for exclusion                                     |
|---------------------|-------------------|--|---|--|
| 2004                | Buckley et al.    | Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia  | Schizophr Res                             | Overlapping sample                                       |
| 2004                | Chong et al.      | Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change   | Psychiatry Clin Neurosci                  | No TRS assessment  |
| 2004                | Corrigan et al.   | Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial  | Biol Psychiatry                           | Insufficient trials / duration or lacking AP information |
| 2004                | Green et al.      | First episode schizophrenia-related psychosis and substance use disorders: Acute response to olanzapine and haloperidol  | Schizophrenia Research                    | Insufficient trials / duration or lacking AP information |
| 2004                | Huq               | A Trial of Low Doses of Risperidone in the Treatment of Patients with First-Episode Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder  | Journal of Clinical Psychopharmacology    | Insufficient trials / duration or lacking AP information |
| 2004                | Keefe et al.      | Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomized, double-blind trial of olanzapine versus low doses of haloperidol           | American Journal of Psychiatry            | No TRS assessment  |
| 2004                | Kilian et al.     | [The impact of antipsychotic medication on the incidence and the costs of inpatient treatment in people with schizophrenia: results from a prospective observational study]                                | Psychiatr Prax                            | No TRS assessment  |
| 2004                | Meagher et al.    | Longitudinal assessment of psychopathological domains over late-stage schizophrenia in relation to duration of initially untreated psychosis: 3-year prospective study in a long-term inpatient population | Psychiatry Res                            | No TRS assessment  |
| 2004                | Meltzer et al.    | Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder  | American Journal of Psychiatry            | Insufficient trials / duration or lacking AP information |
| 2004                | Mori et al.       | Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia  | Prog Neuropsychopharmacol Biol Psychiatry | Insufficient trials / duration or lacking AP information |
| 2004                | Patel et al.      | Prognostic indicators for early discontinuation of risperidone long-acting injection   | Int Clin Psychopharmacol                  | Insufficient or Wrong population                         |
| 2004                | Perkins et al.    | Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders  | British Journal of Psychiatry             | Insufficient trials / duration or lacking AP information |
| 2004                | Reveley et al.    | Treatment outcome in patients with chronic schizophrenia during long-term administration with risperidone.   | Journal of clinical psychopharmacology    | Insufficient trials / duration or lacking AP information |
| 2004                | Robinson et al.   | Symptomatic and Functional Recovery from a First Episode of Schizophrenia or Schizoaffective Disorder  | American Journal of Psychiatry            | Overlapping sample                                       |
| 2004                | Schuepbach et al. | Early treatment-induced improvement of negative symptoms predicts cognitive functioning in treatment-naïve first episode schizophrenia: A 2-year followup  | Schizophrenia Bulletin                    | Insufficient trials / duration or lacking AP information |
| 2004                | Sernyak et al.    | Clinicians' reasons for antipsychotic coprescribing  | J Clin Psychiatry                         | No TRS assessment  |
| 2004                | Sinibaldi et al.  | Mutations of the nogo-66 receptor (Rtn4r) gene in schizophrenia  | Human Mutation                            | No TRS assessment  |
| 2004                | Strous et al.     | Premorbid functioning in schizophrenia: Relation to baseline symptoms, treatment response, and medication side effects   | Schizophrenia Bulletin                    | No TRS assessment  |
| 2004                | Swanson et al.    | Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment   | Schizophr Bull                            | No TRS assessment  |

| Year of publication | First author    | Title  | Journal                                   | Reason for exclusion                                     |
|---------------------|-----------------|--|---|--|
| 2004                | Szekeres et al. | Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia | Am J Med Genet B Neuropsychiatr Genet     | Insufficient trials / duration or lacking AP information |
| 2004                | Ucok et al.     | Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia  | Journal of Psychiatric Research           | No TRS assessment  |
| 2004                | Wang et al.     | Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model  | J Ment Health Policy Econ                 | Wrong publication type                                   |
| 2003                | Ananth et al.   | Pharmacotherapy for refractory schizophrenia patients  | Expert Review of Neurotherapeutics        | Wrong publication type                                   |
| 2003                | Arango et al.   | The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes   | Am J Psychiatry                           | No TRS assessment  |
| 2003                | Casey et al.    | Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study   | Psychopharmacology (Berl)                 | No TRS assessment  |
| 2003                | de Haan et al.  | Duration of untreated psychosis and outcome of schizophrenia: Delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication                              | Schizophrenia Bulletin                    | No TRS assessment  |
| 2003                | Emsley et al.   | Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia   | J Psychopharmacol                         | Overlapping sample                                       |
| 2003                | Haro et al.     | The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment  | Acta Psychiatr Scand Suppl                | Overlapping sample                                       |
| 2003                | Harrigan et al. | Does treatment delay in first-episode psychosis really matter?   | Psychological Medicine                    | No TRS assessment  |
| 2003                | Herken et al.   | T102C polymorphisms at the 5-HT2A receptor gene in Turkish schizophrenia patients: a possible association with prognosis   | Neuropsychobiology                        | No TRS assessment  |
| 2003                | Inada et al.    | Relationship between catechol-O-methyltransferase polymorphism and treatment-resistant schizophrenia   | Am J Med Genet B Neuropsychiatr Genet     | Wrong definition of TRS                                  |
| 2003                | Kasper et al.   | Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia  | Int J Neuropsychopharmacol                | No TRS assessment  |
| 2003                | Lambert et al.  | Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders   | Int Clin Psychopharmacol                  | Insufficient trials / duration or lacking AP information |
| 2003                | Potkin et al.   | Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial   | Biol Psychiatry                           | Overlapping sample                                       |
| 2003                | Potkin et al.   | Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder  | Schizophrenia Research                    | No TRS assessment  |
| 2003                | Soholm et al.   | Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients A mirror study   | Acta Psychiatr Scand                      | Insufficient or Wrong population                         |
| 2003                | Stirling et al. | Neurocognitive function and outcome in first-episode schizophrenia: a 10-year follow-up of an epidemiological cohort.  | Schizophrenia research                    | Insufficient trials / duration or lacking AP information |
| 2002                | Aguglia et al.  | Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics  | Prog Neuropsychopharmacol Biol Psychiatry | Insufficient or Wrong population                         |

| Year of publication | First author        | Title  | Journal   | Reason for exclusion                                     |
|---------------------|---------------------|--|---|--|
| 2002                | Barbui et al.       | Prescribing second-generation antipsychotics and the evolving standard of care in Italy  | Pharmacopsychiatry  | Insufficient trials / duration or lacking AP information |
| 2002                | Czobor et al.       | Antipsychotic-induced weight gain and therapeutic response: a differential association   | J Clin Psychopharmacol                                    | Insufficient or Wrong population                         |
| 2002                | Goldstein et al.    | Neurocognitive correlates of response to treatment in formal thought disorder in patients with first-episode schizophrenia                                 | Neuropsychiatry, Neuropsychology and Behavioral Neurology | Overlapping sample                                       |
| 2002                | Hotujac et al.      | Efficacy and safety of long-term risperidone treatment   | International Journal of Psychiatry in Clinical Practice  | No TRS assessment  |
| 2002                | Javitt et al.       | A naturalistic study of risperidone treatment outcome using prognosis-adjusted discharge rates in New York State inpatients                                | J Clin Psychiatry   | No TRS assessment  |
| 2002                | Leslie et al.       | From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications   | Am J Psychiatry   | No TRS assessment  |
| 2002                | Liao et al.         | Smoking in chronic schizophrenic inpatients in taiwan  | Neuropsychobiology  | No TRS assessment  |
| 2002                | Lindenmayer et al.  | Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study                            | J Clin Psychiatry   | Insufficient or Wrong population                         |
| 2002                | Malla et al.        | Status of patients with first-episode psychosis after one year of phase-specific community-oriented treatment  | Psychiatric services (Washington, DC)                     | No TRS assessment  |
| 2002                | Novak-Grubic et al. | Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder                                       | European Psychiatry                                       | No TRS assessment  |
| 2002                | Robinson et al.     | Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder   | Schizophrenia Research                                    | No TRS assessment  |
| 2002                | Umbrecht et al.     | Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia   | J Clin Psychiatry   | Insufficient or Wrong population                         |
| 2002                | Volavka et al.      | Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder                   | Am J Psychiatry   | Insufficient trials / duration or lacking AP information |
| 2002                | Voruganti et al.    | Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study  | Schizophr Res   | Insufficient trials / duration or lacking AP information |
| 2001                | Altamura et al.     | Duration of untreated psychosis as a predictor of outcome in first-episode schizophrenia: A retrospective study  | Schizophrenia Research                                    | No TRS assessment  |
| 2001                | Azorin et al.       | A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia  | Am J Psychiatry   | No TRS assessment  |
| 2001                | Citrome et al.      | Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia  | Psychiatr Serv  | No TRS assessment  |
| 2001                | Cramer et al.       | Detecting improvement in quality of life and symptomatology in schizophrenia   | Schizophr Bull  | Insufficient or Wrong population                         |
| 2001                | Davis et al.        | The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials | J Clin Psychiatry   | Wrong publication type                                   |



| Year of publication | First author       | Title   | Journal  | Reason for exclusion                                     |
|---------------------|--------------------|---|--|--|
| 2001                | Dossenbach, et al. | Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone  | J Clin Psychiatry  | No TRS assessment  |
| 2001                | Hotujac et al.     | Efficacy and safety of long-term risperidone treatment  | International Journal of Psychiatry in Clinical Practice | No TRS assessment  |
| 2001                | Kane et al.        | Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison                                    | Arch Gen Psychiatry                                      | Insufficient or Wrong population                         |
| 2001                | Levander et al.    | Schizophrenia--progressive and massive decline in response readiness by episodes  | Acta Psychiatr Scand Suppl                               | No TRS assessment  |
| 2001                | Sevy et al.        | Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder  | Acta Psychiatrica Scandinavica                           | No TRS assessment  |
| 2001                | Tollefson et al.   | Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine                     | Biol Psychiatry  | Insufficient or Wrong population                         |
| 2001                | Zhang et al.       | Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study      | Int Clin Psychopharmacol                                 | Insufficient or Wrong population                         |
| 2000                | Chen et al.        | Using a computer database to monitor compliance with pharmacotherapeutic guidelines for schizophrenia   | Psychiatr Serv   | No TRS assessment  |
| 2000                | Copolov et al.     | A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia                           | Psychol Med  | Insufficient trials / duration or lacking AP information |
| 2000                | Drake et al.       | The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia  | Schizophr Bull   | Wrong definition of TRS                                  |
| 2000                | Essock et al.      | Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals                                   | Arch Gen Psychiatry                                      | Insufficient or Wrong population                         |
| 2000                | Frangou et al.     | Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service                                      | Eur Psychiatry   | Insufficient trials / duration or lacking AP information |
| 2000                | Kaiser et al.      | Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia | Mol Psychiatry   | Insufficient trials / duration or lacking AP information |
| 2000                | Malaspina et al.   | Relation of familial schizophrenia to negative symptoms but not to the deficit syndrome   | Am J Psychiatry  | No TRS assessment  |
| 2000                | Ohaeri             | Naturalistic study of olanzapine in treatment-resistant schizophrenia and acute mania, depression and obsessional disorder                            | East Afr Med J   | Wrong definition of TRS                                  |
| 2000                | Sensky et al.      | A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication                        | Arch Gen Psychiatry                                      | Insufficient or Wrong population                         |
| 2000                | Tavcar et al.      | Choosing antipsychotic maintenance therapy--a naturalistic study  | Pharmacopsychiatry                                       | No TRS assessment  |
| 1999                | Duffett et al.     | Electroconvulsive therapy in Wales  | Psychiatric Bulletin                                     | No TRS assessment  |
| 1999                | Breier et al.      | Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia  | Biol Psychiatry  | Insufficient trials / duration or lacking AP information |
| 1999                | Chengappa et al.   | Risperidone use at a state hospital: a clinical audit 2 years after the first wave of risperidone prescriptions                                       | J Clin Psychiatry  | No TRS assessment  |

| Year of publication | First author     | Title   | Journal                            | Reason for exclusion                                     |
|---------------------|------------------|---|------------------------------------|--|
| 1999                | Chowdhury et al. | Horizon of a new hope: Recovery of schizophrenia in India   | International Medical Journal      | Insufficient trials / duration or lacking AP information |
| 1999                | Daniel et al.    | Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial                     | Neuropsychopharmacology            | Insufficient or Wrong population                         |
| 1999                | Galvin et al.    | Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center  | Clin Ther                          | Insufficient or Wrong population                         |
| 1999                | Hori et al.      | Criteria defining refractory schizophrenia  | Acta Psychiatr Scand               | Insufficient or Wrong population                         |
| 1999                | Howanitz et al.  | The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia   | J Clin Psychiatry                  | No TRS assessment  |
| 1999                | Ito et al.       | A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia  | Psychiatry Clin Neurosci           | No TRS assessment  |
| 1999                | Meltzer          | Suicide and schizophrenia: clozapine and the InterSePT study International Clozaril/Leponex Suicide Prevention Trial  | J Clin Psychiatry                  | Overlapping sample                                       |
| 1999                | Revicki et al.   | Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial | Quality of Life Research           | No TRS assessment  |
| 1999                | Robinson et al.  | Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder  | American Journal of Psychiatry     | Overlapping sample                                       |
| 1999                | Robinson et al.  | Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder  | Archives of General Psychiatry     | Insufficient trials / duration or lacking AP information |
| 1999                | Sajatovic et al. | Health resource utilization and clinical outcomes with risperidone therapy in patients with serious mental illness  | Compr Psychiatry                   | Insufficient or Wrong population                         |
| 1999                | Sanger et al.    | Olanzapine versus haloperidol treatment in first-episode psychosis  | American Journal of Psychiatry     | No TRS assessment  |
| 1999                | Stip et al.      | Discriminant cognitive factors in responder and non-responder patients with schizophrenia   | Eur Psychiatry                     | Insufficient or Wrong population                         |
| 1999                | Williams et al.  | Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia  | Med Care                           | Insufficient trials / duration or lacking AP information |
| 1998                | Agelink et al.   | Cardiovascular autonomic reactivity in schizophrenics under neuroleptic treatment: A potential predictor of short-term outcome?                                     | Neuropsychobiology                 | No TRS assessment  |
| 1998                | Arranz et al.    | Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response  | Pharmacogenetics                   | Insufficient or Wrong population                         |
| 1998                | Bondolfi et al.  | Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study The Risperidone Study Group                              | Am J Psychiatry                    | Insufficient or Wrong population                         |
| 1998                | Buchanan et al.  | Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome   | Am J Psychiatry                    | No TRS assessment  |
| 1998                | Conley et al.    | Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia  | Am J Psychiatry                    | Insufficient or Wrong population                         |
| 1998                | Coryell et al.   | Haloperidol plasma levels and dose optimization.  | The American Journal of Psychiatry | Insufficient trials / duration or lacking AP information |
| 1998                | Davies et al.    | Risperidone versus haloperidol: II Cost-effectiveness   | Clin Ther                          | No TRS assessment  |

| Year of publication | First author            | Title   | Journal                       | Reason for exclusion                                     |
|---------------------|-------------------------|---|-------------------------------|--|
| 1998                | Edwards et al.          | Prolonged recovery in first-episode psychosis   | Br J Psychiatry Suppl         | Overlapping sample                                       |
| 1998                | Ganguli et al.          | The effects of risperidone and olanzapine on the indications for clozapine  | Psychopharmacol Bull          | No TRS assessment  |
| 1998                | Jones et al.            | Risperidone is associated with blunting of D-fenfluramine evoked serotonergic responses in schizophrenia  | Int Clin Psychopharmacol      | No TRS assessment  |
| 1998                | Kiriakakis et al.       | The natural history of tardive dystonia A long-term follow-up study of 107 cases  | Brain                         | No TRS assessment  |
| 1998                | Krebs et al.            | Dopamine D3 receptor gene variants and substance abuse in schizophrenia   | Mol Psychiatry                | No TRS assessment  |
| 1998                | Lahdelma et al.         | Association between HLA-A1 allele and schizophrenia gene(s) in patients refractory to conventional neuroleptics but responsive to clozapine medication                | Tissue Antigens               | Insufficient or Wrong population                         |
| 1998                | Makikyro et al.         | Early developmental differences between DSM-III-R schizophrenics treated with clozapine and typical neuroleptics  | J Psychiatr Res               | Insufficient trials / duration or lacking AP information |
| 1998                | Malla et al.            | An integrated medical and psychosocial treatment program for psychotic disorders: patient characteristics and outcome   | Can J Psychiatry              | No TRS assessment  |
| 1998                | Meltzer et al.          | The evolution of treatment resistance: biologic implications  | J Clin Psychopharmacol        | Insufficient or Wrong population                         |
| 1998                | Power et al.            | Analysis of the initial treatment phase in first-episode psychosis  | British Journal of Psychiatry | No TRS assessment  |
| 1998                | Procyshyn et al.        | Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine   | Clin Ther                     | Insufficient trials / duration or lacking AP information |
| 1998                | Reid et al.             | Psychiatric hospital utilization in patients treated with clozapine for up to 45 years in a state mental health care system   | J Clin Psychiatry             | Insufficient or Wrong population                         |
| 1998                | Wiersma et al.          | Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort   | Schizophr Bull                | No TRS assessment  |
| 1997                | Arvanitis et al.        | Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo                       | Biol Psychiatry               | Insufficient trials / duration or lacking AP information |
| 1997                | Beasley et al.          | Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial   | Eur Neuropsychopharmacol      | Insufficient trials / duration or lacking AP information |
| 1997                | Chabannes et al.        | [Social trajectory and schizophrenia]   | Encephale                     | Wrong publication type                                   |
| 1997                | Fogelson et al.         | A naturalistic pilot study comparing haloperidol, clozapine, sertindole, and risperidone in partially responsive chronic schizophrenia or schizoaffective disorder    | J Clin Psychopharmacol        | Wrong publication type                                   |
| 1997                | McPhillips et al.       | Detecting comorbid substance misuse among people with schizophrenia in the community: a study comparing the results of questionnaires with analysis of hair and urine | Schizophr Res                 | No TRS assessment  |
| 1997                | Meltzer et al.          | Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance   | Am J Psychiatry               | Overlapping sample                                       |
| 1997                | Meyer-Lindenberg et al. | Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study  | Pharmacopsychiatry            | Insufficient or Wrong population                         |
| 1997                | Ohara et al.            | Anticipation and imprinting in schizophrenia  | Biol Psychiatry               | Wrong definition of TRS                                  |
| 1997                | Sajatovic et al.        | Outcome of clozapine therapy for elderly patients with refractory primary psychosis   | Int J Geriatr Psychiatry      | Insufficient or Wrong population                         |

| Year of publication | First author        | Title   | Journal                                   | Reason for exclusion                                     |
|---------------------|---------------------|---|---|--|
| 1997                | Sajatovic et al.    | Clinical characteristics and health resource use of men and women veterans with serious mental illness  | Psychiatr Serv                            | No TRS assessment  |
| 1997                | Sumiyoshi et al.    | Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance   | Biol Psychiatry                           | Overlapping sample                                       |
| 1997                | Tollefson et al.    | Olanzapine Versus Haloperidol in the Treatment of Schizophrenia and Schizoaffective and Schizophreniform Disorders: Results of an International Collaborative Trial                     | Am J Psychiatry                           | Overlapping sample                                       |
| 1997                | Weiden et al.       | Assessment and treatment selection for "revolving door" inpatients with schizophrenia   | Psychiatr Q                               | No TRS assessment  |
| 1996                | Boston et al.       | Serum cholesterol and treatment-resistance in schizophrenia   | Biol Psychiatry                           | Insufficient or Wrong population                         |
| 1996                | Bustillo et al.     | Differential effect of clozapine on weight: a controlled study  | Am J Psychiatry                           | Insufficient trials / duration or lacking AP information |
| 1996                | Chakos et al.       | Incidence and correlates of tardive dyskinesia in first episode of schizophrenia  | Archives of General Psychiatry            | Overlapping sample                                       |
| 1996                | Delini-Stula et al. | Antipsychotic effects of bretazenil, a partial benzodiazepine agonist in acute schizophrenia--a study group report.   | Journal of psychiatric research           | Insufficient or Wrong population                         |
| 1996                | Essock et al.       | Clozapine's effectiveness for patients in state hospitals: results from a randomized trial  | Psychopharmacol Bull                      | Overlapping sample                                       |
| 1996                | Findling et al.     | Pre-morbid asociality in neuroleptic-resistant and neuroleptic-responsive schizophrenia   | Psychol Med                               | Overlapping sample                                       |
| 1996                | Juarez-Reyes et al. | Clozapine eligibility: the effect of stringent criteria on ethnic, gender and age subgroups of schizophrenic patients   | Prog Neuropsychopharmacol Biol Psychiatry | No TRS assessment  |
| 1996                | Lieberman et al.    | Psychobiologic correlates of treatment response in schizophrenia  | Neuropsychopharmacology                   | Overlapping sample                                       |
| 1996                | Malhotra et al.     | Lack of association between polymorphisms in the 5-HT <sub>2A</sub> receptor gene and the antipsychotic response to clozapine   | Am J Psychiatry                           | No TRS assessment  |
| 1996                | Modai et al.        | Neural network based on adaptive resonance theory as compared to experts in suggesting treatment for schizophrenic and unipolar depressed in-patients                                   | J Med Syst                                | No TRS assessment  |
| 1996                | Nimgaonkar et al.   | 5-HT <sub>2</sub> receptor gene locus: association with schizophrenia or treatment response not detected  | Psychiatr Genet                           | Wrong definition of TRS                                  |
| 1996                | Schulz et al.       | Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adults with schizophrenia | J Child Adolesc Psychopharmacol           | Insufficient or Wrong population                         |
| 1996                | Shepski et al.      | Development and implementation of drug use evaluation (DUE) criteria for risperidone in an outpatient psychiatric setting   | Psychopharmacol Bull                      | No TRS assessment  |
| 1996                | Smith et al.        | Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study  | J Clin Psychiatry                         | Insufficient or Wrong population                         |
| 1996                | Weiden et al.       | Atypical antipsychotic drugs and long-term outcome in schizophrenia   | J Clin Psychiatry                         | No TRS assessment  |
| 1996                | Wieselgren et al.   | Symptoms at index admission as predictor for 1-5 year outcome in schizophrenia  | Acta Psychiatr Scand                      | Insufficient trials / duration or lacking AP information |
| 1996                | Wieselgren et al.   | A prospective 1-5 year outcome study in first-admitted and readmitted schizophrenic patients   relationship to heredity, premorbid adjustment,  | Acta Psychiatr Scand                      | Insufficient trials / duration or lacking AP information |

| Year of publication | First author     | Title   | Journal                                   | Reason for exclusion                                     |
|---------------------|------------------|---|---|--|
|                     |                  | duration of disease and education level at index admission and neuroleptic treatment  |   |  |
| 1995                | Jonsson et al.   | Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia   | Acta Psychiatr Scand                      | Insufficient or Wrong population                         |
| 1995                | Keck et al.      | Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders                            | J Clin Psychiatry                         | No TRS assessment  |
| 1995                | Kendler et al.   | Gender and schizophrenia Results of an epidemiologically-based family study   | Br J Psychiatry                           | No TRS assessment  |
| 1995                | Klieser et al.   | Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia                                     | J Clin Psychopharmacol                    | Insufficient trials / duration or lacking AP information |
| 1995                | Meltzer et al.   | Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment                         | Am J Psychiatry                           | Overlapping sample                                       |
| 1995                | Miller et al.    | Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate   | J Clin Pharm Ther                         | Insufficient trials / duration or lacking AP information |
| 1994                | Buchanan et al.  | The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance   | Biol Psychiatry                           | No TRS assessment  |
| 1994                | Heinrich et al.  | Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial                         | Prog Neuropsychopharmacol Biol Psychiatry | Insufficient trials / duration or lacking AP information |
| 1994                | Honer et al.     | Diagnostic reassessment and treatment response in schizophrenia   | J Clin Psychiatry                         | No TRS assessment  |
| 1994                | Klieser et al.   | The tolerability and efficacy of the atypical neuroleptic remoxipride compared with clozapine and haloperidol in acute schizophrenia                  | Acta Psychiatr Scand Suppl                | Insufficient trials / duration or lacking AP information |
| 1994                | Lieberman et al. | Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome   | Am J Psychiatry                           | Insufficient or Wrong population                         |
| 1994                | Mauri et al.     | Prediction of response to haloperidol in schizophrenia: neuroendocrine, neuromorphological and clinical variables                                     | Int Clin Psychopharmacol                  | No TRS assessment  |
| 1994                | Sokolski et al.  | Effects of substance abuse on hallucination rates and treatment responses in chronic psychiatric patients   | J Clin Psychiatry                         | No TRS assessment  |
| 1994                | Szymanski et al. | Clozapine response in treatment-refractory first-episode schizophrenia  | Biol Psychiatry                           | Insufficient or Wrong population                         |
| 1993                | Maden et al.     | The treatment and security needs of patients in special hospitals   | Criminal Behaviour and Mental Health      | No TRS assessment  |
| 1993                | Chouinard et al. | A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients      | J Clin Psychopharmacol                    | Insufficient trials / duration or lacking AP information |
| 1993                | Hori et al.      | The biological background of refractory schizophrenia: a study on clinical states, serum drug concentration, cognitive function and brain CT findings | Jpn J Psychiatry Neurol                   | Wrong definition of TRS                                  |
| 1993                | Kinon et al.     | Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects              | Psychopharmacol Bull                      | No TRS assessment  |
| 1993                | Kinon et al.     | Treatment of neuroleptic-resistant schizophrenic relapse  | Psychopharmacol Bull                      | No TRS assessment  |
| 1993                | O'Connor et al.  | Assessment of contributions to disability in people with schizophrenia during rehabilitation  | Aust N Z J Psychiatry                     | No TRS assessment  |

| Year of publication | First author        | Title  | Journal                                  | Reason for exclusion                                     |
|---------------------|---------------------|--|--|--|
| 1993                | Vartiainen et al.   | A long-term study of remoxipride in chronic schizophrenic patients   | Acta Psychiatr Scand                     | No TRS assessment  |
| 1992                | Collins et al.      | The pharmacoepidemiology of treatment-refractory schizophrenia   | Can J Psychiatry                         | Insufficient trials / duration or lacking AP information |
| 1992                | Loebel et al.       | Duration of psychosis and outcome in first-episode schizophrenia   | American Journal of Psychiatry           | Overlapping sample                                       |
| 1992                | Mohr et al.         | [Drug management and therapy resistance A cross-sectional study of schizophrenic patients in a large psychiatric hospital]   | Psychiatr Prax                           | No TRS assessment  |
| 1992                | Pere et al.         | [Clozapine (Leponex) in France]  | Encephale                                | Insufficient or Wrong population                         |
| 1991                | Govorin             | [HLA immunogenetic markers in predicting therapeutic resistance in paranoid schizophrenia]   | Zh Nevropatol Psikhiatr Im S S Korsakova | Insufficient trials / duration or lacking AP information |
| 1991                | Govorin et al.      | [Antibodies to neuroleptics and their role in the mechanisms of the development of drug resistance in psychopharmacotherapy of patients with paranoid schizophrenia] | Zh Nevropatol Psikhiatr Im S S Korsakova | Insufficient trials / duration or lacking AP information |
| 1990                | Bowers et al.       | Psychotogenic drug use and neuroleptic response  | Schizophr Bull                           | Insufficient or Wrong population                         |
| 1990                | Pelonerio et al.    | Ethical and clinical considerations in selecting patients who will receive clozapine   | Hosp Community Psychiatry                | Wrong publication type                                   |
| 1989                | McCreadie et al.    | The Scottish first episode schizophrenia study VII Two-year follow-up  | Acta Psychiatr Scand                     | No TRS assessment  |
| 1988                | Hegerl et al.       | Auditory evoked potentials as possible predictors of outcome in schizophrenic outpatients  | Int J Psychophysiol                      | No TRS assessment  |
| 1988                | Lerner et al.       | Lithium combined with haloperidol in schizophrenic patients  | Br J Psychiatry                          | Insufficient trials / duration or lacking AP information |
| 1987                | Claghorn et al.     | The risks and benefits of clozapine versus chlorpromazine  | J Clin Psychopharmacol                   | Insufficient or Wrong population                         |
| 1987                | Harada et al.       | Effectivity of zotepine in refractory psychoses: possible relationship between zotepine and non-dopamine psychosis   | Pharmacopsychiatry                       | Insufficient or Wrong population                         |
| 1987                | Higashi et al.      | Clinical and EEG studies of zotepine, a thiepine neuroleptic, on schizophrenic patients  | Pharmacopsychiatry                       | Insufficient trials / duration or lacking AP information |
| 1987                | Silverman et al.    | Familial schizophrenia and treatment response.   | Journal of Affective Disorders           | Insufficient trials / duration or lacking AP information |
| 1986                | Heim                | [Changes in the health state of schizophrenic patients in neuroleptic therapy]   | Psychiatr Neurol Med Psychol (Leipz)     | No TRS assessment  |
| 1985                | Kolakowska et al.   | Schizophrenia with good and poor outcome, I: early clinical features, response to neuroleptics, and signs of organic dysfunction                                     | Br J Psychiatry                          | No TRS assessment  |
| 1985                | Tang                | Prediction of treatment response in schizophrenia: clinical use of neuroleptic blood levels  | Can J Psychiatry                         | Wrong publication type                                   |
| 1984                | Fischer-Cornelissen | Fluperlapine in 104 schizophrenic patients Open multicenter trial  | Arzneimittelforschung                    | Insufficient trials / duration or lacking AP information |
| 1983                | Neppe               | Non-responsive psychosis--a biochemical difference?  | S Afr Med J                              | Wrong publication type                                   |
| 1981                | Itil et al.         | Computerized EEG as a predictor of drug response in treatment resistant schizophrenics   | J Nerv Ment Dis                          | No TRS assessment  |
| 1981                | Singh et al.        | Territorial behavior of schizophrenics A phylogenetic approach   | J Nerv Ment Dis                          | No TRS assessment  |
| 1980                | Kolakowska et al.   | Drug-related and illness-related factors in the outcome of chlorpromazine treatment: testing a model   | Psychol Med                              | Wrong definition of TRS                                  |

| Year of publication | First author     | Title  | Journal                          | Reason for exclusion                                     |
|---------------------|------------------|--|----------------------------------|--|
| 1980                | Kucharski et al. | Tardive dyskinesia and hospital discharge  | J Nerv Ment Dis                  | Wrong definition of TRS                                  |
| 1980                | Welbel           | [Differences in the clinical effect of various neuroleptics]   | Psychiatr Pol                    | No TRS assessment  |
| 1979                | Morselli et al.  | Clinical significance of monitoring plasma levels of psychotropic drugs  | Ciba Found Symp                  | Wrong publication type                                   |
| 1979                | Ruther           | [Anti-psychotic therapy with haloperidol and clozapine]  | Fortschr Med                     | No TRS assessment  |
| 1979                | Shopsin et al.   | Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison                | Arch Gen Psychiatry              | Insufficient or Wrong population                         |
| 1978                | Woggon           | Effects and side-effects of bromperidol in comparison with other antipsychotic drugs   | Acta Psychiatr Belg              | Wrong definition of TRS                                  |
| 1977                | Itoh et al.      | Some methodological considerations for the clinical evaluation of neuroleptics--comparative effects of clozapine and haloperidol on schizophrenics | Folia Psychiatr Neurol Jpn       | No TRS assessment  |
| 1977                | Spohn et al.     | Phenothiazine effects on psychological and psychophysiological dysfunction in chronic schizophrenics   | Arch Gen Psychiatry              | No TRS assessment  |
| 1976                | Ciurezu et al.   | [Double-blind clinical study of HF 1854 (LX 100-129, clozapine or leponex) as compared with haloperidol]   | Neurol Psychiatr (Bucur)         | No TRS assessment  |
| 1976                | Jus et al.       | A long-term study of penfluridol in chronic schizophrenia.   | Journal of clinical pharmacology | Insufficient or Wrong population                         |
| 1976                | van Praag et al. | Clozapine versus perphenazine: the value of the biochemical mode of action of neuroleptics in predicting their therapeutic activity                | Br J Psychiatry                  | Insufficient or Wrong population                         |
| 1975                | Dick et al.      | [Comparison of two antipsychotic drugs: chlorpromazine and clozapine (author's transl)]  | Ther Umsch                       | No TRS assessment  |
| 1975                | Kay et al.       | A developmental approach to delineate components of cognitive dysfunction in schizophrenia   | Br J Soc Clin Psychol            | No TRS assessment  |
| 1975                | Vencovsky et al. | [Comparison of therapeutic effect of clozapin and chlorpromazin (author's transl)]   | Cesk Psychiatr                   | Insufficient trials / duration or lacking AP information |
| 1975                | Weiser et al.    | [Advantages of the initial therapy of acute schizophrenia with large doses of droperidol/A comparative study (author's transl)]                    | Arzneimittelforschung            | Insufficient trials / duration or lacking AP information |
| 1974                | Ekblom et al.    | Clozapine (Leponex) compared with chlorpromazine: a double-blind evaluation of pharmacological and clinical properties                             | Curr Ther Res Clin Exp           | No TRS assessment  |
| 1973                | Donlon et al.    | A therapeutic aftercare setting for "refractory" chronic schizophrenic patients  | Am J Psychiatry                  | Wrong definition of TRS                                  |
| 1973                | Holden et al.    | Echoencephalographic patterns in chronic schizophrenia (relationship to therapy resistance)  | Biol Psychiatry                  | Wrong definition of TRS                                  |
| 1973                | Rodova et al.    | A blind comparison of clozapine and perphenazine in schizophrenics   | Act Nerv Super (Praha)           | Wrong publication type                                   |
| 1971                | Singer et al.    | Thiopropazate hydrochloride in persistent dyskinesia   | Br Med J                         | Insufficient or Wrong population                         |

**Table S4** Overall prevalence of TRS (all methods of prevalence extraction)

|                       |       | Test of heterogeneity |               |                             |         | Linear regression test of funnel plot asymmetry<br>(based on sample size) |                    |             |      |       |                |                |
|-----------------------|-------|-----------------------|---------------|-----------------------------|---------|---|--------------------|-------------|------|-------|----------------|----------------|
|                       |       | Prevalence (%)        | 95% CI        | I <sup>2</sup> (%) [95% CI] | p       | Number of studies   | Number of subjects | Peters test |      |       |                |                |
|                       |       |                       |               |                             |         |   |                    | t           | d.f. | p     | Bias (SE)      | Intercept (SE) |
| Intent-to-treat (ITT) | MC *1 | 36.81%                | 33.07 – 40.62 | 97.3% [96.9 – 97.7]         | <0.0001 | 49  | 28 753             | 2.05        | 47   | 0.046 | 10.397 (5.082) | 0.590 (0.020)  |
|                       | MC *2 | 36.74%                | 33.09 – 40.47 | 97.3% [96.9 – 97.7]         | <0.0001 | 50  | 29 390             | 2.07        | 48   | 0.044 | 10.388 (5.030) | 0.591 (0.019)  |
|                       | LC    | 37.38%                | 33.38 – 41.46 | 97.6% [97.2 – 97.9]         | <0.0001 | 48  | 27 755             | 2.11        | 46   | 0.040 | 11.215 (5.307) | 0.587 (0.021)  |
| Observed cases (OC)   | MC    | 37.92%                | 33.87 – 42.05 | 97.6% [97.2 – 97.9]         | <0.0001 | 48  | 27 561             | 2.23        | 46   | 0.031 | 11.550 (5.173) | 0.586 (0.021)  |
|                       | LC    | 38.22%                | 34.16 – 42.38 | 97.7% [97.4 – 98.0]         | <0.0001 | 49  | 28 260             | 2.26        | 47   | 0.029 | 11.791 (5.223) | 0.587 (0.021)  |

MC = Most conservative - LC = Less conservative

\*1 Only including studies that provided a ITT MC prevalence

\*2 Including also the OC LC prevalence provided by the CATIE study



**Table S5** Characteristics of the included studies

| Study                         | Country        | Study design               | Type of setting/type of patients                              | Described patients as "chronic" | Illness phase     | Diagnostics included                       | TRS proportion provided by the original study | Parameters for TRS definition | Number of participants | Prevalence: ITT (MC) (%) |
|-------------------------------|----------------|----------------------------|---|---------------------------------|-------------------|--|---|-------------------------------|------------------------|--------------------------|
| Panov et al. <sup>49</sup>    | Bulgaria       | Longitudinal observational | Not informed  | Yes                             | Multiple episodes | Only schizophrenia                         | Yes, primary objective                        | TRRIP                         | 105                    | 42.86                    |
| Chan et al. <sup>69</sup>     | China          | Longitudinal observational | Combined (inpatient and outpatients)                          | No                              | First episode     | Schizophrenia, schizoaffective and others  | Yes, primary objective                        | Non-standardized              | 1234                   | 15.40                    |
| Kogure et al. <sup>37</sup>   | Japan          | Cross-sectional            | Not informed  | No                              | Not informed      | Schizophrenia and schizoaffective          | Yes, secondary objective                      | Non-standardized              | 763                    | 22.41                    |
| Soares et al. <sup>68</sup>   | Brazil         | Cross-sectional            | Combined (outpatients)  | No                              | Both              | Only schizophrenia                         | Yes, primary objective                        | TRRIP                         | 205                    | 75.61                    |
| Spangaro et al. <sup>56</sup> | Italy          | Cross-sectional            | Not informed  | No                              | Not informed      | Only schizophrenia                         | Yes, secondary objective                      | TRRIP                         | 93                     | 65.59                    |
| Aytac et al. <sup>26</sup>    | Turkey         | Cross-sectional            | Not informed  | No                              | Not informed      | Only schizophrenia                         | Yes, secondary objective                      | Conley & Kelly <sup>6</sup>   | 113                    | 22.12                    |
| Werner et al. <sup>63</sup>   | Norway         | Cross-sectional            | Combined  | No                              | Not informed      | Schizophrenia, schizoaffective, and others | Yes, primary objective                        | TRRIP                         | 321                    | 33.64                    |
| Freitas et al. <sup>33</sup>  | International  | Cross-sectional            | Combined (outpatients)  | No                              | Not informed      | Only schizophrenia                         | Yes, secondary objective                      | Non-standardized              | 1429                   | 35.06                    |
| Sosin et al. <sup>55</sup>    | Russia         | Cross-sectional            | Combined  | No                              | Not informed      | Only schizophrenia                         | Yes, secondary objective                      | Non-standardized              | 130                    | 39.23                    |
| Iasevoli et al. <sup>34</sup> | Italy          | Longitudinal experimental  | Outpatient clinic for chronic schizophrenia /clozapine clinic | Yes                             | Multiple episodes | Only schizophrenia                         | Yes, secondary objective                      | APA                           | 60                     | 46.67                    |
| Moretti et al. <sup>45</sup>  | Brazil         | Cross-sectional            | Outpatient clinic for chronic schizophrenia /clozapine clinic | Yes                             | Not informed      | Only schizophrenia                         | Yes, secondary objective                      | IPAP                          | 162                    | 48.15                    |
| Thien et al. <sup>62</sup>    | Australia      | Longitudinal experimental  | Services for FEP patients (outpatients)                       | No                              | First episode     | Schizophrenia, schizoaffective, and others | Yes, primary objective                        | TRRIP                         | 335                    | 18.21                    |
| Demjaha et al. <sup>16</sup>  | United Kingdom | Longitudinal observational | Populational  | No                              | First episode     | Only schizophrenia                         | Yes, primary objective                        | NICE                          | 210                    | 33.33                    |
| Ortiz et al. <sup>48</sup>    | Brazil         | Longitudinal observational | Acute hospital admissions                                     | No                              | Both              | Only schizophrenia                         | Yes, secondary objective                      | IPAP                          | 203                    | 36.95                    |
| Lally et al. <sup>38</sup>    | United Kingdom | Longitudinal observational | Services for FEP patients (inpatient and outpatient)          | No                              | First episode     | Schizophrenia, schizoaffective, and others | Yes, primary objective                        | NICE                          | 240                    | 33.75                    |
| Martin et al. <sup>42</sup>   | Australia      | Cross-sectional            | Combined (inpatient and outpatient)                           | No                              | Not informed      | Only schizophrenia                         | Yes, secondary objective                      | Non-standardized              | 612                    | 37.09                    |
| Üçok et al. <sup>66</sup>     | Turkey         | Longitudinal observational | Combined (inpatient and outpatient)                           | No                              | First episode     | Only schizophrenia                         | Yes, secondary objective                      | Non-standardized              | 154                    | 22.72                    |

|                                  |                |                            |  |     |                   |                                   |                          |                             |      |       |
|----------------------------------|----------------|----------------------------|--|-----|-------------------|-----------------------------------|--------------------------|-----------------------------|------|-------|
| Wimberley et al. <sup>64</sup>   | Denmark        | Longitudinal observational | Populational   | No  | First episode     | Only schizophrenia                | Yes, primary objective   | Non-standardized            | 8044 | 21.17 |
| Silveira et al. <sup>54</sup>    | Brazil         | Cross-sectional            | Community mental health centers                              | No  | Not informed      | Schizophrenia and schizoaffective | Yes, primary objective   | IPAP                        | 406  | 25.37 |
| Suzuki et al. <sup>58</sup>      | Japan          | Cross-sectional            | Combined (inpatient and outpatient)                          | No  | Not informed      | Schizophrenia and schizoaffective | Yes, secondary objective | Non-standardized            | 539  | 25.42 |
| Bilic et al. <sup>29</sup>       | Croatia        | Longitudinal observational | Acute hospital admissions                                    | Yes | Not informed      | Only schizophrenia                | Yes, secondary objective | Non-standardized            | 173  | 53.18 |
| Cezaretto et al. <sup>30</sup>   | Brazil         | Cross-sectional            | Outpatient clinic for chronic schizophrenia/clozapine clinic | No  | Not informed      | Only schizophrenia                | Yes, secondary objective | IPAP                        | 68   | 52.94 |
| Lopes et al. <sup>41</sup>       | United Kingdom | Cross-sectional            | Long-term/security/rehabilitation center                     | No  | Not informed      | Schizophrenia and schizoaffective | Yes, primary objective   | NICE                        | 125  | 31.20 |
| Patel et al. <sup>50</sup>       | United Kingdom | Cross-sectional            | Populational   | No  | Not informed      | Schizophrenia and schizoaffective | Yes, primary objective   | Non-standardized            | 5055 | 43.96 |
| Schreiner et al. <sup>71</sup>   | International  | Longitudinal experimental  | Combined (inpatient and outpatients)                         | No  | Not informed      | Only schizophrenia                | No                       | N/A                         | 998  | 38.76 |
| Terzić et al. <sup>61</sup>      | Slovenia       | Cross-sectional            | Not informed   | No  | Not informed      | Only schizophrenia                | Yes, secondary objective | Conley & Kelly <sup>6</sup> | 138  | 31.88 |
| ElGamal et al. <sup>31</sup>     | Kuwait         | Cross-sectional            | Long-term/security/rehabilitation center                     | Yes | Multiple episodes | Schizophrenia and schizoaffective | Yes, primary objective   | Kane et al. <sup>4</sup>    | 95   | 37.89 |
| Chen et al. <sup>70</sup>        | Taiwan         | Longitudinal experimental  | Acute hospital admissions                                    | No  | Multiple episodes | Only schizophrenia                | No                       | N/A                         | 48   | 50.00 |
| Agid et al. <sup>25</sup>        | Canada         | Longitudinal experimental  | Services for FEP patients (outpatients)                      | No  | First episode     | Schizophrenia and schizoaffective | Yes, primary objective   | Nonresponders to trials     | 244  | 20.49 |
| Takebayashi et al. <sup>60</sup> | Japan          | Longitudinal observational | Acute hospital admissions                                    | No  | Not informed      | Only schizophrenia                | Yes, secondary objective | Non-standardized            | 129  | 24.81 |
| Mortimer et al. <sup>46</sup>    | United Kingdom | Cross-sectional            | Long-term/security/rehabilitation center                     | No  | Not informed      | Schizophrenia and schizoaffective | Yes, primary objective   | NICE                        | 132  | 46.97 |
| Sánchez et al. <sup>51</sup>     | Spain          | Longitudinal experimental  | Long-term/security/rehabilitation center                     | No  | Not informed      | Only schizophrenia                | Yes, secondary objective | Kane et al. <sup>4</sup>    | 95   | 54.74 |
| Suzuki et al. <sup>57</sup>      | Japan          | Longitudinal experimental  | Acute hospital admissions                                    | No  | Both              | Only schizophrenia                | Yes, primary objective   | Nonresponders to trials     | 78   | 25.64 |
| CATIE study <sup>40</sup>        | United States  | Longitudinal experimental  | Combined (inpatient and outpatients)                         | Yes | Multiple episodes | Only schizophrenia                | No                       | N/A                         | 637  | 34.22 |
| Mundo et al. <sup>47</sup>       | Italy          | Cross-sectional            | Long-term/security/rehabilitation center                     | No  | Not informed      | Schizophrenia and schizoaffective | Yes, secondary objective | Kane et al. <sup>4</sup>    | 120  | 46.67 |
| McGurk et al. <sup>44</sup>      | United States  | Cross-sectional            | Acute hospital admissions                                    | No  | Not informed      | Schizophrenia and schizoaffective | Yes, secondary objective | Kane et al. <sup>4</sup>    | 34   | 41.18 |

|                                  |                |                           |  |     |                   |  |                          |                              |      |       |
|----------------------------------|----------------|---------------------------|--|-----|-------------------|--|--------------------------|------------------------------|------|-------|
| Woodall et al. <sup>65</sup>     | Wales          | Cross-sectional           | Combined (inpatient and outpatients)     | No  | Not informed      | Schizophrenia, schizoaffective, and others | Yes, secondary objective | NICE                         | 91   | 64.84 |
| Meltzer et al. <sup>67</sup>     | International  | Cross-sectional           | Combined                                 | No  | Not informed      | Schizophrenia and schizoaffective          | Yes, secondary objective | Non-standardized             | 980  | 26.84 |
| Sayal et al. <sup>52</sup>       | United Kingdom | Cross-sectional           | Long-term/security/rehabilitation center | No  | Not informed      | Only schizophrenia                         | Yes, primary objective   | Kane et al. <sup>4</sup>     | 80   | 67.50 |
| Barnes et al. <sup>27</sup>      | United Kingdom | Cross-sectional           | Services for FEP patients (inpatients)   | No  | First episode     | Only schizophrenia                         | Yes, secondary objective | Brenner et al. <sup>76</sup> | 48   | 16.67 |
| Emsley et al. <sup>32</sup>      | International  | Longitudinal experimental | Combined                                 | No  | Not informed      | Only schizophrenia                         | No                       | N/A                          | 365  | 50.41 |
| McGurk et al. <sup>43</sup>      | United States  | Cross-sectional           | Long-term/security/rehabilitation center | Yes | Multiple episodes | Only schizophrenia                         | Yes, secondary objective | Kane et al. <sup>4</sup>     | 31   | 54.84 |
| Breier et al. <sup>29</sup>      | International  | Cross-sectional           | Combined (inpatient and outpatient)      | No  | Multiple episodes | Schizophrenia, schizoaffective, and others | Yes, secondary objective | Non-standardized             | 1996 | 26.35 |
| Swinton et al. <sup>59</sup>     | United Kingdom | Cross-sectional           | Long-term/security/rehabilitation center | Yes | Not informed      | Schizophrenia and schizoaffective          | Yes, primary objective   | Non-standardized             | 74   | 43.24 |
| Jeste et al. <sup>36</sup>       | United States  | Cross-sectional           | Combined (inpatient and outpatient)      | No  | Multiple episodes | Only schizophrenia                         | Yes, secondary objective | Kane et al. <sup>4</sup>     | 910  | 27.58 |
| Essock et al. <sup>8</sup>       | United States  | Cross-sectional           | Long-term/security/rehabilitation center | Yes | Multiple episodes | Schizophrenia and schizoaffective          | Yes, primary objective   | Eligible for clozapine       | 803  | 48.82 |
| Juarez-Reyes et al. <sup>7</sup> | United States  | Cross-sectional           | Populational                             | No  | Both              | Schizophrenia and schizoaffective          | Yes, primary objective   | Eligible for clozapine       | 293  | 32.42 |
| Lieberman et al. <sup>39</sup>   | United States  | Longitudinal experimental | Services for FEP patients (inpatients)   | No  | First episode     | Schizophrenia and schizoaffective          | Yes, primary objective   | Non-standardized             | 70   | 17.14 |
| Shalev et al. <sup>53</sup>      | Israel         | Longitudinal experimental | Acute hospital admissions                | No  | Not informed      | Only schizophrenia                         | Yes, primary objective   | Nonresponders to trials      | 60   | 15.00 |
| Itil et al. <sup>35</sup>        | United States  | Longitudinal experimental | Long-term/security/rehabilitation center | Yes | Not informed      | Only schizophrenia                         | Yes, secondary objective | Nonresponders to trials      | 62   | 54.84 |

APA = American Psychiatric Association; FEP = first-episode psychosis; IPAP = International Psychopharmacology Algorithm Project; ITT = intent-to-treat; MC = most conservative; N/A = not available; NICE = National Institute of Clinical Excellence; TRRIP = Treatment Response and Resistance in Psychosis Working Group; TRS = treatment-resistant schizophrenia.


**Table S6** Prevalence of early- and late-TRS

|                  | Prevalence (%) | 95% CI        | Test of heterogeneity |          |        | Number of studies | Number of subjects |
|------------------|----------------|---------------|-----------------------|----------|--------|-------------------|--------------------|
|                  |                |               | I2 (%)                | 95% CI   | p      |                   |                    |
| <b>Early-TRS</b> | 23.57%         | 20.47 – 26.81 | 36.5                  | 0 – 79.8 | 0.207  | 3                 | 694                |
| <b>Late-TRS</b>  | 9.32%          | 6.78 – 12.21  | -                     |          | 0.6125 | 2                 | 450                |


Obs. ITT MC, ITT LC, OC MC and OC LC were identical

**Figure S2** Forest plots for early- and late- TRS prevalences

**Early-TRS prevalences**



**Late-TRS prevalences**



**Table S7** Subgroup analysis

|  | ITT MC <sup>2</sup> Prevalence (%) | 95% CI        | Test of heterogeneity |         | Number of studies | Test for subgroup differences |      |         |
|--|------------------------------------|---------------|-----------------------|---------|-------------------|-------------------------------|------|---------|
|  |                                    |               | I <sup>2</sup> (%)    | p       |                   | Q                             | d.f. | p       |
| <i>Diagnosis included</i>                          |                                    |               |                       |         |                   |                               |      |         |
| Only schizophrenia                                 | 40.02%                             | 34.69 – 45.47 | 97.0%                 | <0.0001 | 29                |                               |      |         |
| Schizophrenia and schizoaffective disorder         | 33.37%                             | 27.53 – 39.48 | 96.4%                 | <0.0001 | 15                |                               |      |         |
| Schizophrenia, schizoaffective disorder and others | 30.38%                             | 21.85 – 39.64 | 96.9%                 | <0.0001 | 6                 |                               |      |         |
| Total  | 36.74%                             | 33.09 – 40.47 | 97.3%                 | <0.0001 | 50                | 4.39                          | 2    | 0.111   |
| <i>Illness phase</i>                               |                                    |               |                       |         |                   |                               |      |         |
| First episode                                      | 21.98%                             | 18.40 – 25.78 | 87.8%                 | <0.0001 | 9                 |                               |      |         |
| Multiple episode                                   | 39.49%                             | 32.19 – 47.03 | 95.0%                 | <0.0001 | 9                 |                               |      |         |
| Total  | 30.07%                             | 25.44 – 34.90 | 96.3%                 | <0.0001 | 18                | 18.27                         | 1    | <0.0001 |
| <i>Chronic subjects</i>                            |                                    |               |                       |         |                   |                               |      |         |
| No   | 34.58%                             | 30.64 – 38.62 | 97.5%                 | <0.0001 | 40                |                               |      |         |
| Yes  | 45.75%                             | 40.26 – 51.29 | 80.5%                 | <0.0001 | 10                |                               |      |         |
| Total  | 36.74%                             | 33.09 – 40.47 | 97.3%                 | <0.0001 | 50                | 10.44                         | 1    | 0.001   |
| <i>Study design</i>                                |                                    |               |                       |         |                   |                               |      |         |
| Cross-sectional                                    | 39.54%                             | 35.17 – 43.99 | 96.3%                 | <0.0001 | 29                |                               |      |         |
| Longitudinal observational                         | 30.65%                             | 24.22 – 37.48 | 95.8%                 | <0.0001 | 9                 |                               |      |         |

|   | ITT MC <sup>2</sup> Prevalence (%) | 95% CI        | Test of heterogeneity |         | Number of studies | Test for subgroup differences |      |        |
|---|------------------------------------|---------------|-----------------------|---------|-------------------|-------------------------------|------|--------|
|   |                                    |               | I <sup>2</sup> (%)    | p       |                   | Q                             | d.f. | p      |
| Longitudinal experimental                                       | 34.49%                             | 27.22 – 42.13 | 93.8%                 | <0.0001 | 12                |                               |      |        |
| Total   | 36.74%                             | 33.09 – 40.47 | 97.3%                 | <0.0001 | 50                | 4.99                          | 2    | 0.083  |
| <i>Continent</i>  |                                    |               |                       |         |                   |                               |      |        |
| International - Multicenter                                     | 35.03%                             | 28.22 – 42.16 | 96.7%                 | <0.0001 | 5                 |                               |      |        |
| Europe  | 42.58%                             | 35.11 – 50.22 | 98.2%                 | <0.0001 | 19                |                               |      |        |
| Asia  | 24.73%                             | 20.05 – 29.72 | 86.9%                 | <0.0001 | 10                |                               |      |        |
| North America   | 35.34%                             | 27.58 – 43.51 | 94.3%                 | <0.0001 | 9                 |                               |      |        |
| Oceania   | 27.21%                             | 11.07 – 47.26 | 97.5%                 | <0.0001 | 2                 |                               |      |        |
| South America   | 47.68%                             | 28.47 – 67.24 | 97.5%                 | <0.0001 | 5                 |                               |      |        |
| Total   | 36.74%                             | 34.09 – 40.47 | 97.3%                 | <0.0001 | 50                | 19.75                         | 5    | 0.0014 |
| <i>TRS criteria: How was TRS criteria defined?</i>              |                                    |               |                       |         |                   |                               |      |        |
| Kane et al.   | 46.71%                             | 33.8 - 59.84  | 93.0%                 | <0.0001 | 7                 |                               |      |        |
| Brenner et al.  | 16.67%                             | 7.26 – 28.7   | --                    | --      | 1                 |                               |      |        |
| IPAP  | 39.98%                             | 27.6 – 53.03  | 92.2%                 | <0.0001 | 4                 |                               |      |        |
| NICE  | 41.45%                             | 31.06 – 52.24 | 89.2%                 | <0.0001 | 5                 |                               |      |        |
| APA   | 46.67%                             | 34.13 – 59.42 | --                    | --      | 1                 |                               |      |        |
| Conley & Kelly  | 27.03%                             | 18.07 – 37.04 | 66.1%                 | <0.0001 | 2                 |                               |      |        |
| TRRIP   | 46.73%                             | 24.70 – 69.45 | 98.2%                 | <0.0001 | 5                 |                               |      |        |
| Original study defined TRS criteria, but it wasn't standardized | 29.69%                             | 23.97 – 35.74 | 98.6%                 | <0.0001 | 15                |                               |      |        |

|   | ITT MC <sup>2</sup> Prevalence (%) | 95% CI        | Test of heterogeneity |         | Number of studies | Test for subgroup differences |      |       |
|---|------------------------------------|---------------|-----------------------|---------|-------------------|-------------------------------|------|-------|
|   |                                    |               | I <sup>2</sup> (%)    | p       |                   | Q                             | d.f. | p     |
| Original study didn't define a TRS criteria                               | 36.56%                             | 29.98 – 43.40 | 93.3%                 | <0.0001 | 10                |                               |      |       |
| Total   | 36.74%                             | 33.09 – 40.47 | 97.3%                 | <0.0001 | 50                | 23.44                         | 8    | 0.003 |
| <i>TRS criteria: Use of clozapine also included as criteria for TRS?*</i> |                                    |               |                       |         |                   |                               |      |       |
| No  | 37.20%                             | 32.72 – 41.79 | 95.1%                 | <0.0001 | 37                |                               |      |       |
| Yes   | 35.37%                             | 27.90 – 43.22 | 98.9%                 | <0.0001 | 12                |                               |      |       |
| Total   | 36.71%                             | 32.97 – 40.52 | 97.3%                 | <0.0001 | 49                | 0.17                          | 1    | 0.679 |
| <i>TRS criteria: Intolerability also considered for AP switch?</i>        |                                    |               |                       |         |                   |                               |      |       |
| No  | 39.67%                             | 35.77 – 43.63 | 95.5%                 | <0.0001 | 34                |                               |      |       |
| Yes or NI   | 30.00%                             | 25.49 – 34.71 | 94.6%                 | <0.0001 | 16                |                               |      |       |
| Total   | 36.74%                             | 33.09 – 40.47 | 97.3%                 | <0.0001 | 50                | 9.53                          | 1    | 0.002 |
| <i>Was a TRS proportion provided by the original study?</i>               |                                    |               |                       |         |                   |                               |      |       |
| No  | 42.15%                             | 34.79 – 49.68 | 89.2%                 | <0.0001 | 4                 |                               |      |       |
| Yes, secondary objective  | 37.77%                             | 37.66 – 41.97 | 92.9%                 | <0.0001 | 25                |                               |      |       |
| Yes, primary objective  | 34.07%                             | 27.54 – 40.93 | 98.5%                 | <0.0001 | 21                |                               |      |       |
| Total   | 36.74%                             | 33.09 – 40.47 | 97.3%                 | <0.0001 | 50                | 2.48                          | 2    | 0.299 |
| <i>Inpatient / Outpatient</i>   |                                    |               |                       |         |                   |                               |      |       |
| Inpatient   | 38.26%                             | 30.52 – 46.31 | 91.3%                 | <0.0001 | 13                |                               |      |       |



|  | ITT MC <sup>2</sup> Prevalence (%) | 95% CI        | Test of heterogeneity |         | Number of studies | Test for subgroup differences |      |        |
|--|------------------------------------|---------------|-----------------------|---------|-------------------|-------------------------------|------|--------|
|  |                                    |               | I <sup>2</sup> (%)    | p       |                   | Q                             | d.f. | p      |
| Outpatient   | 38.04%                             | 30.92 – 45.43 | 96.7%                 | <0.0001 | 13                |                               |      |        |
| Both   | 32.48%                             | 27.90 – 37.23 | 96.5%                 | <0.0001 | 16                |                               |      |        |
| Total  | 36.09%                             | 32.05 – 40.23 | 97.5%                 | <0.0001 | 42                | 2.48                          | 2    | 0.290  |
| <i>Study evaluated only symptomatic at baseline (inclusion criteria)</i>                     |                                    |               |                       |         |                   |                               |      |        |
| No   | 38.03%                             | 33.45 – 42.71 | 97.7%                 | <0.0001 | 35                |                               |      |        |
| Yes  | 33.89%                             | 28.00 – 40.04 | 94.8%                 | <0.0001 | 15                |                               |      |        |
| Total  | 36.74%                             | 33.09 – 40.47 | 97.3%                 | <0.0001 | 50                | 1.11                          | 1    | 0.291  |
| <i>Did the study only include subjects who had already been non-responders one AP trial?</i> |                                    |               |                       |         |                   |                               |      |        |
| No   | 36.30%                             | 32.20 – 40.49 | 97.4%                 | <0.0001 | 44                |                               |      |        |
| Yes  | 39.88%                             | 31.68 – 48.38 | 95.5%                 | <0.0001 | 6                 |                               |      |        |
| Total  | 36.74%                             | 33.09 – 40.47 | 97.3%                 | <0.0001 | 50                | 0.57                          | 1    | 0.452  |
| <i>Diagnostic criteria</i>   |                                    |               |                       |         |                   |                               |      |        |
| DSM-III  | 26.28%                             | 22.49 – 30.26 | 64.4%                 | <0.0001 | 4                 |                               |      |        |
| DSM-IV or DSM-5  | 36.29%                             | 31.92 – 40.77 | 92.0%                 | <0.0001 | 25                |                               |      |        |
| ICD-10   | 39.75%                             | 31.67 – 48.13 | 98.8%                 | <0.0001 | 14                |                               |      |        |
| Other  | 35.51%                             | 19.78 – 53.00 | 90.8%                 | <0.0001 | 3                 |                               |      |        |
| Total  | 36.50%                             | 32.85 – 40.22 | 97.0%                 | <0.0001 | 46                | 15.02                         | 3    | 0.0018 |

|  | ITT MC <sup>2</sup> Prevalence (%) | 95% CI        | Test of heterogeneity |         | Number of studies | Test for subgroup differences |      |         |
|--|------------------------------------|---------------|-----------------------|---------|-------------------|-------------------------------|------|---------|
|  |                                    |               | I <sup>2</sup> (%)    | p       |                   | Q                             | d.f. | p       |
| <i>Method to evaluate response</i>                             |                                    |               |                       |         |                   |                               |      |         |
| Standardized scale (eg· PANSS, BPRS, SANS, SAPS)               | 36.63%                             | 31.52 – 41.88 | 93.2%                 | <0.0001 | 20                |                               |      |         |
| Other scale (eg· CGI, GAF)                                     | 34.29%                             | 23.25 – 46.25 | 93.9%                 | <0.0001 | 6                 |                               |      |         |
| Clinical evaluation  | 35.12%                             | 32.9 – 37.37  | 0.0%                  | 0.264   | 3                 |                               |      |         |
| Total  | 35.89%                             | 31.99 – 39.88 | 92.6%                 | <0.0001 | 29                | 0.34                          | 2    | 0.845   |
| <i>Type of facility</i>  |                                    |               |                       |         |                   |                               |      |         |
| Acute hospital admissions                                      | 34.59%                             | 24.43 – 45.50 | 88.0%                 | <0.0001 | 7                 |                               |      |         |
| Long-term admissions / Security unity / Rehabilitation centers | 48.06%                             | 42.38 – 53.77 | 74.6%                 | <0.0001 | 10                |                               |      |         |
| Community mental health centers                                | 25.37%                             | 21.25 – 29.72 | --                    | --      | 1                 |                               |      |         |
| Services for FEP patients                                      | 21.52%                             | 15.25 – 28.52 | 81.3%                 | <0.0001 | 5                 |                               |      |         |
| Outpatient clinic for chronic schizophrenia / clozapine clinic | 48.96%                             | 43.17 – 54.77 | 0.0%                  | 0.745   | 3                 |                               |      |         |
| Populational   | 32.43%                             | 18.33 – 48.38 | 99.6%                 | <0.0001 | 4                 |                               |      |         |
| Total  | 37.31%                             | 31.83 – 42.95 | 97.5%                 | <0.0001 | 30                | 75.09                         | 5    | <0.0001 |
| <i>Mean duration of illness</i>                                |                                    |               |                       |         |                   |                               |      |         |
| < 5 years  | 23.49%                             | 17.23 – 30.38 | 84.2%                 | <0.0001 | 6                 |                               |      |         |
| > 10 years   | 46.60%                             | 40.29 – 52.97 | 94.2%                 | <0.0001 | 18                |                               |      |         |
| Total  | 40.33%                             | 34.67 – 46.12 | 94.7%                 | <0.0001 | 24                | 22.99                         | 1    | <0.0001 |
| <i>Duration of follow-up</i>                                   |                                    |               |                       |         |                   |                               |      |         |
| < 6 months   | 40.34%                             | 30.96 – 50.09 | 85.7%                 | <0.0001 | 6                 |                               |      |         |

|                                     | ITT MC <sup>2</sup> Prevalence (%) | 95% CI        | Test of heterogeneity |         | Number of studies | Test for subgroup differences |      |       |
|-------------------------------------|------------------------------------|---------------|-----------------------|---------|-------------------|-------------------------------|------|-------|
|                                     |                                    |               | I <sup>2</sup> (%)    | p       |                   | Q                             | d.f. | p     |
| 6 - 12 months                       | 31.22%                             | 18.09 – 46.06 | 94.4%                 | <0.0001 | 4                 |                               |      |       |
| > 12 months                         | 25.01%                             | 20.21 – 30.13 | 94.2%                 | <0.0001 | 8                 |                               |      |       |
| Total                               | 31.03%                             | 25.76 – 36.56 | 96.3%                 | <0.0001 | 18                | 8.32                          | 2    | 0.016 |
| <i>Minimal duration of AP trial</i> |                                    |               |                       |         |                   |                               |      |       |
| 4 weeks                             | 33.08%                             | 27.08 – 39.37 | 95.4%                 | <0.0001 | 14                |                               |      |       |
| 6 weeks                             | 38.41%                             | 32.26 – 44.75 | 97.5%                 | <0.0001 | 24                |                               |      |       |
| 8 weeks or longer                   | 35.94%                             | 26.03 – 46.49 | 94.0%                 | <0.0001 | 5                 |                               |      |       |
| Total                               | 36.32%                             | 32.05 – 40.69 | 97.5%                 | <0.0001 | 43                | 1.43                          | 2    | 0.490 |
| <i>Decade of publication</i>        |                                    |               |                       |         |                   |                               |      |       |
| 1970-1979                           | 54.84%                             | 42.28 – 67.10 | --                    | --      | 1                 |                               |      |       |
| 1990-1999                           | 30.03%                             | 22.16 – 38.54 | 96.1%                 | <0.0001 | 7                 |                               |      |       |
| 2000-2009                           | 42.27%                             | 33.04 – 51.78 | 94.3%                 | <0.0001 | 10                |                               |      |       |
| 2010-2019                           | 35.61%                             | 30.64 – 40.75 | 97.6%                 | <0.0001 | 25                |                               |      |       |
| 2020-2029                           | 38.69%                             | 23.46 – 55.14 | 98.5%                 | <0.0001 | 7                 |                               |      |       |
| Total                               | 36.74%                             | 33.09 – 40.47 | 97.3%                 | <0.0001 | 50                | 12.06                         | 4    | 0.017 |


**Table S8** Meta-regression analysis (ITT MC2)

| Category                             | Estimate | SE     | Lower   | Upper   | p       | Number of studies |
|--------------------------------------|----------|--------|---------|---------|---------|-------------------|
| <i>Overall study characteristics</i> |          |        |         |         |         |                   |
| Date of publication                  | -0.0007  | 0.0020 | -0.0046 | 0.0033  | 0.7468  | 50                |
| Intercept                            | 1.9719   | 4.078  | -6.0399 | 9.9838  | 0.6295  |                   |
| Mean age                             | 0.0066   | 0.0033 | 0.0002  | 0.0131  | 0.0436  | 36                |
| Intercept                            | 0.4161   | 0.1279 | 0.1655  | 0.6668  | 0.0011  |                   |
| % Male                               | 0.032    | 0.0019 | -0.0005 | 0.0069  | 0.0923  | 38                |
| Intercept                            | 0.4582   | 0.1247 | 0.2138  | 0.7025  | 0.0002  |                   |
| % Caucasian                          | 0.0020   | 0.0020 | -0.0018 | 0.0058  | 0.3022  | 11                |
| Intercept                            | 0.4891   | 0.1336 | 0.2272  | 0.7510  | 0.0003  |                   |
| % African descendants                | -0.0025  | 0.0022 | -0.0069 | 0.0018  | 0.2582  | 8                 |
| Intercept                            | 0.6951   | 0.0597 | 0.5782  | 0.8121  | <0.0001 |                   |
| % Asian                              | 0.0014   | 0.0088 | -0.0160 | 0.0187  | 0.8756  | 6                 |
| Intercept                            | 0.6376   | 0.0595 | 0.5210  | 0.7542  | <0.0001 |                   |
| Mean illness duration                | 0.0052   | 0.0078 | -0.0101 | 0.0205  | 0.5022  | 17                |
| Intercept                            | 0.6540   | 0.1187 | 0.4215  | 0.8866  | <0.0001 |                   |
| Mean age of onset                    | -0.0223  | 0.0196 | -0.0608 | 0.0162  | 0.2567  | 17                |
| Intercept                            | 1.2306   | 0.4545 | 0.3398  | 2.1215  | 0.0068  |                   |
| Mean total PANSS - final score       | 0.0006   | 0.0021 | -0.0035 | 0.0047  | 0.7906  | 12                |
| Intercept                            | 0.6458   | 0.1522 | 0.3475  | 0.9442  | <0.0001 |                   |
| Mean CGI - final score               | 0.0265   | 0.1064 | -0.1820 | 0.2350  | 0.2490  | 9                 |
| Intercept                            | 0.6404   | 0.4397 | -0.2213 | 1.5021  | 0.1452  |                   |
| Mean GAF - final score               | -0.0260  | 0.0122 | -0.0498 | -0.0022 | 0.0324  | 4                 |
| Intercept                            | 2.0595   | 0.6621 | 0.07618 | 3.3573  | 0.0019  |                   |
| Mean DUP                             | 0.0035   | 0.0084 | -0.0129 | 0.0199  | 0.6767  | 7                 |
| Intercept                            | 0.5947   | 0.1162 | 0.3670  | 0.8224  | <0.0001 |                   |
| % UTRS                               | 0.0223   | 0.0141 | -0.0054 | 0.0500  | 0.1140  | 8                 |
| Intercept                            | 0.1150   | 0.3706 | -0.6113 | 0.8413  | 0.7563  |                   |
| % Clozapine users                    | 0.0056   | 0.0016 | 0.0025  | 0.0087  | 0.0003  | 22                |
| Intercept                            | 0.5285   | 0.0496 | 0.4313  | 0.6257  | <0.0001 |                   |
| Dropout rate                         | 0.0023   | 0.0016 | -0.0008 | 0.0054  | 0.1508  | 17                |
| Intercept                            | 0.5771   | 0.0332 | 0.5119  | 0.6422  | <0.0001 |                   |

| Category   | Estimate | SE     | Lower   | Upper   | p       | Number of studies |
|--|----------|--------|---------|---------|---------|-------------------|
| Mean final antipsychotic dose                    | 0.0577   | 0.1196 | -0.1767 | 0.2921  | 0.6295  | 12                |
| Intercept  | 0.6394   | 0.0932 | 0.4568  | 0.8220  | <0.0001 |                   |
| Response criteria: % of PANSS (or equivalent)    | -0.0038  | 0.0034 | -0.0106 | 0.0029  | 0.2635  | 14                |
| Intercept  | 0.7838   | 0.0891 | 0.6093  | 0.9584  | <0.0001 |                   |
| <i>TRRIP criteria</i>                            |          |        |         |         |         |                   |
| Total score                                      | -0.0143  | 0.0052 | -0.0244 | -0.0041 | 0.0059  | 50                |
| Intercept  | 0.7598   | 0.0439 | 0.6738  | 0.8458  | <0.0001 |                   |
| Current Symptoms: Assessment                     | -0.0353  | 0.0246 | -0.0835 | 0.0129  | 0.1513  | 50                |
| Intercept  | 0.6852   | 0.0304 | 0.6257  | 0.7447  | <0.0001 |                   |
| Current Symptoms: Severity                       | -0.0641  | 0.0322 | -0.1272 | -0.0011 | 0.0462  | 50                |
| Intercept  | 0.7031   | 0.0325 | 0.6394  | 0.7669  | <0.0001 |                   |
| Current Symptoms: Duration                       | -0.0220  | 0.0278 | -0.0764 | 0.0324  | 0.4281  | 50                |
| Intercept  | 0.6674   | 0.0269 | 0.6146  | 0.7202  | <0.0001 |                   |
| Current Symptoms: Functioning                    | -0.0439  | 0.0211 | -0.0853 | -0.0025 | 0.0376  | 50                |
| Intercept  | 0.6812   | 0.0242 | 0.6338  | 0.7285  | <0.0001 |                   |
| Adequate Treatment: Assessment of past response* | NA       |        |         |         |         | 50                |
| Intercept  |          |        |         |         |         |                   |
| Adequate Treatment: Duration                     | -0.0427  | 0.0270 | -0.0956 | 0.0102  | 0.1138  | 50                |
| Intercept  | 0.6678   | 0.0217 | 0.6252  | 0.7103  | <0.0001 |                   |
| Adequate Treatment: Dosage                       | -0.0417  | 0.0264 | -0.0934 | 0.0101  | 0.1144  | 50                |
| Intercept  | 0.6666   | 0.0215 | 0.6244  | 0.7088  | <0.0001 |                   |
| Adequate Treatment: Number of antipsychotics     | -0.0504  | 0.0351 | -0.1191 | 0.0183  | 0.1508  | 50                |
| Intercept  | 0.6731   | 0.0246 | 0.6249  | 0.7213  | <0.0001 |                   |
| Adequate Treatment: Current adherence            | -0.0169  | 0.0677 | -0.1496 | 0.1159  | 0.8033  | 50                |
| Intercept  | 0.6531   | 0.0197 | 0.6442  | 0.6917  | <0.0001 |                   |
| Symptom domain                                   | -0.0264  | 0.0200 | -0.0656 | 0.0129  | 0.1880  | 50                |
| Intercept  | 0.6804   | 0.0292 | 0.6233  | 0.7376  | <0.0001 |                   |
| Time course                                      | -0.0634  | 0.0296 | -0.1215 | -0.0053 | 0.0326  | 50                |
| Intercept  | 0.6679   | 0.0208 | 0.6272  | 0.7086  | <0.0001 |                   |

\*All studies scored the same.

**Figure S3** Sensitivity analysis with individual studies – Forest plot (ITT MC<sup>2</sup>)




**Table S9** Sensitivity analysis with individual studies (ITT MC<sup>2</sup>)

| Omitting                   | ITT MC <sup>2</sup><br>Prevalence<br>(%) | 95% CI          | Test of heterogeneity       |         | Number<br>of<br>studies | Number<br>of<br>subjects |
|----------------------------|--|-----------------|-----------------------------|---------|-------------------------|--------------------------|
|                            |  |                 | I <sup>2</sup> (%) [95% CI] | p       |                         |                          |
| Chan et al., 2021          | 37.27%                                   | 33.65% - 40.95% | 97.04% [96.58% - 97.45%]    | <0.0001 | 49                      | 28 156                   |
| Shalev et al., 1993        | 37.18%                                   | 33.49% - 40.94% | 97.32% [96.92% - 97.68%]    | <0.0001 | 49                      | 29 330                   |
| Barnes et al., 2000        | 37.12%                                   | 33.43% - 40.88% | 97.33% [96.92% - 97.68%]    | <0.0001 | 49                      | 29 342                   |
| Lieberman et al. (B), 1993 | 37.14%                                   | 33.45% - 40.91% | 97.33% [96.92% - 97.68%]    | <0.0001 | 49                      | 29 320                   |
| Thien et al., 2018         | 37.18%                                   | 33.49% - 40.96% | 97.29% [96.88% - 97.65%]    | <0.0001 | 49                      | 29 055                   |
| Agid et al., 2011          | 37.12%                                   | 33.42% - 40.90% | 97.32% [96.91% - 97.67%]    | <0.0001 | 49                      | 29 146                   |
| Wimberley et al., 2016     | 37.10%                                   | 33.55% - 40.71% | 96.17% [95.51% - 96.73%]    | <0.0001 | 49                      | 21 346                   |
| Aytac et al., 2020         | 37.05%                                   | 33.36% - 40.83% | 97.33% [96.93% - 97.68%]    | <0.0001 | 49                      | 29 277                   |
| Kogure et al., 2021        | 37.09%                                   | 33.36% - 40.89% | 97.29% [96.88% - 97.65%]    | <0.0001 | 49                      | 28 627                   |
| Üçok et al., 2016          | 37.05%                                   | 33.35% - 40.83% | 97.33% [96.92% - 97.68%]    | <0.0001 | 49                      | 29 236                   |
| Takebayashi et al., 2011   | 37.00%                                   | 33.30% - 40.78% | 97.33% [96.93% - 97.69%]    | <0.0001 | 49                      | 29 261                   |
| Silveira et al., 2015      | 37.01%                                   | 33.29% - 40.81% | 97.33% [96.92% - 97.68%]    | <0.0001 | 49                      | 28 984                   |
| Suzuki et al. (A), 2015    | 37.01%                                   | 33.28% - 40.82% | 97.33% [96.92% - 97.68%]    | <0.0001 | 49                      | 28 851                   |
| Suzuki et al. (B), 2007    | 36.96%                                   | 33.27% - 40.73% | 97.34% [96.93% - 97.69%]    | <0.0001 | 49                      | 29 312                   |
| Breier et al., 1999        | 37.01%                                   | 33.19% - 40.91% | 97.30% [96.89% - 97.66%]    | <0.0001 | 49                      | 27 394                   |
| Meltzer et al., 2003       | 36.98%                                   | 33.22% - 40.82% | 97.32% [96.92% - 97.68%]    | <0.0001 | 49                      | 28 410                   |
| Jeste et al., 1997         | 36.97%                                   | 33.21% - 40.80% | 97.33% [96.92% - 97.68%]    | <0.0001 | 49                      | 28 480                   |
| Lopes et al., 2014         | 36.86%                                   | 33.16% - 40.64% | 97.34% [96.93% - 97.69%]    | <0.0001 | 49                      | 29 265                   |
| Terzic et al., 2014        | 36.85%                                   | 33.15% - 40.62% | 97.34% [96.93% - 97.69%]    | <0.0001 | 49                      | 29 252                   |
| Juarez-Reyes et al., 1995  | 36.84%                                   | 33.13% - 40.63% | 97.34% [96.93% - 97.69%]    | <0.0001 | 49                      | 29 097                   |
| Demjaha et al., 2017       | 36.82%                                   | 33.11% - 40.60% | 97.34% [96.93% - 97.69%]    | <0.0001 | 49                      | 29 180                   |
| Werner et al., 2020        | 36.81%                                   | 33.10% - 40.61% | 97.34% [96.93% - 97.69%]    | <0.0001 | 49                      | 29 069                   |
| Lally et al., 2016         | 36.81%                                   | 33.10% - 40.60% | 97.34% [96.93% - 97.69%]    | <0.0001 | 49                      | 29 150                   |
| CATIE study, 2005          | 36.81%                                   | 33.07% - 40.62% | 97.33% [96.93% - 97.68%]    | <0.0001 | 49                      | 28 753                   |
| Freitas et al., 2019       | 36.80%                                   | 33.01% - 40.66% | 97.32% [96.91% - 97.67%]    | <0.0001 | 49                      | 27 961                   |

|                         |        |                 |                          |         |    |        |
|-------------------------|--------|-----------------|--------------------------|---------|----|--------|
| Ortiz et al., 2017      | 36.74% | 33.04% - 40.52% | 97.33% [96.93% - 97.68%] | <0.0001 | 49 | 29 187 |
| Martin et al., 2016     | 36.74% | 33.02% - 40.55% | 97.32% [96.91% - 97.67%] | <0.0001 | 49 | 28 778 |
| ElGamal et al., 2013    | 36.72% | 33.03% - 40.49% | 97.33% [96.93% - 97.69%] | <0.0001 | 49 | 29 295 |
| Schreiner et al., 2014  | 36.71% | 32.97% - 40.52% | 97.30% [96.88% - 97.65%] | <0.0001 | 49 | 28 392 |
| Sosin et al., 2019      | 36.69% | 33.00% - 40.46% | 97.33% [96.93% - 97.68%] | <0.0001 | 49 | 29 260 |
| McGurk et al. (A), 2004 | 36.68% | 33.00% - 40.43% | 97.33% [96.93% - 97.69%] | <0.0001 | 49 | 29 356 |
| Panov et al., 2022      | 36.62% | 32.94% - 40.39% | 97.33% [96.92% - 97.68%] | <0.0001 | 49 | 29 285 |
| Swinton et al., 1999    | 36.62% | 32.94% - 40.38% | 97.33% [96.92% - 97.68%] | <0.0001 | 49 | 29 316 |
| Patel et al., 2014      | 36.55% | 33.01% - 40.16% | 96.46% [95.87% - 96.97%] | <0.0001 | 49 | 24 335 |
| Mundo et al., 2005      | 36.55% | 32.87% - 40.30% | 97.33% [96.92% - 97.68%] | <0.0001 | 49 | 29 330 |
| Iasevoli et al., 2018   | 36.57% | 32.89% - 40.32% | 97.32% [96.91% - 97.67%] | <0.0001 | 49 | 29 270 |
| Mortimer et al., 2010   | 36.54% | 32.86% - 40.30% | 97.32% [96.91% - 97.67%] | <0.0001 | 49 | 29 258 |
| Moretti et al., 2018    | 36.51% | 32.83% - 40.26% | 97.31% [96.90% - 97.66%] | <0.0001 | 49 | 29 228 |
| Essock et al., 1996     | 36.47% | 32.83% - 40.18% | 97.16% [96.72% - 97.54%] | <0.0001 | 49 | 28 587 |
| Chen et al., 2012       | 36.52% | 32.85% - 40.27% | 97.33% [96.92% - 97.68%] | <0.0001 | 49 | 29 342 |
| Emsley et al., 2000     | 36.44% | 32.79% - 40.18% | 97.25% [96.82% - 97.61%] | <0.0001 | 49 | 29 025 |
| Cezaretto et al., 2014  | 36.45% | 32.78% - 40.20% | 97.32% [96.91% - 97.67%] | <0.0001 | 49 | 29 322 |
| Bilic et al., 2014      | 36.40% | 32.75% - 40.14% | 97.28% [96.87% - 97.64%] | <0.0001 | 49 | 29 217 |
| Sanchez et al., 2010    | 36.40% | 32.74% - 40.14% | 97.30% [96.89% - 97.66%] | <0.0001 | 49 | 29 295 |
| McGurk et al. (B), 2000 | 36.48% | 32.81% - 40.22% | 97.33% [96.92% - 97.68%] | <0.0001 | 49 | 29 359 |
| Itil et al., 1975       | 36.42% | 32.76% - 40.17% | 97.31% [96.91% - 97.67%] | <0.0001 | 49 | 29 328 |
| Woodall et al., 2004    | 36.20% | 32.57% - 39.92% | 97.27% [96.85% - 97.63%] | <0.0001 | 49 | 29 299 |
| Spangaro et al., 2021   | 36.19% | 32.55% - 39.90% | 97.27% [96.85% - 97.63%] | <0.0001 | 49 | 29 297 |
| Sayal et al., 2002      | 36.16% | 32.53% - 39.88% | 97.27% [96.85% - 97.63%] | <0.0001 | 49 | 29 310 |
| Soares et al., 2021     | 35.89% | 32.38% - 39.48% | 97.05% [96.58% - 97.45%] | <0.0001 | 49 | 29 185 |



**Figure S4** Funnel plot (ITT MC<sup>2</sup> - including the CATIE study)



**Table S10** Quality assessment (modified Newcastle-Ottawa Scale) – individual scores

| Study                      | Representativeness | Sample size | Non-respondents | Ascertainment of TRS | Statistical quality | Total score |
|----------------------------|--------------------|-------------|-----------------|----------------------|---------------------|-------------|
| Agid et al., 2011          | 1                  | 1           | 1               | 1                    | 1                   | 5           |
| Aytac et al., 2020         | 1                  | 0           | 1               | 0                    | 1                   | 3           |
| Barnes et al., 2000        | 1                  | 0           | 0               | 0                    | 1                   | 2           |
| Bilic et al., 2014         | 0                  | 0           | 0               | 1                    | 1                   | 2           |
| Breier et al., 1999        | 0                  | 1           | 0               | 1                    | 0                   | 2           |
| CATIE study, 2005          | 0                  | 1           | 0               | 1                    | 1                   | 3           |
| Cezaretto et al., 2014     | 0                  | 0           | 1               | 0                    | 1                   | 2           |
| Chan et al., 2021          | 1                  | 1           | 1               | 0                    | 0                   | 3           |
| Chen et al., 2012          | 0                  | 0           | 0               | 1                    | 1                   | 2           |
| Demjaha et al., 2017       | 1                  | 1           | 1               | 1                    | 0                   | 4           |
| ElGamal et al., 2013       | 0                  | 0           | 0               | 0                    | 1                   | 1           |
| Emsley et al., 2000        | 0                  | 1           | 1               | 1                    | 1                   | 4           |
| Essock et al., 1996        | 0                  | 1           | 0               | 0                    | 0                   | 1           |
| Freitas et al., 2019       | 1                  | 1           | 0               | 0                    | 1                   | 3           |
| Iasevoli et al., 2018      | 0                  | 0           | 0               | 1                    | 1                   | 2           |
| Itil et al., 1975          | 0                  | 0           | 0               | 1                    | 1                   | 2           |
| Jeste et al., 1997         | 1                  | 1           | 0               | 0                    | 1                   | 3           |
| Juarez-Reyes et al., 1995  | 1                  | 1           | 0               | 0                    | 1                   | 3           |
| Kogure et al., 2021        | 0                  | 1           | 0               | 0                    | 1                   | 2           |
| Lally et al., 2016         | 1                  | 1           | 0               | 1                    | 1                   | 4           |
| Lieberman et al. (B), 1993 | 1                  | 0           | 1               | 1                    | 1                   | 4           |
| Lopes et al., 2014         | 0                  | 0           | 0               | 0                    | 0                   | 0           |

| Study                    | Representativeness | Sample size | Non-respondents | Ascertainment of TRS | Statistical quality | Total score |
|--------------------------|--------------------|-------------|-----------------|----------------------|---------------------|-------------|
| Martin et al., 2016      | 1                  | 1           | 0               | 0                    | 0                   | 2           |
| McGurk et al. (A), 2004  | 0                  | 0           | 0               | 0                    | 1                   | 1           |
| McGurk et al. (B), 2000  | 0                  | 0           | 0               | 0                    | 1                   | 1           |
| Meltzer et al., 2003     | 1                  | 1           | 0               | 0                    | 1                   | 3           |
| Moretti et al., 2018     | 0                  | 0           | 1               | 0                    | 1                   | 2           |
| Mortimer et al., 2010    | 0                  | 0           | 0               | 0                    | 0                   | 0           |
| Mundo et al., 2005       | 0                  | 0           | 0               | 0                    | 0                   | 0           |
| Ortiz et al., 2017       | 1                  | 1           | 1               | 0                    | 0                   | 3           |
| Panov et al., 2022       | 0                  | 0           | 0               | 1                    | 0                   | 1           |
| Patel et al., 2014       | 1                  | 1           | 0               | 0                    | 1                   | 3           |
| Sanchez et al., 2010     | 0                  | 0           | 1               | 0                    | 1                   | 2           |
| Sayal et al., 2002       | 0                  | 0           | 0               | 0                    | 1                   | 1           |
| Schreiner et al., 2014   | 0                  | 1           | 0               | 1                    | 1                   | 3           |
| Shalev et al., 1993      | 0                  | 0           | 1               | 1                    | 1                   | 3           |
| Silveira et al., 2015    | 1                  | 1           | 1               | 0                    | 0                   | 3           |
| Soares et al., 2021      | 0                  | 1           | 0               | 0                    | 1                   | 2           |
| Sosin et al., 2019       | 0                  | 0           | 0               | 0                    | 1                   | 1           |
| Spangaro et al., 2021    | 0                  | 0           | 0               | 0                    | 1                   | 1           |
| Suzuki et al. (A), 2015  | 1                  | 1           | 1               | 0                    | 0                   | 3           |
| Suzuki et al. (B), 2007  | 0                  | 0           | 1               | 1                    | 1                   | 3           |
| Swinton et al., 1999     | 0                  | 0           | 0               | 0                    | 0                   | 0           |
| Takebayashi et al., 2011 | 0                  | 0           | 1               | 1                    | 1                   | 3           |

| <b>Study</b>           | <b>Representativeness</b> | <b>Sample size</b> | <b>Non-respondents</b> | <b>Ascertainment of TRS</b> | <b>Statistical quality</b> | <b>Total score</b> |
|------------------------|---------------------------|--------------------|------------------------|-----------------------------|----------------------------|--------------------|
| Terzic et al., 2014    | 0                         | 0                  | 1                      | 0                           | 1                          | 2                  |
| Thien et al., 2018     | 1                         | 1                  | 1                      | 1                           | 0                          | 4                  |
| Üçok et al., 2016      | 1                         | 0                  | 1                      | 1                           | 1                          | 4                  |
| Werner et al., 2020    | 1                         | 1                  | 0                      | 0                           | 0                          | 2                  |
| Wimberley et al., 2016 | 1                         | 1                  | 0                      | 0                           | 0                          | 2                  |
| Woodall et al., 2004   | 0                         | 0                  | 0                      | 0                           | 1                          | 1                  |

**Table S11** Quality assessment (Newcastle-Ottawa Scale modified) – Subgroup analysis

|  | ITT MC <sup>2</sup><br>Prevalence (%) | 95% CI        | Test of heterogeneity |         | Number of studies | Test for subgroup differences |      |         |
|--|---------------------------------------|---------------|-----------------------|---------|-------------------|-------------------------------|------|---------|
|  |                                       |               | I <sup>2</sup> (%)    | p       |                   | Q                             | d.f. | p       |
| <b>Representativeness</b>  |                                       |               |                       |         |                   |                               |      |         |
| Clear selection bias (e.g. long-term admissions, clozapine clinics, chronic SCZ) | 44.09%                                | 38.78 – 49.46 | 95.1%                 | <0.0001 | 30                | 20.77                         | 1    | <0.0001 |
| Truly (population-based studies) OR Somewhat representative                      | 27.16%                                | 22.42 – 32.17 | 98.1%                 | <0.0001 | 20                |                               |      |         |
| <b>Sample size</b>   |                                       |               |                       |         |                   |                               |      |         |
| <200   | 40.86%                                | 35.09 – 46.75 | 88.9%                 | <0.0001 | 27                | 4.61                          | 1    | 0.032   |
| ≥200   | 32.67%                                | 27.90 – 37.63 | 98.5%                 | <0.0001 | 23                |                               |      |         |
| <b>Non-respondents</b>   |                                       |               |                       |         |                   |                               |      |         |
| If any of the above data is missing or not satisfactory                          | 41.12%                                | 36.47 – 45.84 | 97.8%                 | <0.0001 | 32                | 8.97                          | 1    | 0.003   |
| 2 adequate trials (≥ 4w., ≥400mg CPZ eq., scale with cutoff)                     | 29.31%                                | 23.51 – 35.46 | 94.6%                 | <0.0001 | 18                |                               |      |         |
| <b>Ascertainment of TRS</b>  |                                       |               |                       |         |                   |                               |      |         |
| Both retrospective (e.g. chart review, previous history)                         | 38.91%                                | 33.97 – 43.96 | 98.0%                 | <0.0001 | 32                | 2.64                          | 1    | 0.104   |
| At least one prospective trial   | 32.98%                                | 28.02 – 38.14 | 93.1%                 | <0.0001 | 18                |                               |      |         |

|   | ITT MC <sup>2</sup><br>Prevalence (%) | 95% CI        | Test of heterogeneity |         | Number of studies | Test for subgroup differences |      |         |
|---|---------------------------------------|---------------|-----------------------|---------|-------------------|-------------------------------|------|---------|
|   |                                       |               | I <sup>2</sup> (%)    | p       |                   | Q                             | d.f. | p       |
| <b>Quality of descriptive statistics reporting</b>  |                                       |               |                       |         |                   |                               |      |         |
| Statistics not reported/incomplete, or no proper measures of dispersion                             | 32.38%                                | 27.30 – 37.67 | 97.0%                 | <0.0001 | 16                |                               |      |         |
| Statistics to describe the population (age, sex) with proper measures of dispersion (SD, SE, range) | 38.87%                                | 34.73 – 43.10 | 95.2%                 | <0.0001 | 34                | 3.67                          | 1    | 0.055   |
| <b>NOS: Total score</b>   |                                       |               |                       |         |                   |                               |      |         |
| Score = 5   | 20.49%                                | 15.65 – 25.80 | --                    | --      | 1                 |                               |      |         |
| Score = 4   | 28.96%                                | 18.57 – 40.58 | 95.0%                 | <0.0001 | 6                 |                               |      |         |
| Score = 3   | 28.62%                                | 23.36 – 34.19 | 97.5%                 | <0.0001 | 15                |                               |      |         |
| Score = 2   | 40.89%                                | 33.76 – 48.21 | 97.5%                 | <0.0001 | 15                | 58.07                         | 5    | <0.0001 |
| Score = 1   | 51.41%                                | 44.19 – 58.59 | 81.3%                 | <0.0001 | 9                 |                               |      |         |
| Score = 0   | 41.87%                                | 34.15 – 49.80 | 65.2%                 | 0.0033  | 4                 |                               |      |         |
| <b>NOS: Cutoff</b>  |                                       |               |                       |         |                   |                               |      |         |
| Total score ≥ 3 (Lower risk of bias)  | 28.35%                                | 23.90 – 33.01 | 96.9%                 | <0.0001 | 22                |                               |      |         |
| Total score < 3 (Higher risk of bias)   | 44.35%                                | 38.29 – 50.50 | 97.3%                 | <0.0001 | 28                | 17.11                         | 1    | <0.0001 |

**Figure S5** Sensitivity analysis between low risk of bias studies (Forest plot)

